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Preface 
As the Maine Bureau of Health has become increasingly involved with ~ 
conducting and evaluating risk assessments, the need has arisen for the 
establishment of a risk assessment policy. The intent of this document is to 
identify relevant risk assessment policy issues, and to provide science 
policy guidance for addressing these issues. The scope of this document is 
broad enough to be applicable to any situation requiring risk assessments for 
toxic substances. 
The scope of each risk assessment should be defined by its purpose. For 
example, the word "environment" is used extensively in this document. The 
term refers not just to the ambient environment, but to the total ~pvironment 
surrounding an organism or group of organisms. This distinction is ·_important, 
as it does not limit the scope of the policy to any single exposure: medium 
(such as air, water, or food), or to any particular category of exposure (for 
example, indoor air pollution in residential environments v~rsus ?iJ;;.P9llution 
in occupational environments). It is possible that some' assessments may 
require the evaluation of all exposure media and exposure categories. 
Conversely, other risk assessments may require only a limited evaluation of 
exposure, or perhaps none at all. ·· 
Sufficient latitude is also required in defining the scope of the health 
assessment. The health effects identified in the policy are not restricted to 
any disease endpoint or group of endpoints. Unless specifically st?t~d in the 
assessment's purpose (for example, that the assessment will only ~onsider 
carcinogenic effects), this policy allows the · :~. assessments ,sufficient 
flexibility to consider all potentially relevant parameters ef. · adverse 
biological effects. Consideration of all relevant pa:r~meters ~9-Y.~: provide a 
better scientific insight into both the biological basis for ari:y· pa~ticular 
effect, or for the mechanisms of toxicity, than" .~would bet·,~athfeved by 
consideration of a limited number of health endpoints. 
It should be continually emphasized, however, that risk ·asse~srtie~t is a 
tool, not a substitute, for the determination .of responsible .sochn policy. 
It is an attempt to combine wha~ is known and what is not ~kn.Qwn about a 
chemical into an abstract concept loosely defined a.s an "~_<;1t(ofl,. level." As . 
such, it generates a dynamic process which inevitably iniprove:s-~·'the methods by 
which risk assessments are conducted. It does not, unfortunately, provide 
much comfort when our scientific understanding fails to meet the challenges we 
increasingly impose upon it. 
iv 
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EXECUTIVE SUMMARY 
Since the inception of its Environmental Health Unit in 1981 (M.R.S.A., 
1981), the Maine Bureau of Health has become increasingly involved with 
conducting and evaluating risk assessments. With this responsibility has come 
the growing need for the Maine Bureau of Health to develop a risk assessment 
policy. This document describes the issues of potential concern in risk 
assessment, and the Bureau's policies regarding how these issues should be 
addressed. 
The policy considerations contained in this document are guided by three 
basic principles: 1) that uncertainties associated with the assessment of 
health risk should be reflected by a conservative approach towards the 
protection of public health, 2) to the extent feasible, all relevant data 
should be evaluated in the assessment process, and 3) that risk assessments 
should reflect the best scientific understanding of chemically related health 
effects. Conformity to these princip~es results in a dynamic approach to risk 
assessment while ensuring that the public is given adequate health protection. 
Risk assessments consist of four basic steps: exposure assessment, 
hazard identification, hazard assessment, and risk characterization. Within 
the first three risk assessment steps, specific parameters need to be evalu-
ated. These parameters provide the basis for an overall characterization of 
risk. It is in the evaluation of these parameters that specific risk 
assessment policy choices must be made. Criteria are either followed or 
established to provide guidance in making these choices. Inadequacies 
identified in this process are incorporated into the recommendations for 
further study. 
Risk assessment policy issues begin with defining the scope of the 
assessment and, subsequently, with the procedures by which studies are 
identified and selected for evaluation. The goal of identifying and reviewing 
all relevant data must be weighed against the limitations of data availability 
and the extent to which resources can be devoted to the assessment. The 
procedure should indicate how priority is given to studies critical to key 
risk assessment issues and specify those studies which were selected for 
review but could not be retrieved. 
Studies selected for risk assessment are used to identify and evaluate 
key exposure and health parameters. Because this process generally requires 
information from several lines of investigation, it is important that the 
selection process identify different types of studies as well as different 
risk assessment parameters. Exposure parameters may need to be evaluated for 
different environmental media and for different exposure routes. Relevant 
exposure information may come from either monitoring or modelling studies. 
Health parameters should describe effects as a function of exposure duration 
and exposure dose. Relevant health information may come from epidemiological 
studies, controlled human exposure studies, animal studies, and cell culture 
studies. 
X 
Studies reviewed in the exposure assessment are used to determine how much 
is known about the extent and magnitude of population exposure. Studies 
reviewed in the hazard identification section are used to determine what is 
known and what needs to be known about the hazard potential of a chemical. 
Estimates of the health risks, which are derived in the hazard assessment 
section, need to consider both what is known and what is not known. Specific 
areas of uncertainty considered in the exposure assessment and hazard 
assessment sections should be identified. In addition, manner in which these 
uncertainties are quantitatively or qualitatively addressed should be 
specified. The distinction between the _contributions of the empirical 
findings and those of the uncertainty factors to the risk estimates should be 
clearly made in the assessment. 
The findings of the hazard assessment section are commonly expressed 
quantitatively in terms of action levels. Exposures greater than the action 
levels indicate a basis for health concern; exposures less than the action 
levels indicate an insignificant health risk. For threshold effects, action 
levels are estimates of no adverse effect levels for the general population. 
For non-threshold effects, such as carcinogenesis, any level of exposure is 
associated with some degree of risk. Action levels for non-threshold effects 
thus depend on the level of risk which society is willing to assume. In the 
absence of specific risk management policy: guidance, exposure doses 
corresponding to lifetime cancer risks of 10 -5, 10 -6, and 10-7 should be 
presented in the risk assessment. The action level is the exposure dose 
corresponding to a lifetime cancer risk of lo-5. In the risk 
characterization section, the action levels for threshold and non-threshold 
effects are compared with the exposure estimates to determine whether a 
current or projected exposure warrants a significant health concern. 
The derivation of action levels relies on the use of reasonable worst case 
assumptions for estimating the health risks associated with chemical 
exposure. By using worst case assumptions, a plausible upper bound can be set 
on the estimation of uncertainty. Uncertainty exists in both the exposure 
assessment and the hazard assessment. Worst case assumptions thus need to be 
developed in both of these steps, as well as in the final, risk 
characterization step. Given the uncertainties associated with risk 
estimation,, risk assessments may also describe approaches using less 
conservative assumptions. Unless these alternative assumptions reflect a 
greater certainty in the estimation of the actual exposure and toxicity, 
however, estimates based on these less extreme assumptions lack the scientific 
confidence necessary to ensure that the public's health is adequately 
protected. 
After the risk assessment has been completed and sufficiently reviewed, 
its findings should be communicated to the appropriate agencies or 
individuals. While a procedure exists for chemicals evaluated in the 
Hazardous Air Pollutant Program, risk assessments done for other purposes have 
no defined risk communication procedures. The development of such procedures 
would enhance the effectiveness of risk assessment as a tool in public 
policymaking. 
xi 
SECTION I: INTRODUCTION 
1. Purpose of Risk Assessment. 
The National Research Council (1983a) defines risk assessment as "the 
qualitative or quantitative characterization of potential health effects of 
particular substances on individuals or populations." Often in the risk 
assessment process, choices must be made from an array of scientifically 
plausible alternatives. These choices which are made in risk assessment 
comprise the risk assessment policy (NRC, 1983a). 
The general goal of a risk assessment is to identify and evaluate the 
contribution of chemical exposure to the adverse human health effects. Risk 
assessments are conducted for a variety of reasons. They may be done to 
assess the health impacts of a current or anticipated exposure to a toxic 
substance. They may be conducted to assess chemical impacts from specific 
environmental media, or on specific population groups. Risk assessments may 
also be conducted to provide the basis for regulatory guidelines or 
standards. The purpose will, therefore, define the scope and focus of the 
risk assessment, the parameters which need to be evaluated, and the specific 
criteria which the assessment should address. 
Once a risk assessment is completed, its findings need to be presented to 
interested, or potentially interested, parties. This process is called risk 
communication. Often, a risk assessment provide health criteria to be usea-In 
establishing public policies for particular chemicals or mixtures of 
chemicals. The process by which public policies are established for 
regulating population exposures to chemicals is called risk management (NRC, 
1983a). Risk management decisions reflect a number of criteria in addition to 
health criteria. They include economic and political factors, statutory 
requirements, analytical limitations, technological feasibility, and impacts 
of alternative actions. 
Since the inception of its Environmental Health Unit in 1981 (M.R.S.A., 
1981), the Maine Bureau of Health has become increasingly involved with 
conducting and evaluating risk assessments. In particular, the Hazardous Air 
Pollutant Program (M.R.S .A., 1984) mandated the Bureau of Health to conduct 
risk assessments on potentially hazardous air pollutants emitted in the 
state. The legislation \vhich established the program also established a peer 
review committee of scientists, the Scientific Advisory Panel, to provide 
critical review of these assessments. While carrying out their res pons i-
b ili ties, both the Bureau of Health staff and the Scientific Advisory Panel 
have realized the need for a consistent and scientifically defensible approach 
to risk assessment. This need has also been expressed by representatives from 
state regulatory agencies who request the Bureau of Health's advice on various 
environmental health issues. This risk assessment policy document was 
developed in response to these concerns. 
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This document has three principal uses. Structurally, it specifies the 
general format which the Maine Bureau of Health will use when conducting 
formal risk assessments. In terms of content, it identifies the specific 
parameters which assessments may need to consider when evaluating the· health 
risks of toxic chemicals. Thirdly, it states the general science policy 
issues associated with the evaluation of these risk assessment parameters, the 
criteria used in their evaluation, and the general approaches recommended by 
the Bureau of Health when a policy judgment needs to be made. In many cases, 
establishment of all parameters may not be necessarye Decisions to evaluate 
or not evaluate parameters depend on the purpose and scope of the assessment., 
The policy considerations contained in this document are guided by three 
basic principles. The first principle is that the uncertainties associated 
with the assessment of health risk should be reflected by a conservative 
approach towards the protection of public health. In this context, a 
conservative approach means that when confronted with scientific uncertainty, 
errors associated with the pol icy choices should be in the direction of 
increased public health protection. The second principle is that, to the 
extent feasible, all relevant data should be evaluated in the assessment 
process. The third principle is that the risk assessments should reflect the 
best scientific understanding of chemically related health effects. 
COnformity to these choices implies a complex and dynamic approach to risk 
assessment policy. Specific risk assessment policy issues have been evaluated 
by the International Agency for Research on Cancer (!ARC, 1980), National 
Research Council (1977a-b, 1986), the U.S. Environmental Protection Agency 
(USEPA, 1986a-e), the Occupational Safety and Health Administration (OSHA., 
1985), and the Office on Science and Technology Policy (OSTP, 1985), among 
others. The criteria developed by such organizatioo.s as these provide the 
science policy guidance for most of the issues examined by the Maine Bureau of 
Health. Policy choices associated with these specific issues are modified as 
new scientific information becomes available. 
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2. Substance Identification and General Properties. 
Once the purpose of the assessment is defined, the investigation of the 
substance begins with its chemical identification. This chapter contains 
information of the chemical formula, synonyms, and important identification 
codes for the substance being assessed. This chapter also contains a short, 
qualitative description of the substance's general characteristics, its major 
physical and chemical properties, and appropriate conversion factors. This 
information is useful to several areas of the assessment. In the exposure 
assessment, for example, such data may be helpful in determining likely routes 
of exposure and the substance's ability to be transferred across different 
environmental media. The data may also be useful in the pharmacokinetics 
chapter (Chapter 10), when specific data concerning partition coefficients 
within the body are not available. Finally, information on sustance's 
properties may provide assistance when describing the mechanism of action 
( Olapter 14 .4). 
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SECTION II: MElliODS 
The procedure by which information is systematically identified, retrieved 
and evaluated is described in the Methods section. Although the degree of 
information gathering and analysis depends on the purpose of the assessment, 
there is a general protocol which is applicable to all assessments. First, 
the scope of the assessment is defined. Definition of the scope is followed 
by the procedure for 1) selecting the studies to be assessed, 2) how these 
studies are to be evaluated, and 3) how these findings of the assessment are 
to be communicated. 
3. Scope of the Risk Assessment. 
The scope of the assessment broadly determines its nature and the level of 
effort to be applied to it. The failure of the assessment to consider certain 
key areas may lead to erroneous conclusions. The assessment may also suffer 
from the failure to include information not directly related to its primary 
purpose, but which may provide insight into the overall nature of the prob-
lem. On the other hand, consideration of information not directly relevant to 
the assessment's purpose may create a drain on available resources and time 
which could better directed elsewhere. At a minimum, the scope should include 
those areas critical to satisfying the primary purpose of the assessment. 
Decisions to include additional areas should consider how such additional 
effort would divert resources from other environmental health assessments. 
3.1 Risk Assessment Steps. 
Risk assessment steps are the general areas of investigation and analysis 
which risk assessments should consider. According to the National Research 
Council, risk assessment contains one or more of the following steps: exposure 
assessment, hazard identification, hazard (or dose response) assessment, and 
risk characterization (NRC, 1983a). The extent to which these steps are 
investigated depends on the assessment's scope. The National Research 
Council's recommendations concerning how risk assessment steps should be 
combined and integrated into the risk management process is presented in 
Figure 3.1. The Maine Bureau of Health follows this general guidance when 
conducting risk assessments. 
3.2 Risk Assessment Parameters and Criteria. 
Assessment of each risk assessment step requires consideration of specific 
risk assessment policy issues. Resolution of these issues is important if the 
health and exposure parameters critical to the assessment of human health 
risks are to be appropriately determined. In many cases, these parameters are 
determined by using specific risk assessment criteria. Health parameters 
identified in the Hazard Identification section (Section IV) are evaluated in 
the Hlzard Assessment section (Section V). The assessment of these parameters 
in combination with the exposure parameters (Section III) provides a 
characterization of the types and severity of potential health effects at 
exposure levels of concern (Section VI). 
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The param~ters identified and evaluated in the Exposure Assessment address 
the potential for human exposure from various emission· sources and through 
different exposure routes, and the fate of the substance in the environment. 
These parameters are used in the derivation of quantitative exposure estimates 
and estimates of the body burdens. Criteria need to be followed or developed 
in order to judge the validity and precision of these exposure values. 
The Hazard Assessment contains both a qualitative and a quantitative 
evaluation of health risk. The qualitative assessment analyzes all findings 
from the Hazard Identification which relate to a qualitative basis for 
toxicological concern. Hazard identification parameters for a particular 
substance are identified from studies on pharmacokinetics, health effects, 
environmental effects, and comparisons with other substances which have 
similar biological or chemical characteristics. From this information, an 
overall weight of evidence determination is made which relates substance 
exposure to potential health effects. As with the exposure assessment 
section, criteria should be followed or developed in this section from which 
to judge weight of evidence and other qualititative measures of toxicological 
concern. 
Once the potential for a health effect to occur is established, parameters 
for estimating the quantitative relationship between dose and response should 
be determined. Included in these determinations should be an evaluation of 
the adequacy of the database for quantitative risk assessment purposes. If a 
sufficient quantitative basis exists for risk estimation, the assessment could 
benefit from a discussion of how different assumptions or results may 
influence the estimation process. This sensitivity analysis should provide an 
appreciation for the robustness of the estimates. Because the approach to 
quantitative assessment is different for threshold and non-threshold effects, 
such derivations must be done separately. Criteria discussed in this section 
concern the basis for the quantitative adjustments made to the data described 
in the Hazard Identification section. 
In the final, Risk Characterization, section on the assessment (Section 
VI), estimates of the actual health risks associated with substance exposure 
are presented. These estimates are developed from information reviewed or 
derived in the previous sections. This overall assessment of health risk 
represents criteria from which decisions may be made regarding risk 
communication ·and risk management. Thus, the risk characterization section 
presents information which should be considered within the broader contexts of 
public health and social policy, where stricti y scientific criteria are not 
the only areas of interest. 
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4. Selection of Studies. 
4.1 Selection Procedure for Chemical Mixtures. 
Risk assessments are generally conducted on individual chemicals. 
Knowledge of the toxicological properties of individual chemicals may not be 
sufficient indicators of toxicity, however, when chemicals are present in a 
mixture. Chemicals may interact in a number of ways. They may react 
chemically in the environment, thus possibly producing additional toxic 
substances (USEPA, 1986c). They may also modify each other's pharmacokinetics 
and activity at biological receptor sites (USEPA, 1986c). 
Because these chemical interactions can be complex, the desired approach 
regarding the assessment of chemical mixtures is to evaluate information on 
the mixture as a whole. If the information on the mixture is found to be 
inadequate for risk assessment, subsequent efforts should be directed towards 
the assessment of the most toxic components of the mixture. This approach has 
been used in the chemical ranking system and formal risk assessment process 
developed for Maine's Hazardous Air Pollutant Program (Anderson, 1986). 
4.2 Identification and Retrieval of Information. 
Once the relevant steps and parameters of the risk assessment have been 
identified, the method for identifying and selecting applicable information 
should be described. Initial efforts usually focus on surveys of pertinent 
databases, bibliographic references in recent secondary sources, and 
information contained in the files of federal regulatory agencies. Relevant 
studies may then be identified from these information sources. 
Risk assessment policy implications are associated with the manner in 
which the information sources are identified and selected. Failure to 
identify and retrieve critical studies may limit the ability of the assessment 
to reflect current scientific understanding. Consequently, findings based on 
a limited data set may be substantially different from those based on a more 
complete information base, even though the same risk assessment assumptions 
are applied in both cases. On the other hand, a thorough review of all 
relevant studies may easily overwhelm the risk assessor's capacity. In this 
case, such an expectation may preclude an assessment from being done in a 
timely fashion. 
The level of effort devoted to the identification of risk assessment 
information is subject to the scope and purpose of the assessment, as well as 
to the amount of time, money, and personnel that can be committed to the 
search. Factors influencing this process include the number and nature of the 
available databases, and how they are searched. The identification process 
also depends on the quality and comprehensiveness of the secondary sources, 
the extent to which they are reviewed, and the amount and avai lability of 
information contained in the government files. The overall degree of 
identification is thus a function of the data avai lability and the resources 
that can be devoted to identifying the data. As the resulting level of effort 
may change with each assessment, the procedure by which information was 
identified should be described in each case. 
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A description of the procedure for selecting studies is also neededG The 
selection of studies should be consistent with the purpose and scope of the 
assessment. When many relevant studies have been identified, a hierarchy 
should be established to ensure that a manageable amount of the most important 
information is reviewed. Specifically, decisions must be made regarding which 
issues can be adequately addressed by review of secondary sources, and which 
issues require and in depth analysis of primary sources. As a result, the 
process of selecting studies is apt to be a dynamic one; as the review of the 
scientific literature progresses, issues are identified which warrant 
particular scrutiny. 
In certain situations, studies critical to the assessment are not 
available for review. These situations may occur when the studies are 
considered to be proprietary information, when they have been written in a 
foreign language for which no translation is available, or when they are still 
works in progress. Problems associated with access to proprietary information 
may be overcome if arrangements to maintain confidentiality. can be made with 
the sources of that information. Because the inability to retrieve 
information may significantly influence the findings of the assessment, 
mention should be made when such critical studies have been identified but 
could not be retrieved. 
4a3 Types of Exposure Assessment Studies. 
Data in the Exposure Assessment (Section 3) are analyzed in order to 
derive quantitative estimates of exposure for each exposure medium and 
exposure route. This information comes from two areas of investigation: 
monitoring and modelling. Precision varies with the analytical methods 
employed and the extent of the analysis. 
Monitoring information is generally considered to be more important that 
modelling information, in that monitored values reflect actual exposure 
concentrations.. Varying degrees of uncertainty are associated with these 
values, however. Apart from factors influencing the precision of the sampling 
and analytical procedures, substance levels may vary temporally and 
spatially. They may also be present in media not where no sampling has been 
conducted. These potential gaps and fluctuations introduce uncertainty as to 
whether or not the monitored values represent the true exposure patterns. 
Selection criteria should therefore address the need to reduce this 
uncertainty. 
When monitoring data do not adequately reflect the true exposure patterns, 
assessments must rely on modelling information in order to estimate the extent 
and magnitude of exposure. Different types of modelling information 
information may be necessary for assessments which consider exposures from 
more than one pathway. Models are not able to consider all of the factors 
which influence the fate and transport of the substance in the environment, 
however. Therefore, the correlations between model results and actual 
exposure conditions may vary substantially from one location to the next. 
Consequently, selection criteria for modelling information should therefore 
consider the types of exposure information required in the assessments and the 
extent to which monitoring data must be supplemented by modelling information. 
4-2 (88) 
4.4 Types of Hazard Identification Studies. 
Health effects information on a chemical comes from four principal areas 
of study: observational epidemiology, experimental epidemiology (that is, 
environmentally controlled studies with human volunteers), whole animal (in 
vivo) toxicology, and in vitro experiments. Each area of study has its own 
set of advantages and Olsadvantages, and each can provide information on an 
aspect of a chemical's toxicity unobtainable from other areas of research. In 
some instances, experiments are performed using both in vivo and in vitro 
procedures, such as the host mediated assay (!ARC, 1980)--. Thus, evaluation of 
information from all study categories should contribute to the overall 
understanding of a substance's toxicity. 
4 .. 4 .. 1 Observational Epidemiological Studies·. 
Observational epidemiological investigations concern the study of disease 
patterns in human populations. Observational studies may either be 
predominantly descriptive or predominantly analytical. Descriptive studies 
are usually undertaken when very little is known about the risk factors for a 
particular disease. In its simplest form, a descriptive study may involve the 
identification of a potential risk factor in a case or cluster of cases. 
Ecologic studies involve larger groups of people, most often defined 
geographically. Disease patterns are studied either over time or in relation 
to different exposure parameters. Both types of descriptive studies are 
useful for generating specific hypotheses regarding the association between a 
potential risk factor and disease. Generally, however, they do not provide 
enough information on the exposed and non-exposed populations from which a 
causal inference may be made. 
Analytical studies include cross-sectional studies, case-control studies, 
and cohort studies (Kleinbaum et al., .1982; MacMahon and Pugh, 1970). In a 
cross-sectional study, prevalence rates at a particular time are compared 
among populations with different .risk factor characteristics. Cross-sectional 
studies are particularly useful when the risk factors are stable over time and 
when the diseases are those which occur frequently and which have long 
durations (Kleinbaum et al., 1982). By only considering prevalence, however, 
cross-sectional studies cannot establish a temporal association between the 
risk factor and disease. 
In a case-control study, individuals with a disease are compared with 
individuals without a disease to identify potential risk factors within the 
diseased individuals. A case-control study is especially useful when the 
disease of interest rarely occurs. It is limited, however, by several 
factors. Firstly, risk factor information is obtained in this type of study 
after the occurrence of the disease (Kleinbaum et al., 1982). Also, it is 
difficult to ensure that the cases and non-cases in the study population are 
similar with respect to extraneous risk factors (Kleinbaum et al., 1982). 
Finally, because it concerns a specific disease outcome, a case-control study 
may not be appropriate when a variety of possible health effects are being 
investigated (Kleinbaum et al., 1982). 
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In a cohort study, populations are identified in relation to an 
independent study variable (for example, exposed and non-exposed 
populations). A retrospective study investigates relevant data bases to 
determine whether the incidence of a particular disease differs significantly 
between the exposure groups. A prospective study follows these individuals 
over time to determine whether disease incidence varies significantly between 
the groups. Cohort studies, particularly prospective studies, are useful for 
establishing temporal associations between a risk factor and diseaseo On the 
other hand, these types of investigations are likely to be expensive, 
especially if the disease of interest occurs with a rare frequencye Also, 
certain kinds of studies, such as prospective studies, may take many years to 
complete. In the meantime, many people may suffer disease as a result of 
exposure, and many more may be at risk of developing disease even after the 
exposure is reduced or discontinued. 
For risk assessment purposes, analytical studies are most useful for 
establishing causal associations between chemical exposure and disease. They 
thus represent the strongest evidence for a toxic effect. Establishing causal 
relationships is difficult, however, because there are usually other agents in 
the environment which have the potential to cause the same health effects .. 
Also, differences in lifestyles and exposure patterns among members of the 
study and control populations preclude any precise characterization of these 
cohorts. In addition, exposure information is rarely determined with 
prec1s1on. This last shortcoming affects the ability of epidemiological 
studies to establish dose-response relationships in the populations under 
studys Because of these limitations, most epidemiological studies are 
inherently capable of detecting only comparatively large increases (50 
percent) in the relative risks of chronic health effects (OSHA, 1980). 
4.4.2 Experimental Epidemiology Studies. 
Some of the problems associated with observational epidemiological studies 
can be eliminated if controlled studies with human volunteers are undertaken. 
In these studies, direct causal relationships can be more easily established 
because potential confounding factors are removed. Dose-response 
relationships can be precisely derived because the exposure to the substance 
is monitored and controlled. 
Traditionally, controlled human exposure studies have been undertaken to 
test the effects of pharmaceuticals. In these cases, the study populations 
were likely to benefit greatly from a successful experiment. Human volunteers 
do not benefit from exposure to toxic, non-therapeutic chemicals, however. 
Thus, the use of experimental epidemiology for assessing the human health 
impacts of chemical contaminants is very circumscribed. For ethical reasons, 
therefore, experimentation with human subjects is not carried out when the 
chemical in question may produce irreversible effects, or at dose levels at 
which severe reversible effects may occur. Thus, controlled human studies 
have limited usefulness in risk assessment, which is mainly concerned with the 
irreversible effects of long-term exposure. Rather, environmental health 
studies using controlled human exposures are primarily designed to detect 
subtle and reversible acute effects. 
4-4 (88) 
4.4.3 Whole Animal Studies. 
Whole animal (or in vivo) studies provide much of the substance-specific 
information on toxicity. -rnls is particularly true when information is needed 
on irreversible effects, or when toxicological and pharmacological information 
can only be obtained by invasive means. Animal studies can be performed under 
carefully monitored and controlled conditions and are therefore capable of 
being reproduced or compared. They also can provide precise dose-response 
information. They are generally cheaper than large-scale epidemiological 
studies and can be completed in relatively short periods of time. 
For new substances, toxicological studies can detect potentially 
irreversible effects, such as cancer, and thus serve as a screen for the 
introduction of potentially hazardous substances into the marketplace. For 
substances currently in use, they may identify harmful substances not 
identified through epidemiological investigations. On the other hand, 
significant interspecies differences may exist in a substance's toxicity, and 
there is generally no a priori way of knowing whether the response of any 
particular species is tlie most predictive of the response in human beings. 
Thus, it is possible that an effect found to occur in any laboratory animal 
may also occur in human beings. Similarly, if the same effect occurs in 
different species or strains, it is possible that the most potent response 
observed in the test animals is also representative of a human response. 
Exceptions to the use of the most sensitive species may be considered if the 
experiment contained significant flaws or if it can be demonstrated that the 
response is not qual ita ti ve ly or quanti ta ti ve ly similar to the response in 
human beings. Generally, however, these findings can only be made during the 
course of the assessment. The study selection process, therefore, should be 
especially directed towards the retrieval of studies which indicate the lowest 
observed effect levels without regard as to whether or not the studies are 
relevant to human health. One ini tia 1 source of this information is the 
Registry of Toxic Effects of Chemical Substances, or RTECS (NIOSH, 1986). 
RTECS lists by effect and species the study in which the most sensitive 
response was observed. 
4.4.4 In Vitro Studies. 
Given the large numbers of chemicals in and entering the marketplace, it 
is unlikely that existing laboratory facilities ·will be able, financially or 
logistically, to provide an adequate data base on chemical hazards (OTA, 
1981). Because in vitro studies can be done quickly and inexpensively, they 
are critical for setting priori ties on which chemicals should undergo more 
extensive testing, or for providing a toxicological basis for concern in the 
absence of adequate data on human beings or laboratory animals. Also, use of 
in vitro techniques can help to elucidate the biochemical basis for toxicity, 
and---u:> predict structure- activity relationships. Understanding the 
mechanisms by which a toxic effect is produced provides the conceptual basis 
for interpreting the results of epidemiological or animal toxicology studies, 
or for predicting the toxicity of a substance in the absence of such data. 
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5. Analysis of Study Results. 
5.1 Biological and Statistical Significance. 
Health effects studies may demonstrate a positive association between 
chemical exposure and an adverse response. They cannot, however, prove the 
absence of an adverse response. At most, they can only demonstrate that the 
magnitude of the response in the exposed population was below the level at 
which the study could detect a statistically positive association. When a 
significantly positive association between exposure and effect is found in a 
properly designed and conducted study (that is, when there is a sufficiently 
low probability that the association may have ·occurred by chance), the study 
is referred to as·a "positive" study for that health parameter. Studies which 
fail to demonstrate a significantly positive association are referred to as 
"non-positive" studies. Non-positive studies may include "negative" studies, 
or those studies in which clearly no positive associations were observed. 
There may also be studies in which positive responses or trends were 
suggested, but whose findings lacked statistical significance ("suggestive" 
studies). Finally, apart from issues of statistical significance, studies 
which had deficiencies in their design or conduct are limited in their 
abilities to produce biologically meaningful results. Depending on the nature 
of these deficiencies, these studies may be referred to as - either 
"inconclusive" or "inadequate." 
From a statistical standpoint, the ability of a study to detect a 
significantly positive association depends on the significance level used, the 
size of the exposed and control populations, and the background incidence of 
the effect. Most cancer epidemiology studies, for example, are unable to 
identify a positive association unless the response in the exposed population 
is SO percent above the background rates (OSH~, 1980). In the case of animal 
bioassays, the finding of no tumors in a test population of 100 animals does 
not demonstrate that a zero cancer risk is associated with exposure to the 
chemical. Instead, a statistical analysis would demonstrate that we can be 95 
percent confident that the actual incidence of tumors is no more than 4.5 
percent ( OTA, 1981). Thus, statistical methods may be employed on 
non-positive studies to estimate an upper bound on potential risk. 
In addition to statistical analyses, study results may be evaluated on the 
basis of their biological significance. Information related to the assessment 
of biological significance may come directly from the epidemiological or 
animal bioassay studies in which the effect was investigated. It may also 
come from other toxico logical areas, such as genetic toxicity, biochemical 
assays, and structure-activity relationships. As an example of such an 
assessment, an elevated incidence for a rare tumor in an exposed population 
may be judged to be biologically significant despite a lack of statistical 
significance relative to concurrent controls. Similarly, several studies 
showing non-significant elevations in the same tumor type may indicate a 
biologically significant effect. When considering such suggestive findings, 
the assessment should also be made concerning whether or not the design and 
conduct of the experiment were likely to increase or decrease the study's 
ability to detect a positive response. Conversely, a study may identify a 
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statistically significant association between exposure and effect which has 
limited biological significance. For example, a positive teratogenicity study 
in which the mother was administered toxic doses of a chemical may not be able 
to dissociate the direct effects on the embryo from the secondary effects 
resulting from maternal toxicity. 
5.2 The Use of Worst Case Risk Assessment. 
Estimates of the health risks associated with exposure to a substance 
depend on the assumptions employed in the risk assessment. A worst case 
assessment of public health risks is defined by the consistent use of 
reasonable worst case assumptions. If the current or projected exposure 
levels are below the levels derived from worst case risk assessment, then the 
conclusion can be drawn that, on the basis of the available information, 
exposure to the substance does not present a significant public health risk., 
If current or projected levels are at or above the levels derived from a worst 
case assessment, however, it may become necessary for risk assessments to more 
rigorously investigate the worst case assumptions. The intent of such an 
evaluation is to determine if less extreme assumptions are justified based on 
the best available data for the chemical in question. It is also possible 
that closer scrutiny may determine that assumptions more extreme than the 
worst case should be applied. 
The worst case assumptions are used to set a plausible upper bound on the 
level of health risk associated with a particular exposure, or a plausible 
lower bound on the exposure level below which no significant health effects 
are expected to occure If worst case assumptions are replaced by assumptions 
more reflective of the substance's observed toxicity, the confidence in the 
resulting degree of protection provided to the population depends on how 
closely the response of the study population reflects the response of the 
general population. Justification for this procedure may come from pertinent 
data on the exposure-response relationships, variations in population 
susceptibility and sensitivity, or the mechanisms of action. If greater 
certainty can be achieved, the confidence belt surrounding a risk estimate can 
be narrowed with no loss of public health protection. If, however, the 
confidence be 1 t surrounding a particular estimate of risk is narrowed in the 
absence of greater certainty, a loss of public health protection may result. 
Worst case assessment is, therefore, the primary means by which risks 
associated with chemical exposures are identified. If predicted exposure 
levels are less than those associated with health risks under worst case 
assumptions, a more rigorous analysis of these assumptions may be un-
necessary. In the absence of a more thorough analysis, or if the data are 
inadequate to precisely characterize the uncertainty regarding the toxic 
response to exposure, the worst case risk risk assessment represents the 
procedure upon which public health policy recommendations must rely. 
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5.3 Derivation of Action Levels. 
The analysis of the relationship between exposure and response results in 
an estimate of an "action level," or an exposure level above which there is a 
basis for health concern. The nature of the health concern is a function of 
the degree of analysis performed in the assessment, the severity and nature of 
the adverse effect, and the characteristics of the exposed population. Action 
levels are determined by considering the most sensitive effect of biological 
significance for the various exposure durations of concern. Action levels 
protective against the most sensitive effects consequently provide protection 
against the less sensitive effects as well. Depending on the risk 
extrapolation process, or the degree .of uncertainty associated with the 
assessment . of human risk, a range of potential action levels may be 
presented. Public health recommendations can then be developed using these 
action levels as a basis. 
The method by which action levels are derived depends on whether or not a 
threshold is presumed to exist. If a threshold is presumed, exposure to a 
substance below a certain level should not increase health risks. 
Non-threshold effects may occur through even a single interaction between a 
substance and a biologically critical molecule, and no exposure level can be 
estimated for which there is an absence of risk. Most health effects are 
considered to exhibit thresholds, although the existence of thresholds cannot 
be experimentally determined solely on the basis of quantal responses from 
whole animal or epidemiological data (IRLG, 1986; Klaasen, 1986). A 
non-threshold response is presumed when an effect may occur through a single 
irreversible lesion, as could occur when a substance interacts with DNA. This 
is a presumed mechanism of action for many chemical carcinogens (Flamm and 
Lorentzen, 1985; OTA, 1981; USEPA, l986a; Tomatis et al., 1982). Some 
carcinogens, referred to as "epigenetic" carcinogens (Shank and Barrows, 
1985), . may exert their effects through indirect mechanisms for which 
thresholds may exist. There is currently much uncertainty regarding the 
characterization of epigenetic carcinogens. Unless the dose-response 
relationship is developed to the degree that a threshold model can be 
presumed, therefore, action levels for carcinogenic substances should be 
derived using non-threshold assumptions. 
For threshold effects, the action level should be the estimated no adverse 
effect level (ENAEL). This estimation process involves the application of 
various uncertainty factors and adjustment factors to a response level 
determined from a health effects study. For non-threshold effects, any 
exposure is associated with some degree of health risk. Thus, the ENAEL for a 
chemical carcinogen is zero unless it can be demonstrated that its effect is 
produced through a threshold mechanism. In some cases, such as when decisions 
are made concerning whether or not a chemical should be produced commercially, 
a qualitative finding of carcinogenicity implying a zero action level may be 
sufficient. In the majority of cases, however, a non-zero estimate of an 
action level is needed. Instead of an estimated no adverse effect level, a 
level is specified for non-threshold effects at which the risk is considered 
to be insignificant. As a general principle, a lifetime risk one per one 
hundred thousand is used as a reference. Risk levels above one per one 
hundred thousand indicate the presence of a health concern, and that decisions 
regarding risk communication or risk management should reflect this concern. 
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Science policy decisions to use assumptions less extreme than the worst 
case in intraspecies and interspecies extrapolations result in higher 
estimates for recommended action levels. Action levels would be higher, for 
example, if the decision is made to use the median response from animal 
bioassays, rather than the most sensitive reponse, as a basis for estimating 
human risk. Action levels-would also be higher if the dose equivalency among 
animals is based on body weight when there is reason to believe that a surface 
area adjustment is warrantede In keeping with the principles of this policy, 
action levels based on less extreme toxicological assumptions than the worst 
case should be accompanied by documentation as to why these less ·extreme 
assumptions were chosen. 
Action levels may also increase as the assumptions regarding the degree 
and duration of exposure become less extreme. Cancer risk estimates, for 
example, are commonly expressed in terms of continuous exposure over a 70 year 
lifetime. Less extreme assumptions may sometimes be warranted if the 
exposures are intermittent or if the exposure occurs only during a fraction of 
one's lifetime. Other risk assessments may evaluate the degree of risk 
associated with food contaminants. In these cases, worst case estimates of 
risk are based on assumptions of maximum contaminant levels found or predicted 
to be found in food. These worst case risk estimates may be lowered if data 
are available from which to derive more certain estimates of exposure. As 
with the toxicological assessment, adequate documentation is needed if action 
levels are based on exposure assumptions less extreme than the worst case .. 
It should be emphasized, however, that the cornerstone of public health 
policy is the prevention of disease. It is not the intention of the Maine 
Bureau of Health, therefore, to advocate a deterioration in environmental 
quality to the level of the derived action level. Conversely, if background 
levels of a substance are high enough to present a health concern, public 
health policy would indicate that exposure levels not be significantly 
increased over background concentrations, and even that they be decreased when 
it is feasible. 
So4 Peer Review of Risk Assessments. 
Peer review is necessary to the proper evaluation of a scientific issue. 
Peer review of risk assessments is especially important in that these 
assessments often involve consideration of information from several scientific 
disciplines. Agencies or organizations conducting risk assessments rarely 
have expertise in all relevant disciplines. Instead, assurance that the 
studies are properly conducted and that sound judgments are drawn from them 
can be accomplished by peer review from appropriate scientists. 
The Maine Bureau of Health has a peer review committee, the Scientific 
Advisory Panel (SAP), which was established by the same legislation which 
created the Hazardous Air Pollutant Program (M.R~S.A., 1984). The SAP reviews 
the Bureau of Health's assessments on hazardous air pollutantso The Panel may 
also review the health risks pertaining to other environmental issues, if such 
additional reviews are determined by the Bureau of Health to be justified. In 
carrying out its review, the SAP may request further assistance of experts in 
particular scientific disciplines. 
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Because of its principal role as a peer review committee for risk 
assessments, the Scientific Advisory Panel has been asked, and has agreed, to 
review this risk assessment policy and may review all subsequent additions and 
revisions. By separating the science policy issues from issues pertaining to 
the interpretation of scientific studies, the attention given to the 
development and review of risk assessments can be more clearly focused. This 
increase in the efficiency of the risk assessment process greatly assists the 
Bureau of Health and the SAP in their efforts to have the assessments reflect 




6. Risk Communication. 
Risk assessment findings provide the health criteria for the assessment of 
environmental quality. As suCh, they influence both individual and societal 
decisions regarding the control of exposures to toxic substances. Because 
they must often be considered in a such contexts, these findings must be 
communicated in a way that is comprehensible to the public. Communication is 
made both to individual citizens who must make decisions regarding the 
management of their own health status, and to risk managers who must make 
societal decisions regarding acceptable health risks. 
The precise communication of risk assessment findings is perhaps the most 
difficult part of the entire risk evaluation process. There are few areas of 
consensus among the scientific community on risk assessment policy issues. 
While this lack of agreement is beneficial to the development of better risk 
assessment methods, it may result in much confusion when risk assessment 
findings provide a basis for political decisions. Furthermore, many of the 
studies useful to risk assessment are not directly translatable into a 
description of human health risks. This limitation is particularly relevant 
when the health risks of low-leve 1, long term exposures are to be estimated. 
Finally, given the increasing numbers of chemicals present in the environment 
with the potential to cause adverse effects, as well as the growing 
recognition of the hazards associated with accidents involving toxic 
substances, risk communication efforts must recognize the cumulative impacts 
on society's perception of risk resulting from the identification of new 
environmental health threats. In order for the scientific process to remain 
credible, the limitations of the underlying database must be described. Also, 
the extent of our knowledge and ignorance about a particular exposure 




SECTION I II. EXPOSURE ASSESSMENT 
The objective of the exposure assessment is to characterize as fully as 
possible the potential for, and degree of human exposure to a substance. This 
includes a qualitative or quantitative estimate of the exposure level, as well, 
as estimates of the exposure durations associated with each exposure level. 
As will be demonstrated later, this exposure information applies directly to 
the quantitative assessment and to the ultimate determination of whether or 
not exposure to this substance presents a public health threat. 
Information on exposure may be direct or indirect. Direct information 
includes actual measurements of chemical concentrations in ambient or indoor 
environments, biological tissues, or food. Indirect sources of information 
include data related to the sources of chemical release into the environment. 
Another indirect estimate of exposure can be obtained through the use of 
various theoretical models. 
7. Sources of Exposure 
The source assessment provides information on the sources of exposure to 
the substance under investigation. Its purpose is to identify all potential 
avenues of human exposure to the substance. It begins with a general 
description of the substance's production and use, followed by a quantitative 
description of the releases of this substance into the indoor and ambient 
environments. 
7.1 Production and Use. 
Information presented in this subchapter should include a description of 
the amount of the substance produced and how it is produced. Special mention 
should be made of any production facilities in Maine. Production and use 
information also includes a description of how and to what extent this 
substance is used, again emphasizing usage information in Maine. From this 
information, an assessment can be made of prevalence of exposure, as well as 
the areas of the state where significant exposures are most likely to occur. 
7.2 Bnissions. 
Information presented here describes the substance's ability to be emitted 
into various environmental media. Emissions can be described both 
qualitatively and quantitatively. A qualitative description involves a review 
of the substance's physical and chemical properties, as well as production and 
usage characteristics. The quantitative description is a presentation of 
either emission factors or actual test results regarding substance levels in 
air or water effluents. These kinds of quantitative data are generally 
unavailable, but could be very useful for modelling purposes if they are 
obtained. The Maine Bureau of Health recognizes the potential health risks 
associated with occupational environments, and the growing concern that 
non-occupational indoor exposure to toxic substances may present significant 
health risks. Thus, these exposure situations may need to be discussed in 
addition to the discussion of the emissions into the ambient environment. 
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7s2.1 Methods of Estimation or Measurement. 
Quantitative estimates of human exposure to a toxic substance may depend, 
at least in· part, on estimates of its emissions into the environment., These 
emissions estimates may vary according to the measurement or estimation method 
method employed. Thus, in developing its exposure assessment findings, the 
risk assessment may consider the methodologies used to produce the 
quantitative estimates. 
Depending on the importance of the emissions estimate to the exposure 
assessment, a discussion of the methods used to derive emissions may require 
discussion. This discussion may include a description of what emission 
factors are available, the methods associated with the actual measurement of 
emissions, or how physical and chemical properties are to be evaluated when 
emissions estimates cannot be derived by more direct means. A discussion 
concerning the quality of the estimation or measurement methods should also be 
included. 
7.2.2 Emissione into Occupational Environments. 
Little quantitative information exists on substance emissions in 
occupational environments. MUch of the available information is qualitativeo 
Based on the physical and chemical properties of the substance, and the 
industrial processes involved in its use or formation, some assumptions may be 
made regarding emissions. Volatile substances, as well as combustion or 
comminution processes leading to air entrainment of particles, are of 
particular concern in this regard. 
The usefulness of these emissions estimates depends on the methods used, 
and the uncertainties associated with their design and conduct. A discussion 
of these uncertainties may be necessary in order to place the quantitative 
findings into a qualitative perspective of their significance. The 
uncertainties associated with emissions estimates in occupational environments 
may be relatively unimportant if sufficient exposure monitoring data are 
available. When, however, exposure monitoring data are inadequate, emissions 
estimates from specific sources may provide valuable information for use in 
the estimation of exposure levels. 
7.2.3 Emissions into Non-Occupational Indoor Environments. 
Toxic substance emissions in non-occupational indoor environments may come 
from a variety of sources. Air contamination of indoor environments may 
result from the same volatilization, or from combustion or communition 
processes, just as they do in occupational environments. Volatilization may 
occur from either solid or liquid surfaces. Combustion emissions may result 
from cigarette smoking, or from utilization of gas stoves or indoor heating 
devices. emissions may also result through the use of a particular consumer 
product. Generally, quantitative information is limited with regard to toxic 
substance emissions of this type. Qualitative information, based on the 
substance's physical and chemical properties or product usage rates, may 
provide general guidance for the estimation of emission potential in the 
absence of quantitative data. 
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Uncertainties associated with the estimation of emissions in these indoor 
environments need to to discussed. This discussion is particularly relevant 
when the · air emissions of volatile substances · in drinking water are 
estimated. These emissions, while as yet poorly quantified, may contibute 
significantly to the human exposure. (NRC, 1986). 
7.2.4 Emissions into the Ambient Environment. 
Emission factors or emission test results may be available for certain 
substances emitted into the ambient environment from specific sources. In 
addition, generic emission factors may exist from which environmental releases 
can be estimated in the absence of source-specific data. In general, however, 
few data exist for emission sources of toxic substances. Thus, the same 
concerns regarding the adequacy of emissions data on occupational or indoor 
environments apply as well to the discussion of most chemical emissions into 
the ambient environment. 
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8. Parameters for Deriving Quantitative Estimates of Exposure 
8.1 Monitoring Information 
Monitoring information is the key exposure component for quantitatively 
assessing risks presented by chemical substances. It is an important factor 
in the evaluation of epidemiological studies and is needed in order to assess 
the health significance of current exposures. Monitoring data provide actual 
measurements of exposure, and thus provide concrete evidence concerning the 
extent and magnitude of an environmental problem. For this reason, monitoring 
data are highly relevant to risk assessment. 
Unfortunately, several limitations must be considered when evaluating 
moni taring information. The adequacy of the monitoring data base must be 
considered, therefore, when deriving conclusions concerning the correlation 
between exposure and effect. Monitoring data are rarely collected in any 
systematic way. Except when published in scientific journals, they are 
difficult to access. Moreover, consideration needs to be made that the 
presence of other substances in the environment could confound the health 
assessment. This is true for assessments of situations in which not all of 
the potentially toxic substances may have been identified, including those 
which must make use of historical information for chronic disease 
investigations. 
In addition to design considerations, attention should be given to 
limitations in the sampling and analytical procedures. The assessment should 
specify negative data within the context of sampling and analytical 
limitations, and the degree of assurance that the monitoring was conducted in 
the right place or during the right time periods. For example, even if 
monitoring indicates the presence of a substance, it may be possible that 
higher levels of the substance were present in an area which was not 
monitored. Also, detection limits and analytical sensitivities vary for 
different compounds or when different sampling and analytical protocols are 
used. 
8.1.1 Sampling and Analytical Methodologies. 
There are various methodologies available for measuring substance 
concentrations. It is important that these methodologies be described for the 
particular substance under investigation. Of primary importance are the 
sampling time, and the accuracy, precision, reliability, and detection limits 
of the analysis with regard to different environmental media. Also of concern 
are the potential for losses during sampling and analysis and the possible 
interferences resulting from the presence of other substances. Many of these 
concerns could be addressed by suitable quality control and quality assurance 
procedures. Depending on the purpose and scope of the risk assessment, these 
procedures may warrant discussion. 
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8.1.2 Levels in Occupational Environments. 
Monitoring data from occupational environments is used to relate exposure 
to the observed health effects. Relevant information includes the type of 
industry monitored, the type of job monitored within that industry, the range 
of measured values, the averaging times, the analytical methodology used, and 
the number of samples taken. Because many studies examine chronic effects, 
this criterion should also reflect historical trends in these parameters. For 
chemicals which show significant acute effects, such as the aggravation of 
asthma, exposure data should include short-term or peak concentrations. For 
chronic effects, such as cancer, information relevant to the determination of 
long-term average concentrations is needed. 
8.1.3 Levels in Non-Occupational Indoor Environments. 
Monitoring information from non-occupational indoor environments includes 
data on contaminant levels in water supplies, indoor air, and on surfaces. 
Contaminated water supplies have received considerable attention, as evidenced 
by the passage of the Safe Drinking Water Act and the development of health 
advisories and standards by such agencies as the U.S. Environmental Protection 
Agency, the National Research Council, and the World Health Organization. 
Attention to indoor air pollution problems has been considerably less 
involved. For certain chemicals, such as radon and formaldehyde, 
epidemiological studies have been conducted in non-occupational indoor 
environments (see, for example, Vaughan et al., 1986). Such monitoring data 
thus provides a needed exposure database for conducting risk assessments on 
these environments, as well as a quantitative basis for comparing the health 
risks in non-occupational environments to occupational settings. Even when 
monitoring data from non-occupational indoor environments are available, 
however, they are not 1 ikely to be accompanied by relevant or useful health 
data. Nonetheless, this monitoring information could still be used to 
identify potentially significant sources of exposure and, possibly, sources of 
potential health risk. 
The presence of toxic substances in residential environments may be of 
particular concern with respect to infants and small children. Skin 
absorption of substances may be high in infants, especially premature infants, 
relative to other human populations (Dugard, 1987). In addition to 
pharmacological concerns, there are also behavioral factors associated with 
infants, whose oral exploration of their environment may include a wide 
variety of substances not normally regarded as food (WHO, 1986). 
8.1.4 Levels in the Ambient Environment. 
Exposure to toxic substances in the ambient environment may come from the 
air, water, or soil. A single emissions source may have impacts on more than 
one environmental mediume For example, air emissions of persistent compounds 
may be deposited on land, where they can accumulate in the soil and, possibly, 
throughout the food chain. Conversely, chemicals adsorbed onto soil particles 
may create an air pollution concern through particle re-entrainment. 
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Environmental sampling may be conducted to assess impacts from particular 
point sources, or to assess the general environmental quality of urban, rural, 
and remote locations. Ambient air concentrations for a particular substance 
depend on the meteorological conditions and the rate at which 'the substance is 
released into the ambient air. Thus, several samples may be needed to assess 
the peak and average air concentrations of a substance at a particular 
location. Ambient water measurements are done to assess the quality of 
surface or groundwater supplies. Concentrations of toxic substances in water 
may vary depending on the proximity of these substances to a contamination 
source, the rate at which they are released into the environment, and the 
depth at which water samples are taken. Finally, surface and subsurface soil 
samples may be taken. Surface samples measure levels resulting from spills, 
intentional land spreading, or the deposition of airborne substances on land 
or water. Measurement of soil contamination is especially important when 
considering risks to young children, who may ingest or absorb through their 
skin potentially harmful levels of these chemicals (WHO, 1986). Subsurface 
samples are taken to measure contamination resulting from leaking underground 
storage or waste sites, or the percolation of contaminants through the soil. 
8.1.5 Levels in Food. 
Certain substances have the potential to be· present in food. This may 
result from direct or inadvertant application of pesticides, through treatment 
of animals with antibiotics or hormones, or through food processing. 
Quantitative exposure information on these substances come predominantly from 
the U.S. Food and Drug Administration. Other data sources may include market 
basket surveys from industry or state agencies. All of these data, 
unfortunately, are generally quite limited (GAO, 1986). · 
In addition to raw and processed foods, a particularly important source of 
food contamination is human milk (WHO, 1986). Levels of highly persistent, 
fat soluble chemicals may accumulate in breast milk to levels which are 
potentially harmful to the infant. As with chemical monitoring of foods, more 
data are needed to properly assess this important route exposure to 
potentially harmful chemicals. 
8.1.6 Levels in Biological Tissues. 
Compounds which bioaccumulate in biological tissues can indicate their 
presence when levels in other environmental media are too low to be 
detectable. Monitoring tissue levels of these compounds can also indicate 
exposures which may be missed by ambient sampling due to spatial or temporal 
variations in environmental levels. 
In addition to data on environmental levels, monitoring can also help to 
provide direct estimates of body burden. These include the measurement of 
compounds in plants and animals consumed by human beings. Data on human 
tissue levels are also direct parameters of exposure. Levels of the parent 
compound or its metabolite in blood, exhaled air, or urine are indicative of 
current or past exposure. Levels of substances in fatty tissues may be used 
to assess cumulative exposures. These measurements are particularly useful 
for fat soluble compounds, such as dioxins and polychlorinated biphenyls, 




8.1.7 Levels of Substances Occurring in Mixtures. 
The presence of chemicals in addition to the substance of concern may also 
have an impact on the risk assessment. In some cases, these additional 
compounds may actually be responsible for the observed or suspected health 
effect. Should this occur, a health effect may be ascribed to a particular 
substance simply because the presence of these other substances was not 
adequately considered. This concern was raised, for example, in the 
interpretation of epidemiological studies which indicated a correlation 
between skin diseases and arsenic levels in drinking water (NAS, 1977). 
Similarly, if an analysis of a water supply does not indicate the presence of 
priority pollutants, a potential cause may be missed if the causative agent is 
a non-priority pollutant. A potential cause may also be missed if the 
pollutant scan indicates the presence of compounds that may eventually prove 
to be the causative agents, but which, because of their known toxicological 
characteristics or concentrations, are not be considered to be associated with 
the health effect of interest. 
Consideration of exposure to other substances is also important to the 
assessment of possible combined or interactive effects. Exposure to one 
chemical may produce additive, synergistic, or antagonistic effects on the 
toxicity of another chemical. Monitoring information on compounds which have 
the potential to interact with the substance under investigation is therefore 
an important component in assessing the public health threat presented by a 
particular exposure situation. 
8.2 Mbdelling Information. 
For situations in which adequate emissions data are available, population 
exposures may be estimated using mathematical models. When monitoring data 
are available, modelling data may be used in conjunction with the actual 
exposure information. Modelling data may, for example, identify probable 
areas of high pollution impacts from air pollution sources, and thus be useful 
in the siting of monitoring devices. For cases in which monitoring data are 
not available, modelling data may provide the only quantitative estimate of 
exposure. MOdelling data are thus particularly useful for estimating 
exposures resulting from anticipated emissions. They may also help in the 
estimation of impacts which are not measurable by available monitoring 
techniques. 
Modelling data, however, are subject ~to limitations. Although they help 
to overcome some of the uncertainties of spatial and temporal fluctuations 
which limit the precision of contaminant impact estimates based on monitoring 
data, the reliability of modelling results also depends upon a number of 
assumptions. The degree of confidence placed on these assumptions depend on 
the quality of the input data, the appropriateness of the model to the 
assessment of the exposure situation of concern, and the extent to which the 
models have been verified in similar field situations. Of particular 
importance is the ability of the models to produce reasonable exposure 
estimates consistent with the assumptions of worst case risk assessment. 
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8.3 Assessment of Body Burden from Different Exposure Routes 
Estimation of the total intake of a toxic substance is needed in order to 
determine whether a critical dose or a reference risk level is reached. The 
body burden criterion is thus important in the proper derivation of action 
levels, and in determining whether or not an action level has been exceeded in 
a particular exposure situation. Exposure from a combination of sources may 
produce a health effect or significant health risk, while exposure to any 
single one of these sources would not. One such circumstance would be in 
derivation of acceptable drinking water levels for contaminants ingested by 
human beings through inhalation or dermal exposure routes. Also, in the 
assessment of the health impacts from a source of environmental contamination, 
indirect as well as direct sources of exposure may need to be considered. 
Lead emitted in the air exhaust of a smelter, for example, will deposit on the 
ground, and thus may present a health risk for children playing in the 
surrounding area. Therefore, the health risk could be underestimated if the 
risk assessment evaluated only the impacts of the air emissions. 
The information obtained from the monitoring and modelling subchapters may 
be used to estimate the body burden from different routes of exposure and from 
different environmental media. As was mentioned above, uncertainties are 
associated with both of the exposure estimation approaches. Typically, 
therefore, exposure estimates are presented as a range of values. 




9. Environmental Fate and Transport. 
9.1 Environmental Dispersion and Chemical Transformations. 
Once a substance is released into the environment from an emission source, 
it may undergo modifications which could influence -its toxicity. Dispersion 
through air, water, or soil may reduce the concentrations to which human 
beings are exposed, and thus, the level of health risk. The substance may 
also be chemically transformed in these media to a form that is either less 
toxic or more toxic than the parent compound. The extent to which these 
substances persist in the environment should also be considered, as 
persistence influences the potential for cumulative exposure impacts over 
time. Knowledge of a substance's environmental persistence or its 
transformation products is also important in assessing the degree to which 
such processes may influence population exposure. 
9.2 Bioconcentration and Bioaccumulation. 
In addition to processes which disperse a substance once it is released 
into the environment, there are processes which result in its concentration. 
Substances such as metals and lipid soluble compounds can bioconcentrate in 
plant and animal tissues. Furthermore, these substances may bioaccumulate 
through the food chain. Bioaccumulation enhances the health risks for human 
beings, who occupy the highest level of the food chain. Consideration of 
bioconcentration and bioaccumulation is especially important when assessing 
long-term, low level emissions of substances into the environment; exposures 
which may initially appear to have negligible environmental importance may be 




SECTION IV. HAZARD IDENTIFICATION 
Information relevant to the identification of a substance's toxicity is 
evaluated in the Hazard Identification section. The manifestation of an 
adverse health effect is a function of the concentration of the toxic 
substance at the site of action and its duration and biological activity at 
the site (Renwick, 1982; Tichy, 1983). The toxicity of a substance may vary 
substantially between different species, strains, or sexes. It may also vary 
within the same species, sex, or strain when the substance is administered 
through different routes of exposure or at different levels of exposure. 
Variability is attributable to differences in the bioavailability of a toxin, 
as well as to differences in the nature of the lesions formed by the inter-
action of the toxin with its biological receptor. The issue of bioavaila-
bili ty is important to risk assessment in that a toxin's concentration and 
duration at the site of action is related the pharmacokinetic characteristics 
in the organism involved. Biological activity is influenced by specific 
genetic and environmental factors. The kinds of biological activity required 
to produce and adverse health response may be simple or complex. Also, some 
kinds of biological activity may only require short periods of time before a 
toxic response occurs, whereas others may require longer periods of exposure. 
The Hazard Identification, therefore, reviews data on the substance's 
pharmacokinetics, as well as on the kinds of biological effects it produces at 
various dose levels and exposure durations. In this section, criteria may 
need to be followed in order to determine the potential health significance of 
particular study findings. Such criteria are especially important when 
determining the statistical significance of dose-response patterns between 
exposed and non-exposed study populations. The overall health significance of 
these toxicological investigations is evaluated in the Hazard Assessment 
section (Section V). 
10. Identification of Relevant Pharmacokinetic Parameters 
Assessment of the pharmacokinetic literature is needed in order to 
understand how and to what extent a substance is absorbed, distributed, 
metabolized, and excreted. These processes determine the dose of a substance 
(or its metabolites) at the target site. These parameters may, in turn, be 
influenced by the physiological characteristics of the organism, and by the 
exposure regimen. Once at the target site, factors influencing cellular 
uptake of a chemical include its rate of diffusion across and between cellular 
membranes, and active or facilitated transport processes. Figure 10.1 
presents a summary of the routes by which chemicals are absorbed, distributed, 
and excreted in the body. Figure 10.2 presents a specialized summary 
pertaining to the pharmacokinetic pathways in pregnant women. 
Factors which affect any of the pharmacokinetic parameters may also affect 
a substance's toxicity. Thus, comparisons of pharmacokinetic parameters may 
help to identify reasons for interspecies and intraspecies differences in the 
toxic response to chemical exposure. These comparisons may also provide a 
basis for assessing the impacts of different exposure doses, durations, and 
routes of administration on toxicity. Such analyses are needed for the Hazard 









Figure 10.1. Routes of Absorption, Distribution, and Excretion of Toxicants 
in the Body. 
Source: Klaasen, C.D9, 1986, "Distribution, Excretion, and Abso:rpti0n of 
Toxicants," in C.,D. Klaasen et al. (eds.), Casarett and Doull's Toxicology, 
Third Edition, ~1.'.lc~illan Publi<:hing Company, New York. P. 33 .. 
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Figure 10.2. Representation of the Relation between Phar11acokinetics and 
Pharmacodynamics. Ff = free toxicant; BT = bound toxicant; T.vi = toxicant 
metabolite. 
Source: IRLG, 1982, Interagency Regulatory Liaison Group Workshop on 
Reproductive Toxicity Risk Assessment, Environ. Health Perspect., Vol. 66, pp. 
193-221. 
findings from different studies in order to determine wi1ether or not the 
findings from specific studies are directly relevant to human beings at the 
exposure levels and exposure routes of concern. 
The toxic respcas~ to a chemical exposure may be due to the action of the 
parent compound, one or more of its metabolites, or a combination of both. 
The neurotoxicity associated with exposure to trichloroethylene, for example, 
is caused both by exposure to trichloroethylene itself, and one of its 
metabolites, trichloroethanol (WHO, 1984). Of all pharmacokinetic }/1·operties, 
metabolism is considered to be the most variable within and between species 
rRall, 1969). Therefore, intraspPcies and interspecies comparisons should 
carefully consider differences in metabolism. Particularly, differences in 
the rate of metabolism and in the pathways leading to different metabolites 
should be analyzed. 
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PHASE I 
Expose or Add 
Functional 
PHASE II 
Groups Primary Biosynthetic Secondary 
XE.NOBIOTIC ----- - Produrt 
~;~~~~~~ p,ol :::::::::~ -Foreign Compounds 
LIPOPHILIC ---------HYOI=\OPHILIC 
(Ionizable) 
Figure 10.3o Integration of Phase I and Phase II Biotransformation Reactions. 
Source: Sipes, I.G., and Gandolfi, A •. J., 1986, "Biotransformation of 
Toxicants," in C.D. Klaasen et al. (eds.), Casarett and Doull's ~oxicology, 
Third Edition, Mac\1illan Publishing Company, New York. p:-64--:--- ·· 
The nature and degree of metabolism depends on the concentration of the 
substance at the site of metabolism, the biochemical characteristics of the 
metabolizing tissue, and the presence of potentially modifying factors. The 
liver is the principal metabolizing organ, although metabolism also occurs at 
other sites, such as the lung, kidney, skin, and gastrointestinal mucosa 
(Sipes and Gandolfi, 1986). The metabolic rates and capa·cities may not be as 
high in these extrahepatic tissues. Their contribution to the total 
pharmacokinetic profile, however, may be significant for low level chemical 
exposures over long periods of time (Sipes and Gandolfi, 1986). 
Metabolism is especially important with regard to lipophilic chemicals, 
which are easily absorbed but poorly excreted from the body. The primary 
purpose of metabolism, therefore, is to make these compounds more water 
soluble and available for excretion. The two general types of metabolic (or 
biotransformation) rea.ctio:1s c.re presented in Figure 10.3. The first type, or 
Phase I reactions, involve oxidation, reduction, or hydrolysis. In addition 
to making these compounds more water soluble, Phase I reactions add or expose 
functional groups which prepare the chemical for Phase II reactons (Sipes and 
Gandolfi, 1986). The chemical is conjugated with endogenous molecules in the 
Phase II reactions, which further increases its water solubility. 
Whether or not a metabolite is toxic depends on the chemical and 
structural properties of the parent compound, as well as on the biochemical 
reactions it undergoes. In addition, other chemicals may modify the 
metabolism of the chemical under study. Several pathways may exist, each of 
which may be described by parameters concerning its enzymatic affinity and 
capacity. A chemical may also possess the potential for enzyme induction or 
inhibition. Thus, a chemical may modify its own metabolism over time through 
its effects on metabolizing enzymes. 
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11. Identification of Relevant Toxicity Endpoin~s. 
All known or suspected adverse health effects resulting from exposure to 
the substance undergoing investigation should be identified. This process 
includes the identification of frank, clinical health effects (for example, 
asthma), as well as subtler indications of toxicity (for example, small 
changes in pulmonary function measurements). For risk assessment purposes, it 
is important that the most sensitive effects of exposure are identified. 
Identification of other, less sensitive responses should also de done. This 
further effort provides the Hazard Assessment section (Section V) lvith the 
basis to evaluate the constellation of health effects associated with 
exposure, and the progression of effects which may occur as the exposure dose 
increases. 
In the health effects identification, therefore, the toxicological and 
epidemiological literature on a particular substance is reviewed. This 
chapter is divided into three parts: Identification of Critical Health 
Effects (genetic toxicity, carcinogenicity, reproductive and developmental 
toxicity, acute/chronic toxicity); Identification of Multiple Chemical 
Exposure Effects; and Identification of Sensitive Populations. The types of 
effects requiring the extensive analysis in most risk assessments have been 
genetic toxicity, carcinogenicity, and reproductive and developmental 
toxicity. Because these effects are of national public health significance, 
and have been recognized as representing particular concern with regard to 
toxic substance exposure, they have been segregated from the general 
acute/chronic toxicity category. 
The classification system for assessing the different types of health 
effects follows the one developed by the National Institute for Occupational 
Safety and Health (NIOSH) to organize health effects information in its 
Registry of Toxic Effects of Chemical Substances (NIOSH, 1986). It also 
conforms f() the paradigm deveioped by the Maine Bureau of Health for ranking 
hazardous air pollutants (Anderson, 1986). These four health effects 
categories may be further divided into subcategories when appropriate. For 
example, as studies more fully document the low level exposure effects 
regarding other health endpoints, such as immunotoxici ty and neurotoxicity, 
this chapter should be modified accordingly. 
The occurrence of a specific health effect in a study population depends . 
largely on the exposure dose and the exposure period. The exposure conditions 
are thus important considerations in evaluating all health effects studies. 
Consequently, evaluation of these studies should be segregated on the basis of 
the exposure periods. The types of responses observed during these exposures 
can be classified according to whether they are reversible or irreversible, 
and as to whether they are immediate, delayed, or latent. A summary of this 
classification system is presented in Table 11.1. For typical animal 
bioassays, exposure periods follow this general classification system: acute 
effects (one day or less), subacute effects (one month or less), subchronic 
effects (one to three months), and c.ltronic effects (more than three months) 
(Klaasen, 1986). These categories are generally applicable to the evaluation 
of human responses as well. Differences may occur., however, especially in the 
assessment of chronic exposure effects. Thus, when defining the exposure 
periods for a particular substance, the assessment should consider the 
underlying health database. 
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Table 11.1 
Health Effects Categories 
I. ACUTE EFFECTS I I I. SUBCHRO~IC EFFECTS 
A. Reversible A. Reversible 
1. I!Til'1ediate 
2. Delayed B. Irreversible 
1. Immediate 
B. Irreversible 2. Latent 
1. Immediate 
2. Latent 
II. SUBACLITE EFFECTS IV. CHRONIC EFFECTS 
A. Reversible A. Re\·ersible 
B. Irreversible B. Irreversible 
1. Immediate 1. Irn:rwjiate 
2. Latent 2. Latent 
The inclusion of the subchapters on interactive effects and sensitive 
populations underscore the fact that most health effects may have several 
potential causes. Most of the risk assessment is devoted to the investigation 
of health effects with a focus on the toxicity of particular substance. The 
purpose of these two subchapters, on the other hand, is to evaluate a 
substance's toxicity within the context of actual or potential human exposure. 
11.1 Identification of Critical Health Effects. 
11.1.1 Identification of Effects on Genetic Material. 
Genetic toxicity concerns the interaction of chemical and physicRl a~ents 
with the pL'ocess of c~llular heredity (Thilly &~d Call, 1986). Genes, .!hich 
comprise the basic units of heredity, are comprised of varying lengths of 
dt:oAyribonucleic acid (DNA) and associated proteins. Genes are organized on 
chromosomes. The human somatic cell normally contains 23 pairs of 
chromosomes. The total length of DNA in all of the chromosomes is more than 5 
billion nucleotides (NRC, 1983b). Only a small part of the DNA (about 1 
percent) is required for known gene functions (NRC, 1983b). The function of 
most of the remaining DNA is unknown (NRC, 1983b). 
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The ability of an agent to interact with genetic material may lead to 
chronic irreversible effects such as cancer or effects on reproduction or 
development. There is a close correlation between genetic toxicity and the 
development of cancer in human beings and laboratory animals (!ARC, 1980; 
OSTP, 1985). Genetic toxicity may also play a role in the development of 
other chronic diseases such as atherosclerosis (NRC, 1983b). 
Three general types of genetic toxicity can be defined (NRC, 1983a; Thilly 
and Call, 1986). Gene mutation (point mutation) affects a single gene by 
producing small changes In the DNA sequence. A chromosomal mutation 
(clastogenesis) affects blocks of genes in one or more chromosomes. A genomic 
mutation (aneuploidy or polyploidy) affects the number of chromosomes without 
altering the chromosome structure itself. All three major types of genetic 
toxicity elicit DNA repair mechanisms (McQueen and Williams, 1985). These 
mechanisms are described in Table 11.2. 
These types of genetic toxicity may occur through a variety of different 
mechanisms. Chemicals may damage DNA by covalent binding, intercalation, 
chromosomal protein binding, or by causing alterations in the synthesis and 
structure of DNA precursors (Bradley et al., 1985). Other types of events may 
occur by errors in DNA synthesis or repair (Bradley et al., 1985; OSTP, 1985), 
by w1.emically-induced alterations in the regulation of gene expression 
(Bradley et al., 1985; OSTP, 1985), or by stimulation via cytotoxic mechanisms 
of chemicals which are capable of damaging DNA (such as free radicals) 
(Halliwell, 1987). 
Although an agent may effectively cause one kind of genetic damage, it 
will not necessarily cause all kinds (Thilly and Call, 1986; NRC, 1983b). 
This finding is understandable in light of the fact that these different types 
of mutations may be created by very different mechanisms. Genomic mutations, 
for example, are typically caused by a chemical interaction with spindle 
fibers, whereas gene and ·chromosomal mutations require chemical interactions 
with DNA (NRC, 1983b). Moreover, agents, such as radiation, can be very 
effective at breaking chromosomes and causing chromosomal mutations, but are 
less effective at producing changes in individual nucleotides (NRC, 1983b). 
Other chemicals may react with DNA bases to produce gene mutations, but are 
less effective at breaking chromosomes (NRC, 1983b). 
Several tests for genetic toxicity have been developed to detect various 
types of genetic damage. A summary of these tests is presented in Table 
11.3. In many cases, a substance may require metabolic activation to become 
biologically active. Therefore, certain metabolizing enzymes may be 
incorporated into in vitro genetic toxicity tests to address this possibility 
(WHO, 1985). Criterra-1tor evaluating genetic toxicity studies have been 
developed by several academic and science policy organizations (NRC, 1983b; 
!ARC, 1980; WHO, 1985; Jackson and Per tel, 1986). These criteria do not 
differ substantially from each other, except in the level of attention they 
devote to the specific genetic toxicity endpoints. Appropriate criteria 
should be followed, therefore, when the findings of these tests are to be 
evaluated in the risk assessment. 
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Base excision repair 









:r.ta!llmalian DNA Repair Mechanisms 
A.:ticr: 
Rerr.:;ves t>:..:lky, ncncc,dir.g !esk...,~ fro!"'". the D~A in :1 ma:-;ner similar ~o 
but not identical \\-ith bacterial nucleotide excision repair 
Permits reinsertion of the proper ba:5e into the gap left in the D:-JA by 
' the action of enzymes that effect the excision of inappropriate bases 
from D~A as the free base (DNA glycosylases), avoiding scission of the 
DNA backbone, as well as a system similar to the bacterial one 
requiring strand scission. Included are direct demethylation by transfer 
of a methyl group to an acceptor protein and AP site repair (direct 
repair of a removed base) 
Rejoins single- and double-strand breaks ~ith the addition of few or no 
additional nucleotides through the action of a sealing enzyme 
Light-activated mechanism specific for the breakage of the t.:V-induced 
covalent bond attaching two pyrimidines in a cyclobutane-type ring 
System once believed to occur in mammalian systems but now 
controversial, by which bulky, noncoding lesions are transferred to 
DNA synthesized after damage 
Process that may function in mammalian cell~ as an alternative to 
recombination repair in which the bulky lesions are bypassed and the 
gap created filled 
Still speculative (for mammalian systems) rt-pair system in which D~A 
damage triggers the induction .of enzyme systems to remove the damage 
Source: OSTP (Office of Science and Technology Policy), 1985, "Chemical 
Carcinogens; A Review of the Science and Its Associated Principles, February, 
1985," Federal Register, Vol. 50, pp. 10371-10442. 
Most genetic toxicity tests are unable to measure DNA damage directly. 
Rather, they measure damage indirectly through observations of phenotypic 
changes. Close surrogates, however, to the direct measurement of DNA damage 
ar~ tests which measure DNA repair. Because it is a measure of DNA repair, 
unscheduled DNA synthesis (UDS) is among those tests with the broadest 
sensi ti vi ty for detecting genotoxic chemicals (McQueen and Williams, 1985; 
lARC, 1980). UDS is a step in the excision repair process that is elicited by 
all major types of DNA damage (McQueen and Williams, 1985). Several other 
methods have also been identified for measuring excision repair (See Table 
11.4), although UDS is regarded as the simplest and most generally applicable 
method for screening (IARC, 1980). 
EJucid&ti·)n of genetic toxicity results may be achieved through studies 
designed to assess the binding or biochemical interactions of chemicals with 
cellular macromolecules s Many carcinogens, for example, are electrophiles 
capable of interacting covalently with DNA (Miller et al., 1966; Miller and 
Miller, 1971). Every nucleoside has the potential for interacting covalently 
with chemicals (Singer, 1975). The interpretation of covalent binding 
studies, however, is subject to considerable uncertainties. The site of 
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Table 11.3 
Sumnkl.ry of C'1mmonly Used Genetic Toxicity Tests 
1_. Bacteric.l Mutation Assays (f:3. 1_mcne11a typhimurium, E::cherichia coli) 
2. Yeast Cultures (Saccharomyces cerev1_sis1ae, Sa1lzos2ccharomyces---poirbe) 
J• Higher Plants 
4. Mammalian Cells 
Unscheduled DNA Synthesis (Human fibroblasts, HeLa Cells, Rat Liver 
Cells) _ 
Cytogenetics and Sister Chromatid Exchanges (Chinese Hamster Ovary, 
Human Peripheral Lymphocytes) 
Cell ~utation Assays (V79, Chinese Hamster Ovary, L4178Y Mouse 
Lymphoma) 
5. Whole Animals 
Sex-Linked Recessive Lethal Assay (Drosophila) 
Cytogenetics: Bone Marrow Metaphase Analysis and Micronucleus Test 
Dominant Lethal Assay 
Source: Adapted from World Health Organi:ation, 1985, Guide to Short-Term 
Tests for Detecting Mutagenic and Carcinogenic Chemica:rs;- Env1ronmental 
Health Cr1ter1a sr:-worra-Health Organization, Geneva, pp. 24-125. 
Table 11.4 
Methods for Studying· DNA Excision Repair in Cultured Cells 
Incision in region of D~A damage 
Excision of damaged region 
Resynthesis of excised region 
Rejr,ining of strand 
Alkaline sucrose gradients 
Alkaline elution 
Loss of damaged bases 
Mass spectral analysis 
Radioimmunoassay 
Loss or enzyme-se11sitive sites 
3H-thymidine incorporation 





Alkaline sucrose gradients 
Alkaline elution 
Source: McQueen, C.A., and Williams, G.M., 1985, '~ammalian Cell DNA Repair 
Assays fof Carcinogens," in Flamm, W.G., and Lorentzen, R.J., (eds.), 
Mechanisms and Toxicity of Chemical Carcinogens and ~futagens, Princeton 
Scientific Publishing Co., Princeton, New Jersey, pp. 129-151. 
11-5 (88) 
alkylation is a major determinant of a chemical's biological effect. Alkyl-
ation of the 06 postion of guanine, for instance, appears to be much better 
correlated with mutagenic and carcinogenic potential than alkylation of the N7 
positions (Bradley et al., 1985). In addition, the quantitative binding of 
several· polynuclear aromatic hydrocarbons does not show a good correlation 
between exposure to these compounds and species variability in susceptibility 
to carcinogenesis (Phillips et al., 1978; Kuroki and Heidelberger, 1971). 
Findings such as those described above strongly indicate that it is the 
nature of the bio- logical interaction, rather than the overall extent to 
which genetic lesions are formed, that is toxicologically important. 
Furthermore, tissues may vary widely in their abilities to repair 
chemically-induced lesions and this varia- bility may also influence the 
overall tissue susceptibility to permanent genetic lesions (Bradley et al., 
1985). Moreover, differences in binding and repair also exist between 
mammalian and non-mammalian species, as well as among different mammalian 
species (OSTP, 1985; Calabrese, 1983). These considerations should be taken 
into account when evaluating the results of genetic toxicity studies. 
The limitations associated with individual genetic toxicity tests can be 
partially overcome through the use of a battery of tests. This approach has 
been called into question recently with regard to carcinogenicity screening 
(Tennant et al, 1987). It does, nonetheless, help to characterize the 
chemical's response spectrum by assessing a variety of genetic toxicity 
endpoints (USEPA, 1987). Given the potential seriousness of a genetic effect, 
any positive finding from a well conducted test should be considered signi-
ficant, particularly if pharmacokinetic data are unable to demonstrate that 
the chemical or its active metabolite are excluded from the site· of 
interaction with the DNA, or if the type of interaction is considered not to 
occur in human cells. 
Vfuile genetic toxicity is correlated with certain chronic effects, 
information is currently lacking from which to predict human health risk 
solely on the basis of a chemical's action on genetic material. Conversely, 
an understanding of the mechanisms for most chronic diseases is not well 
enough developed to discount a laboratory or epidemiological finding in the 
face of negative genetic toxicity findings. The best current uses of genetic 
toxicity data, therefore, are to support the findings from other 
investigations, to help elucidate mechanisms of action, and to provide 
indications of potential concern in the absence of an adequate data base for 
health effects under investigation. 
-- In the future, assessment of the toxicological impact from exposure to 
chemical mutagens may be enhanced by tests designed to measure in vivo genetic 
damage in human beings. These tests would be based on the premiSe-mat chemi-
cal mutagens produce characteristic patterns of mutations in human blood cells 
(Thilly and Call, 1986). This information could provide a crucial component 
to epidemiological studies designed to explore the relationships between 
chemical exposure, genetic toxicity, and irreversible diseases (Thi lly and 
Call, 1986). 
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11.1.2 Identification of Carcinogenic Effects. 
Cancer is a complex of diseases characterized by uncontrolled tissue 
growth (Flamm and Lorentzen, 1985; Berkow, 1982). It is the second leading 
cause of death in the country, next to heart disease. About one in five 
Americans die from cancer ( OTA, 1981). As Table 11.5 shows, cancers of the 
lung, large bowel, and breast account for nearly half of all the cancer deaths 
in this country. 
There are considerable variations in the patterns of cancer incidence 
among human populations (Doll and Peto, 1981; Higginson, 1980; Page and Asire, 
1985). It has been estimated, largely on the basis of these variations, that 
60 to 90 percent of the cancers are caused by factors in our living or working 
environments, and are thus theoretically preventable (Doll and Peto, 1981; 
Tomatis et al., 1982). These factors include man-made or natural chemical 
carcinogens, physical agents, radiation, viruses, nutritional deficiencies or 
excesses, age at reproduction, and a variety of other personal or cultural 
behavior patterns (OSTP, 1985; Doll and Peto, 1981; Higginson, 1980). The 
main causative factors have been identified for about half of the 
environmentally influenced cancers among men in North America and Europe, 
although the percentage is much lower for women (Higginson, 1981). -A summary 
of the factors associated with the major cancers thus far is presented in 
Table 11.6. Despite its currently limited data base, this table demonstrates 
that various combinations of endogenous and environmental factors may 
contribute to the cancer risks. 
Available information indicates that mortality rates for most cancers have 
remained stable throughout this century (Higginson, 1981; Young and Pollack, 
1982). For the white population, however, there have been sharp decreases in 
the incidence of stomach and uterine cervix cancer, and increases in lung, 
breast, uterine corpus, and prostatic cancer (Young and Pollack, 1982). Also, 
there are also indications that incidence rates for bladder and kidney cancers 
are also increasing in males (Young and Pollack, 1982). Except for the 
influence of tobacco smoking on lung cancer, the reasons for these trends are 
not entirely clear (Young and Pollack, 1982). The apparent increases may be 
real. They may also be influenced by increased awareness and more efficient 
reporting methods (Young and Pollack, 1982). Conclusions regarding these 
increases, however, will have to wait until a more thorough analysis of cancer 
incidence trends can be conducted. In the meantime,' the possibility that 
exposure to chemical carcinogens is responsible for increasing cancer rates 
cannot be discounted. 
A brief description of the carcinogenic process is outlined in Figure 
11.1. The diversity of causative agents and the various possible mechanisms 
by which cancers may be induced has prevented the establishment of any unified 
theory of carcinogenesis (Flamm and Lorentzen, 1985). It is generally 
thought, however, that multiple, independent cellular changes must accumulate 
before neoplastic transformation is expressed (Crawford, 1985; Higginson, 
1981). This theory is supported by the fact that the induction of cancer in 
human beings and laboratory animals proceeds through a series of 
histologically distinct stages (Crawford, 1985; Williams and Weisburger, 
1986). Each of these stages is subject to and controlled by a number of 
modifying factors (Williams and We is burger, 1986), some or many of which may 
be at least partly reversible (Higginson, 1981). In addition, latency periods 
of at least 30 cell divisions between exposure to chemical carcinogens and the 
development of cancer have been observed in vitro (Berkow, 1982). These 
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Table 11.5 
Numbers of Dezths Certifi0d as B~ing Due to Various Types of Tumor: 
United S~ates, 1978. 
Type of tumor 
P~r~ent of 
No. of death~ all deaths 
frorr. tumor~ 
Cancer of the 
Lung" 95.086 24} Large bowel (colon and 53.269 13 46 rectum) 
Breast 34,609 9 
Prostate 21.674 j} Pancreas 20.777 Stomach 14.452 46 
29 other types or categories. b 128.705 
each cont·ributing less 
than 3'~ of deaths 
Othu or unspecified tumors' 33.383 8 
Total al! tumors 401.955 100 
Source: Doll, R., and Peto, R., 1981, The Causes of Cancer: Quantitative 
Estimates of Avoidable Risks of Cancer 1n the Uni teo States Today, Oxford 
Un1 vers1 ty Press, New Yoil(,J). IT97 ~ 
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Gallstones, hormonal -changes in woaen 
Industrial exposure to chemicals, farming, (exposure to 
chemicals or viruses), ranching, x-rays, head trauma, 
barbituates (pregnant women and children), family history 
Hormonal chan!leS in w0111en, family history, previous breast 
disease, radiation, high socioeconomic status, obesity, 
high fat diet 
Genetic disorders, congenital anomalies, radiation, exposure 
to viruses (Burk.i tts l)'lllphoma}? 
Family history, history of inflarrvnatory bowel disease, 
urbanization, high fat diet 
Tohacco and alcohol, lo.., socioeconomic status, poor 
nutrition, inflannatory diseases of the esophagus 
Exposure to \' i ruses" 
<*netic an0111alies, exposure to radiation or industrial 
chemicals, exposure to viruses? 
Hepatitis 13 infection, hor~~~ones, cirrhosis, exposure to 
radiation or industrial chemicals 
Tobacco, radiation, exposure to asbestos and other 
industrial cht-micals, Vitamin A deficiency 
Family history, hormonal factors 
Immune HStt'fll disorders, family history, exposure to 
radiation.or industrial chemicals 
Immune system disorders, exposure to viruses, expesure to 
pesticides 
Tobacco, exposure to industrial chemicals 
Hormona 1 chan~es, previous breast or ovarian cancers, 
exposure to asbestos 
Tohacco, diabett>s?, coffee? 
High fat diet, exposure to industrial chemicals 
Radiation, fair skin, faaily history, other diseases 
(tropical ulcers, burns, scars, chronic infectious, wounds) 
Diet, diseases that affect the st011ach lining (pernicious 
anem1a, atrophic gastritis), family history, radiation, 
Tobacco, low socioecon011ic status 
Congenital anomalies, hoi"'IInal drugs 
Tobacco, exposure to industrial chemicals, obesity 
JotJl t iJ:'l e sex partners, ag'" at first intercourse, venereal 
disease! 
S.ll'!l' as fc.~ brt".:~st r.ancer 
Adapted from H.S. Page and A.J. Asire, 1985, Cancer Rates and Risks, 
Third Edition, U.S. Dept. of Health and Human Services, Washington, 
D.C., pp. 73-125. 
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findings are consistent with the observations that most cancer risks increase 
exponentially with age (Doll and Peto, 1981). Thus, the observation that most 
cancers may not appear until late in life or after long latency periods should 
be considered when evaluating the findings of toxicological or epidemiological 
studies. 
The latency period associated with exposure to chemical carcinogens 
implies that some sort of mutational event occurs at an early stage of tumor 
development (Flamm and Lorentzen, 1985). This event, commonly referred to as 
initiation, has been weLL correlated with many known or suspected chemical 
carcinogens (OTA, 1981). It has also been confirmed by experiments which 
demonstrated a monoclonal origin of tumors (Yuspa and Harris, 1982). 
Despite the identification of various stages and risk factors associated 
with carcinogenesis, many areas of uncertainty still exist as to how chemicals 
influence tumor development. Given the lack of knowledge regarding the 
underlying mechanisms of carcinogenesis (OSTP, 1985), a carcinogen or 
carcinogenic risk factor is identified by its association with a significantly 
adverse tumor response in either epidemiological or toxicological 
investigations. These associations are determined through the use of 
statistical tests which compare tumor incidences between treated and control 
groups, and by supporting evidence from cell culture studies. 
Criteria and guidelines have been developed for deterimining the adequacy 
of cancer epidemiology studies (USEPA, 1986a; OSTP, 1985). Factors affecting 
the sensitivity of epidemiological studies include the proper selection and 
characterization of the exposed and control populations, the exposure duration 
and quality of follow-up, the proper identification and characterization of 
confounding factors and biases, the appropriate consideration of the latency 
period, the valid identification of the causes of morbidity and mortality, and 
the ability to detect specific tumor types (USEPA, 1986a). Statistical tests 
used to evaluate the significance of the exposure compare .the incidence of the 
carcinogenic endpoint between case and control populations (for example, the 
odds ratio), or the relative risk of the disease between exposed and 
non-exposed populations (OSTP, 1985). Problems associated with the proper 
identification and characterization of the exposed populations, together with 
cost and time restraints, generally limit the sensitivity of most 
epidemiological studies. Thus, it is useful for these studies to include 
calculations of their statistical power to detect a positive response (USEPA, 
1986a) and, if the results are negative, the upper confidence limits. 
Various guidelines have been developed for evaluating the adequacy of 
cancer bioassays (USEPA, 1986a; OSHA, 1980; IRLG, 1979; OSTP, 1985; IARC, 
1980; NTP, 1984; CHDS, 1985). These guidelines have been designed to ensure 
that the assays are well conducted, and that they have adequate sensitivity 
for detecting carcinogenic chemicals. Risk assessment policy issues relevant 
to bioassay sensitivity are described below. Issues relevant to the 
specificity of the bioassays, or their abilities to correctly identify 
non-carcinogens, are discussed in Chapter 15.5.2. 
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Considering the inherent limitations of epidemiological studies, many more 
animal carcinogens have been identified than human carcinogens. All known 
human carcinogens have been carcinogenic in laboratory animals (NRC, 1986). 
Furthermore, because animals are the closest toxicological models to human 
beings, results from animal bioassays are generally considered to be 
qualitative predictors of the human response (NRC, 1986, IARC, 1982; OSTP, 
1985; OTA, 1981). Although they provide less evidence than chronic animal 
bioassays, in vitro cell transformation assays are also reliable qualitative 
indicators O:rc~ogenicity (IARC, 1980). 
The available data have not identified any single animal species as being 
the most predictive model for the identification of human carcinogens (IARC, 
1980). Ideally, the most appropriate animal model for predicting human 
carcinogenicity is one with no incidence of spontaneous tumors and a high and 
specific susceptibility to all human carcinogens (IARC, 1980). Because no 
animal species is known, it is generally recommended that the chemical be 
tested in at least two animal species (IARC, 1980; NTP, 1984). Most cancer 
bioassays have been conducted on rodents, particularly on rats, mice, and 
hamsters (IARC, 1980; OSTP, 1985; CDHS, 1985; IRLG, 1979). These animals have 
been chosen primarily for practical reasons: relatively short life span (but 
long enough to allow for the development of tumors), small size, and availa-
bility (CDHS, 1985; IARC, 1980; OSTP, 1985). Primates and dogs are not recom-
mended for routine testing because their metabolic characteristics are gener-
ally no more closer to human beings than are those of rodents ( IARC, 1980). 
Sex differences in responses to carcinogens have been found, however. Thus, 
it has been recommended that bioassays routine test both sexes (IARC, 1980). 
Positive results from any well designed and conducted animal bioassay, 
therefore, may be sufficient to identify a substance as being capable of 
producing cancer in human beings (CDHS, 1985; USEPA, 1986a). Also, more than 
half of the known human carcinogens that have been adequately tested in 
animals produced tumors in one or more animal species at organ sites different 
from those produced in exposed human beings (OSHA, 1980). Thus, the 
specification of susceptible human tissues on the basis of bioassays of animal 
carcinogens is subject to significant limitations. 
Most carcinogen testing has been done on inbred or hybrid animal strains. 
The advantages of using inbred strains is that there are generally abundant 
data on the tumor rates at specific organ sites in the untreated animals, and 
that their biological response is generally more pre.cise and stable than those 
of out bred strains (OSTP, 1985). Out bred strains, on the other hand, are 
hardier, less expensive to maintain, less prone to genetic drift, and perhaps 
may more accurately reflect the human response than inbred strains (OSTP, 
1985). The selection of any of these different types of strains may affect 
the sensitivity of the assay. It is possible for example, that a particular 
inbred strain may be especially resistant to the carcinogenic effects of the 
chemical (IARC, 1980). On the other hand, the variabilities in the responses 
of the out bred strains may be large enough to mask a positive response in a 
sensitive animal population (IARC, 1980). These issues have not been 
adequately resolved, although most testing continues to be done on inbred or 
hybrid strains. The National Toxiciology Program, for example, uses the male 
and female inbred Fischer 344 rat and the hybrid in B6C3Fl mouse in its 
bioassays (NTP, 1984). Its protocol is designed to reduce the likelihood that 
a carcinogen will not be identified as a result of sex and strain differences. 
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Concurrent control groups should be included in bioassays ( IARC, 1980; 
USEPA, 1986a; OSTP, 1985). Use of concurrent controls reduces the potentially 
variability caused by different experimental conditions, fluctuations in 
spontaneous tumor rates, and different histopathological analyses. It has 
been argued that if historical rates are higher than the concurrent control 
rates, less \veight may be given to positive results (NIP, 1984; USEPA, 1986a; 
Gart et al., 1979). On the other hand, it is possible that experimental 
conditions which depressed tumor incidence in the concurrent controls would 
have, in the absence of treatment effects, depressed incidence in the treated 
groups as well (Bickis and Krewski, 1985). Furthermore, historical tumor 
rates are of little value if they are unstable (Bickis and Krewski, 1985), as 
the variabilities in the responses are best addressed through the use of 
concurrent controls. Therefore, historical data should not be used to negate 
the significance of a positive bioassay finding unless it can be demonstrated 
that the concurrent controls are not suitable for analysis. 
An important statistical consideration in the evaluation of bioassays is 
the number of animals tested. On the one hand, because these animals are 
serving as surrogates for approcimately 250 million people in the United 
States, and possible many more worldwide, and because even modest increases 
(for example, 0.01 - 1 percent) in cancer risks may be unacceptably high from 
a social welfare standpoint, large numbers of animals are needed to detect 
these small but significant elevations in cancer incidence. On the other 
hand, cost and resource concerns often limit the number of animals that can be 
tested (IARC, 1980; IRLG, 1979). To balance these concerns, it has been 
recommended that each dose and control group should contain at least fifty 
animals of each sex ( OSTP, 1985; IARC, 1980; NTP, 1984). This initial number 
should be increased if interim sacrifices are planned (IARC, 1980; OSTP, 
1985). With this design, the minimum detectability of the assay has been 
estimated to be about 10 to 15 percent (OSHA, 1980; CDHS, 1985). This is 
still a relatively high detection limit; however, moderate increases in sample 
sizes do not significantly increase the the sensitivity· of the assay (OSTP, 
1985; IARC, 1980). 
The sensi ti vi ty of the bioassay also varies with the "spontaneous" (or 
background) incidence of tumors at specific tissue sites. Sites with very low 
spontaneous incidence rates (one percent or less) are more likely to yield 
false negative results than sites with higher spontaneous rates (OSTP, 1985; 
Fears et al., 1977; Gart et al., 1979). Five-fold, or even ten-fold increases 
in the tumor rate in such sites among the treated groups relative to the con-
trols could probably go undetected under generally accepted bioassay protocols 
(See Table 11.7). Similar comparisons are shown in Table 11.8. For example, 
the false negative rate for a simple carcinogenicity screen is 87 percent when 
a 5 percent spontaneous tumor rate is doubled to 10 percent in the treated 
group. The false negative rate drops to 36 percent, however, when a 20 
percent spontaneous tumor rate is doubled in the treated group. The 
relatively high false negative rate for sites with low spontaneous tumor rates 
may be counterbalanced to some degree by using historical control data. If 
historical control tumor rates are stable and similar to the · concurrent 
control rates, historical control data may be used to strengthen marginally 
significant results at these sites (USEPA, 1986a; Gart et al., 1979; Bickis 
and Krewski, 1985). 
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Table 11.7 
False Negative Error Rates for 5- and 10-Fold Increases in 
Spontaneous Tumor Rates for the Simple 1-Dose and 2-Dose Screens 
(SO Animals in the Control Group and Each of the Treated Groups) 
SE£ntaneous Rates s-f0ld increases 10-fo1d increases 
P(FN: 1 dose)* 
0.01 0.9335 0. 5761 
0.02 0.6832 0.1186 
0.03 0.4357 0.0157 
0.04 0.2585 0.0014 
0.05 0.1471 o. 0001 
0.06 0.0791 0.0000 
0.07 0.0393 0.0000 
0.08 0. 0179 0.0000 
0.09 0.0073 0.0000 
0.10 0.0025 0.0000 
P(FN: 2 doses)** 
0.01 0.9935 0. 7870 
0.02 0.8597 0.2073 
0.03 0.6252 0.0297 
0.04 0.4023 0.0028 
0.05 o. 2431 0.0001 
0.06 0.1377 0.0000 
0.07 o. 0711 0.0000 
0.08 0.0333 0.0000 
0.09 0.0140 0.0000 
0.10 0.0050 0.0000 
* Probability of a fa1 se negative result with one treated group and one 
control. A chemical is classified as a carcinogen if it is positive at some 
tissue site of a 1-dose experiment with the specified sex and species. 
**Probability of a false negative result with two treated groups and one 
control. A chemical is classified as a carcinogen if it is positive at some 
tissue site for both the high and low doses of a 2-dose experiment with the 
specified sex and species. 
Source: Fears, T.R., et al., 1977, "False Positive and False Negative Rates 
for Carcinogenicity Screens," Cancer Res., Vol. 37, pp. 1941-1945. 
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T&ble 11.8 
False Negative Rates for a Simple Carcinogenicity Screena 
Excess over 






Spontaneous Rate (\) 
0 1 5 20 
90 88 87 90 
43 49 61 77 
11 18 34 58 
2 5 15 36 
1 1 5 19 
a. Based on Fisher's exact test with 50 animals in each of a control and test 
group and assuming that all animals respond independently. 
b. Difference between the response rates in the test and control groups 
respectively. 
·------------·--------·----------·-·----
Source: Bickis, M., and Krewski, D., 1985, "Statistj::::al Design and Analysis 
of the Long-Term Carcinogenicity Bioassay," in D.B. Clayson et al. (eds.), 
Toxicological Risk Assessment, Vol. 1, Biological and Statistical Criteria, 
CRC Press, Boca Raton, FL, pp. lzs=f47~ 
Particular tumors appear with a very high spontaneous incidence in certain 
strains of rodentso Examples of these include lung adenomas in Strain A mice, 
lymphomas in strain AKR mice, liver cell tumors in C3H/HeN male mice, mammary 
tumors in C3H female mice, and testicular tumors in Fischer 344 male rats 
(IRLG, 1979; IARC, 1980). These sites are of limited usefulness for 
identifying increased incidences of tumors in treated animals because nearly 
all of the untreated controls may develop these tumors before they die. The 
high occurrence of spontaneous tumors at these sites also limits the 
&ppl icabil i ty of total tumor btaring animals as a parameter for identifying 
carcinogens in chronic bioassays (IARC, 1980). This limitation may be 
addressed, in part, by studying the time-to-tumor response and the 
multiplicity of tumors at each site (IRLG, 1979). Time- to-tum0r 
ronsiderations may also be especially important when observing the proportion 
of tumor bearing animals during the earlier periods of the bioassays, before 
spontaneous tumors usually develop (IARC, 1980). 
Because of the limited statistical sensitivity of animal bioassays, it is 
necessary that they be conducted at doses and under experimental conditions 
likely to yield the maximum tumor incidence (OSHA, 1980; NTP, 1984; CDHS, 
1985; IRLG. 1979). Dosing of animals should begin soon after weaning and 
continue for a major portion of the animals' lifespans: 18 months for mice and 
hamsters and 2 years for rats (OSTP, 1985). Because of the potentially long 
latency periods associated with tumor development, negative results decrease 
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in v~1ue as the exposure and observation periods are shortened, and become 
practically meaningless if these periods are shorter than half the lifespans 
c£ the animals (IP~G, 1979). Little attention has been given to variations in 
the dosing sc.ht-:dules (for examp:e, continuous versus intermit tent exposures), 
although they may have potentially significant influences on the tumor 
response (NTP, 1984). 
The grcat"er the ratio between the test expos-i1·e and t.he huinan e:"'posure, 
the gr0ater is the safety margin ·provided by a negative result (IRLG, 1979). 
The doses administered to a laboratory animal strain should thus include the 
highest level that can be tolerated during lifetime administration without 
altering the animals' normal longevity from effects other than carcinogenicity 
(IRLG, 1979). This dose level is commonly referred to as the "maximum 
tolerated dose," or MI'D. If the highest dose level administered is not the 
MfD, the sensitivity of the assay may be greatly reduced (Haseman, 1985). 
Levels which exceed the MI'D may result in premature mortality or depressed 
weight gain, both of which could reduce tumor response and thus weaken the 
sensitivity of the assay (IARC, 1980; IRLG, 1979; NTP, 1984). The policy 
implications of the bioassay findings relative to increased mortality in the 
dosed groups are presented in Table 11.9. 
Table 11.9 
Interpretation of the Unadjusted Analysis of Tumor Incidence 























+ Unadjusted test may underestimate tumorigenicity of treatment. 
0 Unadjusted test gives valid picture of tumorigenicity of treatment. 
TUmors found in treated groups may reflect longer survival of treated groups: 
Time-adjusted analysis is indicated. 
+ Apparent negative findin)(S in tumors may be due to shorter survival in treated 
groups. Time-adjusted analysis and/or retest at lower doses is indicated. 
0 Unadjusted test gives a valid picture of the possible tumor-preventive capacity 
ot treatment. 
Unadjusted test may underestimate the possible tumor-preventive capacity 
of treatment. 
+ High mortality in treated groups ~ay lead to unadjusted test missing a possible 
tumorigen. Adjusted analysis and/or retest at lower doses is indicated. 
0 Unadjusted test gives valid picture of lack of associaticn with treatm~t. 
'Longer survival in treated groups may mask tumor-preventive carocity of 
treatllleflt. 
a Many of these interpretations assume that the MTD was used and that a 
sufficient proportion of animals survived in sufficient numbers for an 
appropriate length of time. 
Source: Gart, J .J., et al., 1979, "Statistical Issues in Interpretation of 
Chronic Bioassay Tests for Carcinogenicity," J. Nat' 1 Cancer Inst., Vol. 62, 
pp. 957-974. 
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It has been suggested that doses in excess of the MTD may lead to tumors 
through either non-specific mechanisms or through mec..l-tanisms which are not 
operative at lower doses (See OSHA, 1980). The evidence in support of these 
hypotheses, however, is limited (OSHA, 1980), and sometimes even contradicted 
by the actual bioassay data (IRLG, 1979). Thus, the observation of 
significant tumor increases in animals administered a substance in excess of 
the MTD should be considered significant unless there is adequate evidence to 
the contrary. Indeed, because excessive doses are likely to decrease the 
sensitivity of the assay through premature mortality, a positive tumor 
response in this situation may increase, rather than decrease, one's concern 
about the substance's carcinogenic potential. Concern over decreased 
sensitivity can only be reduced if the carcinogenic respo~se can be 
demonstrated to be an artifact of high dose administration. Generally 
accepted criteria for estimating the MfD from subchronic studies have been 
developed by the National Toxicology Program (NTP, 1984) and by the 
International Agency for Research on Cancer (IARC, 1980). 
In addition to the MTD, bioassays should also include one or two 
intermediate dose levels (NTP, 1984; IARC, 1980). These additional dose 
levels are needed to ensure that the bioassay produces meaningful results if 
the MTD was exceeded. They are also useful for describing the nature of the 
dose-response, particularly if pharmacokinetic considerations are taken into 
account (NTP, 1984). 
Besides statistical findings, other important toxicological information 
may be obtained from the cancer studies. These include the histological type 
of the tumor, the proportion of benign and malignant tumors and, in the case 
of animal bioassays, information on pre-neoplastic changes. Assessment of 
such qualitative information may indicate a biologically relevant response in 
the absence of statistical significance. Conversely, it may also find that a 
statistically significant result may not be biologically significant. 
Finally, it is hoped that qualitative information will expand the scientific 
understanding of the biological mechanisms associated with the development of 
particular tumors. 
Generally, because tumors may arise from a single interaction between a 
chemical and DNA, no threshold dose which is free of risk can be estimated for 
a carcinogen which also produces genetic toxicity (NAS, 1977; USEPA, 1986a, 
OSHA, 1980; OSTP, 1985; OTA, 1981). Whether or not a threshold actually 
exists is a matter of considerable controversy. It can be argued, for 
example, that detoxification or DNA repair mechanisms should prevent any 
permanent genetic damage when the concentration of a chemical carcinogen is 
well below a level which would saturate these processes. On the other hand, 
errors may occur in this repair process. Also, threshold levels cannot be 
experimentally determined at present for the general population; they may vary 
from tissue to tissue, from individual to individual, and be influenced by 
other environmental agents operating through similar mechanisms. Therefore, 
until the biological activity of these chemicals can be better described, 
exposure to genotoxic carcinogens should be expressed in terms of "risk 
levels" rather than "safe levels" (Hogan and Hoel, 1982)e Methods for 
estimating risks for non-threshold effects are described in the Hazard 
Assessment section (Section V). 
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There are, however, important epigenetic factors which may influence the 
initiation and promotion of tumors. These factors may be derived from either 
hereditary or environmental determinants (Higginson, 1981). The importance of 
initiating factors relative to epigenetic factors in tumor development is 
still poorly understood (Higginson, 1981). Chemicals may influence tumor 
development in an epigenetic fashion regardless of how they perform on genetic 
toxicity tests. Non-genotoxic carcinogens present special problems to the 
assessment of risks associated with low exposure levels. Firstly, their role 
in tumor development may not be detected if toxicological tests do not also 
include appropriate initiating factors. Secondly, even if they are 
identified, the conceptual basis for their mechanisms of action is different 
from that of the genotoxic carcinogens. Too little is known about the 
mechanisms of carcinogenesis, however, to adequately distinguish between the 
effects of genotoxic and non-genotoxic carcinogens (OSTP, 1985). Moreover, it 
is important to note that the three of the most potent carcinogens tested to 
date (2, 3, 7 ,8-tetrachorodibenzodioxin, polybrominated biphenyls, and 
reserpine), produce negative results in conventional genetic toxicity tests 
(Tennant et al., 1987). Similarly to the genotoxic carcinogens, therefore, a 
threshold may be assumed for these non-genotoxic carcinogens only if the 
critical biochemical mechanisms can be identified and quantitatively evaluated 
for different tissues, individuals, and . species. Otherwise, in order to 
conform to the principle of worst case risk assessment, a non-threshold 
mechanism should be assumed. 
Because tumor development may be dependent on multiple mechanisms, studies 
concentrating on complete carcinogens, or on only one factor associated with 
carcinogenesis, may lead to a misrepresentation of risk if potential modifying 
factors are not adequately identified and addressed. These factors could be 
better identified through improved methods of epidemiological surveillance. 
Such improvements could result from an expanded expanding cancer registry 
which includes country-wide information on exposure to potentially 
carcinogenic substances. Such information may include .occupational history 
proximity to hazardous chemical industries or waste sites, and history of 
exposure to water or indoor air contaminants. Because of the multistage 
process of carcinogenisis, as well as its potentially long latency period, 
however, identification of human carcinogens will continue to be a difficult 
process. Because of the many similarities in tumor development between 
laboratory animals and human beings, however, much consideration should 
continue to be placed on the findings from animal experiments. 
11.1.3 Identification of Reproductive and Developmental Effects. 
An estimated one in five couples are involuntarily sterile (Dixon, 1986). 
Over one-third of the early embryos die and about 15 percent of recognized 
pregnancies abort spontaneously (Dixon, 1986). Over 1 percent of the 
approximately 1.3 million live infants born in the United States annually die 
\vithin the first year (:Manson, 1986). Seven percent have low birth weights 
(Manson, 1986). Approximately 2 to 4 percent are born with major congenital 
malformations (:Manson, 1986; NRC, 1983a). Another 3 percent are found to have 
serious developmental effects by the end of the first year (USEPA, 1984). 
When defects that only become apparent later in life are included, the 
estimated frequency of major and minor malformations increases to about 16 
percent (:Manson, 1986). The contribution of toxic chemical exposure to the 
incidence of these adverse health effects is not well known. 
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Reproductive toxicity may be defined as a "dysfunction induced by chemical 
(as well as biological and physical) agents that affect the process of 
gametogenesis from its earliest stage to implantation of the conceptus in the 
endometrium" (Dixon, 1976). As Figure 11.2 and Table 11.10 demonstrate, 
successful reproduction is dependent on the interaction of several biological 
processes. Reproductive toxins may interfere with one or more of these 
processes. Direct associations between chemical exposure and reproductive 
toxicity are difficult to establish, however, in human populations. This is 
particularly true for environmental chemicals. Exposure patterns and levels 
are seldom estimated with precision. In addition, the influence of 
potentially confounding factors has to be considered in the analysis. 
Moreover, methods to reliably estimate damage to human fertility are not 
readily available (Dixon, 1986), and animal models may not be sufficiently 
sensitive to detect adverse reproductive effects in human beings (Dixon, 1986; 
IRLG, 1986). Thus, a limited number of environmental chemicals have been 
linked with reproductive effects in human beings. 
Given the general paucity of information on this health parameter, 
reproductive toxicity is generally evaluated along with the assessment of 
developmental effects. This combination is not meant to imply that the 
mechanisms of toxicity are similar. Indeed, they are not, as reproductive 
toxicity concerns the parent and developmental toxicity concerns the 
conceptus. Thus, when the toxicological database is sufficient to separate 
reproductive effects from developmental effects, a separate subchapter should 
be devoted to the assessment of reproductive toxicity. 
Once the conceptus is implanted in the endometrium, factors affecting 
intrauterine growth are referred to as "developmental toxicity" (Manson, 
1986). There are four general categories of developmental toxicity: death, 
malformation, growth retardation, and functional deficit (Wilson, 1980; 
Schardein, 1985; USEPA, 1986). Developmental toxicity may result directly 
from the effect of a toxin on the conceptus in the -absence of maternal 
toxicity, indirectly as a secondary effect of maternal toxicity, or from a 
combination of both. All categories of developmental toxicity should be 
investigated when assessing the potential developmental hazards, especially as 
there are associations between these health effects categories (Wilson, 
1973). Gro·wth retardation, for example, may be indicative of more severe 
developmental effects (van den Berg and Yerushalmy, 1966; Scott and Usher, 
1966; Low and Galbraith, 1974). Also, the prevalence of embryolethality may 
be explained by the increased number of several malformations which predispose 
the embryo to death (Wilson, 1980). Early toxic effects to the embryo may 
increase the risk of lethality, possibly masking later developmental effects 
(Wilson, 1973). 
In general, embryotoxic effects have a characteristic distribution along 
the dose-response curve (Wilson, 1980). At low doses, no effects are 
observed. As the dosage increases, both lethal and non-lethal effects begin 
to appear, with lethal effects becoming increasingly more prevalent at higher 
doses. At the upper end of the dose-response curve, the possible 
developmental effects of chemical exposure cannot be easily distinguished from 
secondary effects resulting from maternal toxicity. This relationship is 
described in Figure 11.3. 
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Figure 11.2. Schematic representation of the biologic processes that are 
essential for normal reproduction. 
Source: Dixon, R.L., 1986, "Toxic Responses of the Reproductive System," in 
C.D. Klaasen et al. (eds.), Casarett and Doull's Toxicology, MacMillan 
Publishing Company, New York. p. 448. 
Table 11.10 
Various Reproductive Functions Susceptible to Toxic Chemicals 
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Source: IRLG (Interagency Regulatory Liaison Group), 1986, "tnteragency 
Regulatory Liaison Group Workshop on Reproductive Toxicity Risk Assessment," 







Figure 11.3. Types of Respons-es that Occur when Pregnant Animals Are 
Subjected to Increasing Dosage of a Biologically Active Chemical or Physical 
Agent 
Source: Wilson, J .G., 1980, "Environmental Effects on Intrauterine Death in 
Animals," in I .H. Porter and E. B. Hook ( eds.), Human Embryonic and Fetal 
Death, Academic Press, New York, p. 23. 
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Days of Gestation in Rat 
Figure 11.4. Groups of Curves Representing the Susceptibility of Particular 
Organs and Organ Systems in Rat Embryos to a Hypothetical Teratogenic Agent 
Given on Different Days of Gestation. 
Source: Wilson, J.G., 1973, Environment and Birth Defects, Academic Press, 
New York. 
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}fuch emphasis in reproductive and developmental toxicology has been placed 
on the teratogenic potential of a chemical, or the potential of a chemical to 
produce malformations (Brown and Nigel, 1983). As Figure 11.4 indicates, 
organ systems differ in the intervals within the gestation periods at which 
they are most vulnerable to teratogenic insult. Overall, the most critical 
period of susceptibility ranges from shortly after the time of implantation to 
the end of the embryonic stage of development (approximately the first two to 
three months of gestation in human beings (Schardein, 1985)). It is during 
this period that that most organogenesis takes place. Some tissues, however, 
continue to differentiate beyond this time. The cerebrum and cerebellum 
continue differentiation even into the postnatal period (NRC, 1986), and the 
lung continues to differentiate throughout childhood (Kattan, 1979). The 
immune, reproductive, gastrointestinal, and endocrine systems are also 
incompletely developed at birth (WHO, 1986). These tissues, therefore, may 
remain sensitive to developmental toxicants well beyond the embryonic stage. 
A breakdown of malformations by etiology is presented in Table 11.·11. As 
can be seen from the table, most causes of malformations in human beings are 
unknown. Furthermore, subtler manifestations of developmental toxicity may 
also occur, but generally go unreported (USEPA, 1986d). Epidemiological 
studies currently lack an adequate database from which human developmental 
toxins may be identified or compared with animal teratogens. It is 
unfortunate that adequate surveillance in this area is not being implemented, 
as there are arguments that implementation would be relatively cost-effective 
(H.R., 1986). Along with the enormous public health benefits associated with 
the identification and control of developmental toxins, particularly those 
which are able to produce genetic toxicity, such efforts may also reduce risks 
of cancer and other chronic diseases. 
The guidelines for assessing reproductive and developmental risks from 
epidemiological investigations are similar to those associated with the 
identification of carcinogens (IRLG, 1986). In light of .the limited database 
available for epidemiological studies, the rapid association between a 
teratogen and its effects in human beings depends either on a appreciable 
number of cases at one time OF place, or an unusual if not unique defect or 
association· of defects (Wilson, 1973). Yet, the pattern of defects observed 
depends on the dose received as well as the time frame in which the dose is 
administered. Consequently, it is possible that teratogen may only be 
sporadically expressed in human populations or may be expressed without a 
\vell-defined pattern of. effect (Wilson, 1973). Thus, it has not been 
recommended that epidemiological investigations depend on sentinel effects 
solely in the recognition of chemically-induced teratogenesis (Wilson, 1973). 
Despite the lack of comparative data, there is a basis for using animal 
tests to identify potential human developmental toxins. Most known human 
teratogens have also been teratogenic in at least one animal species (See 
Table 11.12 (NRC, 1986; Schardein et al., 1985). The mouse and rat tests 
produce the highest percentage of positive responses. Also, the types of 
effects produced in humans and those produced in laboratory animals are 
correlated, as indicated by Table 11.13. Only specific anticancer drugs, 
anticonvulsants, and lithium failed to produce a pattern of defects in at 
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Source: Schardein, J .L., Chemically Induced Birth Defects, Marcel Dekker, 
Inc., New York, 1985. p. 2. 
Table 11.12 
Predictability of Laboratory Animal Mbdels for Putative Human Teratogensa 
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Source: Scliardein, J.L., et alo, 1985, "Species Sensitivities anZi-Prediction 
of Teratogenic Potential," Environ. Health Perspect., ,Vol .. 61, p. bU. 
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Altbough there was a concordance found between the effects in hum8n beings 
and the effects in some laboratory animal, there was far less concordance when 
the responses of 1nd1vidual species were compared to the human response 
(Schardein et al., 1985). These comparisons are presented in Table 11.13. 
There is, therefore, no a priori way of determining which animal species is 
most reflective of the numan response to a particular chemical (Schardein, 
1985). This drawback may be addressed in the future more insj ght is gained 
into the tuxicoiogical mechanisms and the phannaco~inet.ic ci.~.fferellces amcng 
species (IRLG, 1986). Unless data are available to support an alternative 
animal model, however, a human health . risk should be presumed if an adverse 
reproductive outcome occurs in a well conducted animal study. 
Table 11.13 
Comparisons of Concordant Malformations between Human Beings 
and Laboratory Animals 
Ter-atogen 
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CV, ear, brain 
Concordant 
r.t:>use, dog 
Mouse, rat, guinea pig, pig 
hamster, rabbit, dog, primate 
Rat 




Rat, rabbit, ferret 
r.t:>use 
Mouse, rat, rabbit, guinea pig 
Mouse, rat, primate, ferret 








Rat, guinea pig, pig 
Dog, pig 
Rabbit, primate 






Rat, rabbit, rabbit 
r.t:>use, primate 
Mouse, rat, rabbit 
Hamster 
Mouse, rat, hamster, dog, 
cat, pig, ferret 
Mouse 
Hamster 
Rabbit, guinea pig, pig 
Source: SCharde1n, J.L., et al., 1985, "Species Sensitivities and Prediction 
of Teratogenic Potential," Environ. Health Perspect., Vol. 61 ,, p. 61. 
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As .,Jith chemical carci_nogens, guidelines have been developed to evaluate 
the adequacy of reproductive and developmental toxicity studies (USEPA, 1986d; 
IRLG, 1986; Sdlardein, 1985; Wilson, 1973, 1980). Many o£ the same concerns 
a.ssociattd witi1 ~ens.itivity of the carcinogenicity bioassay apply to the 
de\-eloph,ental toxicity studies as well. A summary of tes't endpoints for 
evaluating developnental and maternal toxicity are presented in Tables 11.14 
and 11.15. Tests to measure the transmission of hereditable changes have also 
:.een developed, an.d (1re dcsc1 ibed e:isev-h~re (JSLJ'A, 198Gb; IARC, 1983; NkC, 
1983b). 
Enough animals should be included in the study to ensure adequate 
sensitivity for detecting an effect. This typically includes at least twenty 
animals per dose group (USEPA, 1986d). Findings of positive associations 
between dose and developmental effects with lower numbers of animals per dose 
group should be seriously considered, as such findings indicate that a much 
stronger response would have been observed had adequate numbers of animals 
been used. 
Also, it is recognized that in all animal species there is a detectable 
incidence of spontaneously occurring developmental effects (Wilson, 1980; 
IRLG, 1979). Concurrent controls should therefore be evaluated as part of the 
assaye As with controls for chemical carcinogenicity studies, primary atten-
tion in developmental effects studies should be given to the effects in the 
treated groups relative to the concurrent controls, especially if there is a 
difference in the incidence rates between the concurrent and historical 
controls. 
Table 11.14 
Endpoints of Maternal Toxicity 
Mortaljty 
Gestation Index (no. with 
implants/no. with sperm 
or seminal plugs 
Body Weight 
Treatment days (at least 
first, middle, and 
last treatment days 
Organ Weights (in cases 
of suspected organ 
toxicity) 
Absolute 
Relative to hody 
weight 
Gross Necropsy and 
histopathology 
Fertility Index (no. with seminal plugs or 
spenn/no. mated) 
Gestation Length (when allowed to deliver 
pups 
Body Weight Change 
Throughout Gestation 
During Treatment (including increments 
of time within treatment period) 
Post-treatment to sacrifice 
Corrected maternal body weight 
(change throughout gestation minus 
gravid uterine weight or litter 
w~ight at sacrif~c~) 
Food/Water Consumption (where relevant) 
Clinical Evaluations (on days of 
treatment and at sacrifice) 
Types and Incidence of Clinical Signs 
Enzyme Markers 
Clinical Chemistries 
Source: USEPA (U.S. Environmental Protection Agency). 1986d, "Guidelines for 
the Health Assessment of Suspect Developmental Toxicants," Federal Register, 
Vol. 51, pp. 34027-34040. 
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Table 11.15 
Endpoints of Developmental Toxicity 
Litters with implants 
No 1mplantat1on sites/dam 
No. corpora lutea (CL)/dama 
Percent preimp1antation loss 
(CL - implantations) Xlooa 
CL 
No. and percent live offspring/ 
litter 
No. and percent resorptions/litter 
No. and percent litters with 
resorptions 
No. and percent late fetal deaths/ 
litter 
No. & percent nonl i ve (late fetal 
deaths & resorptions) implants/ 
litter 
No. and percent litters with non-
live implants 
No. and percent affected (non-live 
& malfonned) implants/litter 
No. and percent litters with 
affected implants 
No. and percent litters with total 
resorptions 
No. and percent stillbirths/litter 
Litters with live offsfringb 
No. a:M percent 1tters with 
live offspring 
Sex ratio/litter 
No. and percent live 
offspring/litter 
Viability of offspringc 
Mean offspring body weight/ 
litterC 
Me~~ male body weight/litterC 
~~an female body weight/litterC 
No. and percent externally 
malformed offspring/litter 
No. and percent viscerally 
malfromed offspring/litter 
No. and percent skeletally 
malformed offspring/litter 
No. and percent malformed 
offspring/litter 
No. 3.nd percent litters with 
malformed offspring 
No. and percent malformed males/ 
litter · 
No. and percent malformed females/ 
litter 
No. and percent :Jffspring "-'i th 
variations/litter 
No. and percent litters having 
offspring with variations 
Types and incidence of individual 
rna If onna ti ons 
1)~s and incidence of individual 
variations 
Individual offspring and their 
malfonnations and variations 
(grouped accouding to litter and 
dose) 
Clinical signsc 
Gross necropsy and· histopathology 
armportant when treatment begins prior to implantation. May be difficult in 
mice 
boffspring refers both to fetuses observed prior to term or to pups following 
birth. The end points examin~d depend on the protocol used for each study. 
CMeasured at selected intervals until termination of the study. 
Source: USEPA (U.S. Environmental Protection Agency). 1986d, "Guidelines for 
t'1e Beal th 1\ssessment of Suspect Developmental Toxicants," Federal Register, 
Vol. 51, pp. 34027-34040. 
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The highest dose level should result in some maternal toxicity, in order 
to ensure that the test has the maximum sensitivity of detecting a positive 
response (USEPA, 1986d). Lower dose levels should not be toxic to the dam, 
and be sufficient to provide information from which a dose-response 
relationship may be established (USEPA, 1986d). These levels should include a 
no observed effect level as well as one or more dose levels in between the no 
observed effect level and the highest dose level (USEPA, 1986d). When 
evaluating the dose response data, the greatest concern should be with those 
agents which produce developmental toxicity at a dose that is not toxic to the 
adult, as this implies that the developing organism is selectively affected or 
more sensitive than the adult (USEPA, 1986d). Findings of developmental 
effects at dose levels which are also toxic to the mother should be inter-
preted cautiously, as it is possible that the developmental effects are secon-
dary to maternal toxicity (USEPA, 1986d). Should this be the case, the study 
could imply that dose levels which do not cause toxicity in the mother should 
not cause harm to the conceptus either. Findings of developmental toxicity 
only at maternally toxic doses should not be summarily discounted, however, as 
current information is inadequate to assume that developmental effects at 
maternally toxic doses result only from maternal toxicity (USEPA, 1986d). 
Because of the differences in species sensitivity to developmental toxins, 
it is possible that testing on only one species may fail to identify a 
substance that is toxic in other species, including human beings. It has been 
recommended, therefore, that at least two species be tested (Wilson, 1973). 
This is consistent with the protocol recommended for the animal testing of 
carcinogens (IARC, 1980; NTP, 1984). It has also been recommended that at 
least one species should be a non-rodent species (Schardein, 1985), preferably 
a non-rodent/non-rabbit species (Calabrese, 1983; Wilson, 1973). These 
recommendations are based on the concern that the reproductive systems in 
rodents and rabbits are similar, and differ significantly from the human 
reproductive system. 
The dosing schedule is generally restricted to the early part of 
gestation, when most organogenesis is taking place and the organisms are most 
susceptible to teratogenic insult (See Table 11.16). Yet, even within this 
restricted interval, effects of repeated dosing may produce different 
embryotoxic outcomes than a single dose administered at a critical time in 
organogenesis. The ways in which these differences mig.ht occur are presented 
in Table 11.17. Several of these mechanisms include chemically-induced 
alterations in metabolic rates. A list of some chemicals known to influence 
metabolic rates is presented in Table 11.18. Of primary importance with 
regard to study sensitivity is the possible induction of catabolizing enzymes 
by high doses before the time of maximum susceptibility (Wilson, 1973). It 
has been reconunended that, to address this concern, treatment intervals be 
subdivided into 3-4 day time spans (Wilson, 1973). 
Mul tigeneration studies have been recommended to identify cumulative and 
genetic effects (Dixon, 1986; Manson, 1986). These studies are designed to 
last for three generations and involve the administration of the test agent to 
the first two generations (Dixon, 1986). The dosing of the· F0 generation 
begins as soon as possible after weaning and acclimation, and continues until 
all the F1 animals selected for the next phase of the study have been 
weaned. Dosing of the F1 generation selected for breeding continues until 
30 days after the F 2 animals have been weaned. Consequently, this protocol 
increases the sensitivity of the assay to identify recessive genetic effects 
and effects which may occur at any stage of the life cycle. 
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Table 11.16 



































b. Also may be given as day 35-70 after last menstrual period. 
Source: Schardein, J.L., Chemically Induced Birth Defects, Marcel Dekker, 
Inc., New York, 1985. 
Table 11.17 
Ways in Which Repeated Treatment Prior to the Peak Susceptible 
Period of the Embryo May Produce Misleading Results 
Time of treatment Primary effect 
Secondary effect capable of 
altering test results ----------------- -------
1. Before implantation 
2. Early organogenesis 
3. Before peak 
susceptibility 
4. Before peak 
susceptibility 
5. Before peak 
susceptibility 
6. Before peak 
susceptibility 









Liver pathology or re-
duced function 






Reduced blood level during 
susceptible period 
Increased blood level during 
susceptible period 
Increased blood level during 
susceptible period 
Increased blood level during 
susceptible period 
Increased blood level during 
susceptible period 
Source: Wilson, J.G., 1973, Enviro~~ent and Birth Defects, Academic Press, New 
York, pp. 137-171. 
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Table 11.18 
Some Cherrical Agents Known to Influence Rates of :Metabolic Degradation 






Some insecticides (DDT, chlordane, aldrin, 
dieldrin, heptachlor) 
Some tranquilizers and antipsychotics 
(meprobamate, Librium, chlorpromazine) 
Some antihistamines (chlorcyclizine, 
diphenhydramine) 















Any that competitively inhibit 
catabolic enz:;rrnes 
Source: Wilson, J .G., 1973, Environment and Birth Defects, Academic Press, 
New York, pp. 137-171. 
In addition to teratogenicity, other measures of developmental or 
reproductive toxicity could be utilized in the identification of substances 
which could produce these hazards. Such additional parameters are often 
associated with teratogenicity, and occur more frequently and consistently in 
animal experiments (Schardein, 1985). For example, low pregnancy rate, 
reduced litter size, and poor viability were observed in the early animal 
tests with thalidomide in r~dents in the absence of teratogenicity (Schardein, 
1985). Also, these parameters are more sensitive indicators of developmental 
effects than are gross malformations (USEPA, 1986d). For example, under a 
testing protocol which uses 20 animals per dose group, it is possible to 
detect an increased incidence of malformations in the range of 5 to 12 times 
above control levels, an increase of 3 to 6 times in the in utero death rate, 
and a decrease of 0.15 to 0.25 times the fetal weight (USEP~86d). Other 
factJrs may need to be :onsidcred, however, when evaluating c1anges jn fetal 
weight. In polytocous animals, for example, fetal and neonatal weights are 
,Jsu.::.lly L·Jversely correlated with litter size (USEPA, 1986d). Also, the 
average body weight of males is greater than that of females in the more 
commonly used laboratory animals (USEPA, 1986d), thus warranting consideration 
of the sex ratios. 
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Sensitive developmental toxicity endpoints which are not commonly 
investigated include those that measure subtle functional defects in organs or 
organ systems (USEPA, 1986d). Often, these effects occur at levels below 
those which cause gross malformations (USEPA, 1986d). Much of the work that 
has been done has focused on behavioral effects, although the cardiopulmonary, 
immune, endocrine, digestive, urinary, nervous, and reproductive systems are 
also subject to alterations in functional competence (USEPA, 1986d). 
Neurotoxicity is a significant concern in this regard, as laboratory animals 
are poor surrogates for the identification of effects on complex human 
neurological function. 
Tests to measure effects on fertility have also been developed (Dixon, 
1986, IRLG, 1986). Positive findings from these studies may have special 
significance in that the fertility of humans is more susceptible to environ-
mental chemicals than is the fertility of laboratory animals (Dixon, 1986; 
IRLG, 1986). Laboratory animals, for example, produce sperm in considerable 
excess over that required for normal reproductive function (IRLG, 1986). 
11.1.4 Identification of Acute/Chronic Toxicity Effects. 
Any organ or organ system in the body may experience toxic effects from 
chemical exposure. For most situations subject to risk assessment, the 
predominant concern is for the identification of chronic health effects. Of 
particular importance are those effects resulting from long-term exposure to 
toxic substances at levels below those which produce acute toxicity. This 
exposure situation warrants considerable attention for several reasons. 
Firstly, the exposed population, as well as the number of potentially 
hazardous chemicals to which this population is exposed, increases as the 
exposure dose decreases. Also, as the exposure duration sufficient to produce 
a toxic effect increases, so does the probability that those experiencing the 
toxic effect are exposed to an increasing number of other risk factors as 
well. This problem limits the ability of epidemiology to attribute an adverse 
health outcome to a particular substance. MOreover, registries of most 
chronic diseases (other than cancer) are not kept. This further limits the 
ability to identify toxic hazards even in the absence of other risk factors. 
Finally, even if a toxic outcome is established in association \vith exposure 
to a toxic substance, many years may have elapsed between the time of the 
chemical's identification and the time of its introduction into the market. 
The shortcomings of disease surveillance, combined with the inherent 
limitations of animal studies (See Chapter 4.4), contribute to much of the 
uncertainty and anxiety concerning the hazard identification of toxic 
substances. 
Traditional measurements of acute and chronic health effects have focused 
on common manifestations of toxicity. These include such overt acute effects 
as irritation, dermatological disorders, behavioral disturbances, central 
nervous system depression, cardiopulmonary depression, and death. They also 
include common biochemical indicators of visceral organ toxicity (such as 
serum liver enzyme levels). As the scientific understanding of 
chemically-induced health effects has expanded, however, an increasing number 
of toxicological endpoints has been investigated. These endpoints include 
effects associated with genotoxic, · carcinogenic, and reproductive/ 
developmental risks discussed earlier. Such effects are not discussed in this 
subchapter, except insofar as they were observed in studies along with other 
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health effects not previously described. Addition&l endpoints also include 
subtler toxic effects associated with reversible or irreversible tissue damage 
(for example, neu1·cpathic or immunosuppressive effects). A S'lffiffiary of 
selected non-carcinogenic health endpoints for various target organs is 
presented in Table 11.19. 
Because different health effects are likely to result from different 
toxicological tuechanisms, there ore limitations associated with the us~;: of one 
endpoint or. group of endpoints as a surrogate for a substance's overall toxic 
potential. This caveat is particularly relevant when evaluating lethality 
studies (for example, LD50, LC50, LDlO), as there may be many toxicologically 
significant endpoints which are not well correlated with acute lethality. For 
example, because of the body's homeostatic responses to acute exposures, and 
its ability to respond to insult following these exposures, the concerns 
associated with chronic exposure may be quite different from those associated 
with acute exposure. Chronic effects may occur as a result of the 
accumulation of subtle tissue damage through repetitive exposures, as a 
consequence of adaptive mechanisms induced by the exposures, or from an 
accumulation of a substance within the body to a level sufficient to cause an 
acute response (Figure 11. 5). 
'f'. 
f\' I ', Residual injury 
I , I , 
' 
I , I '-.... 
' I '....J 
'..J 
Figure 11.5. Diagrammatic View of Dose and Corresponding Measure of Effect. 
Source: Klaasen, C.D., 1986, "Distribution, Excretion, and Absorption of 
Toxicants," in C.D. Klaasen et al. (eds.), Casarett and Doull's Toxicology, 
MacMillan Publishing Company, New York. pp. 33-63. 
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Table 11.19 
Selected Parailleters Associated 










Parameters Indicative of an .Adverse Effect 
Bone marrow depression, Abnormally high reticulocyte 
count, Hypoxia, abnormal hemog"lobin 
Alterations in lymphoid organ weight or histology, 
quantitative changes in perpheral leukocyte counts and 
differentials, depressed cellularity of l}Tiphoid 
tissues, increased susceptability to infections by 
opportunistic organisms, increased incidence of allergy 
and autoimmunity 
Changes in heart rate, conductivity, excitabi1ity, anc! 
contractility, changes in cardiac output, changes in 
arterial blood pressure, hemorrhage, thrombosis, 
structural changes, hypersensitivity 
Irritation of the air passages, damage to cells lining 
the airways, production of fibrosis, constriction of 
airways through allergic responses 
Alterations in functions: coguitive, sensory, 
somatosensory, motor, antonomic, immune effects; 
structural damage 
Lesions of the cornea, lens, and retina; tear secretion, 
ocular pressure, electroretinogram; biochemical assays 
of lens and aqueous humor; eye reflexes 
Interference with bilirubin uptake, excretion and 
conjugation; cytotoxic injury; cholestatic injury; fatty 
liver; cirrhosis; phospholipidosis, vascular lesions; 
chronic active hepatitis; subacute hepatic neurosis 
Decreased elimination of wastes; changes in 
extracellular fluid volume and electrolyte composition; 
changes in hormone levels invul ved in systematic 
metabolic ft.mcticns; changes in prostaglandin and kinin 
levels 
General Sources: C.D. Klaasen et al. (eds.), 1986, Casarett and Doull's 
Toxicology, Third Edition, MacMillan Publishing Company, New 
York, 974 pp.; G.M. Cohen (ed.), 1986 Target Organ Toxicity, 
Volumes I and II, CRC Press, Boca Raton, Florida; National 
Research Council, Drinking Water and Health, Vol. 6, 
National Academy Press, Washington, D.C., pp. 105-138. 
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Most toxicological studies hav~ concerned effects on organs or organ 
systems that receive the most intense exposure, either through direct contact 
or through transport via the blood. Examples of these sites are the blood 
itself, the skin and external organs, the pulmonary and cardiovascular 
systems, the liver, and the kidney. Exposure intensity is not the only 
parameter of concern, however, as tissues may vary widely in their response to 
a given dose of a toxic substance. For example, certain tissues, such as 
heart tissue (Balazs et al., 1986), are less able than the liver and kidney 
tissues to protect themselves from the toxic effects of reactive metabolites. 
Generally, the epidemiological assessment of health effects depends on 
the ability of the studies to identify the populations exposed directly relate 
the observed effects to actual health impairment. Difficulties exist, 
however, in the identification of sensitive health endpoints, in the adequate 
assessment of exposure levels, and in separating the effects of a particular 
exposure from those induced by exposure to other chemical, physical, or 
biological agents. Despite these shortcomings, however, an important focus of 
risk assessments should be the identification of sensitive indicators of 
adverse health effects. Such 1 imitations are overcome through the use of 
laboratory tests. As the health effect parameters become more sensitive, 
however, their association with clinical effects becomes less clear. Thus, a 
distinction has to be made between the significance of a change in a 
particular health parameter and the overall health significance of this 
change. Any chemically-induced perturbation in an organism, regardless of its 
clinical significance, may contribute to a toxic outcome. Therefore, any 
subtle but significant biological change may constitute an adverse health 
effect. Evaluation of this change within the context of the substance's other 
toxicological manifestations is required before conclusions can be made 
regarding its importance to human health. This evaluation is conducted in the 
Hazard Assessment section (Section V). 
11.2 Identification of Multiple Chemical Exposure Effects. 
Human beings are not typically exposed to ·a single compound of 
toxicological concern. Rather, they are exposed to varying numbers of such 
substances. These substances may enter the body through oral, pulmonary, and 
dermal exposure routes. The human response) to any one chemical in this 
exposure mixture may be either independent or dependent on the properties of 
the other chemicals in the mixture. Independent responses which af feet the 
same toxicological endpoint are additive in nature. The severity of the 
response is a function of the toxic potencies of the individual chemicals. 
Dependent responses are interactive in nature. When the response is greater 
than what would be predicted by adding the potencies of the individual 
chemicals, the response is considered synergistic. A special kind of this 
interaction takes place when a chemical w1th no known contribution to a 
particular toxicological effect increases the potency of another chemical 
relative to that effect. This particular synergistic response is 
potentiation. When the interaction of chemicals results in a response which 
IS less than what would be predicted from an additive model, the interaction 
is considered to be antagonistic. 
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The toxicological importance of a substance may also be altered 
significantly when it precedes or follows exposure to another substance. In 
addition to temporal variability, the nature of the interaction also depends 
on the concentrations of the substances to which individuals are exposed. 
Toluene, for example, may antagonize the toxicity of benzene when co-exposure 
occurs at high concentrations (Goldstein, 1983). It does this by competing 
with benzene for enzymes responsible for benzene's metabolic activation. At 
lower concentrations, however, this antagonism should not occur because 
metabolism would not be saturated. To the contrary, it is possible that 
toluene could enhance benzene's toxicity at these lower concentrations, 
through the induction of metabolizing e~zymes. 
Chemical exposures associated with such 1 if estyle factors as diet and 
smoking habits may also interact with a substance's toxicity. For example, 
the synergistic effects of cigarette smoking on the carcinogenicity of 
asbestos have been widely discussed (See, for example, OSHA, 1980). A low 
carbohydrate diet increases hepatic metabolism of various chemicals, whereas a 
high carbohydrate diet decreases it (Sato et al., 1983). Opposite effects to 
those of carbohydrates were observed with ethanol (Sa to et al., 1983). These 
lifestyle factors, therefore, may either enhance or decrease the toxicity of a 
substance, depending on whether the effect of concern is caused by the parent 
compound or its metabolite. 
Consideration of interactive effects is a requisite element in the proper 
assessment of specific exposure situations, and in the proper identification 
of sensitive populations or exposure cohorts. Assessment of interactive 
effects_has been hampered, however, by the focus on the toxicity of individual 
compounds rather than on a matrix of risk factors. Nonetheless, this 
chemical-specific approach is taken because the assessment of the many 
potential risk factors represents a complicated, time-consuming, and costly 
process. 
In the future, problems associated with the assessment of multiple 
chemical exposures may be overcome by a clearer understanding of the 
mechanisms of toxicity, and the influences which various environmental 
stresses have on these mechanisms. Meanwhile, the key risk assessment issue 
in this regard concerns the underprediction of the toxic effects associated 
with these chemical exposures. The problem is addressed to some extent by the 
policy that assessments should first consider the toxicological effects of 
chemical mixtures when they can be identified with an adequate database. If 
this cannot be done satisfactorily, attention should be given to the 
interactive effects observed in the studies on individual chemicals. 
Synergistic interactions, while infrequently reported, should be assessed when 
information is available. Antagonistic interactions, although potentially 
relevant with regard to specific exposure situations or population cohorts, 
may not be generally applicable for risk assessment purposes. 
Even when information on interactive effects is available, however, it may 
be difficult to describe these interactions quantitatively. For most 
situations, therefore, independence of effects is usually assumed unless 
adequate information exists to support a different assumption. While these 
effects may either be additive or non-additive in nature, proper hazard 
identification warrants that they should be assumed additive unless the 
available data indicate otherwise. 
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11.3 Identification of Special Risk Populations 
For any given substance, populations exist which may be especially 
vulnerable to its toxic effects. -These populations may be at special risk 
either because of their exposure circumstances or because of their inherent 
sensitivity to the substance's biological effects. Individuals may thus vary 
widely in their responses to toxic chemicals. 
Specific factors which may influence a chemical's toxicity include 
genettcs, age, sex, health status, diet and nutrition, lifestyle, occupation, 
and environmental setting. Infants and elderly people, and those with 
compromised liver function, have diminished metabolic capability (Sipes and 
Gandolfi, 1986). They also have altered susceptibility to neurotoxic 
disorders (NRC, 1986). Hereditary factors may have a direct or indirect role 
in the development of many chronic diseases (NRC, 1983b). Certain 
occupational toxicants may interact in unpredictable ways with other 
chemicals. Malnutrition is factor in the development of neurotoxic responses 
(NRC, 1986). Malnutrition and infection diminish one's immune system. A 
simplified representation of this variability is presented in Figure 11.6. 
Estimation of an exposure level which protects the population from the 
harmful effects of a substance must consider these potentially l..vide 
differences in susceptibility. Variations in sensi ti vi ty may be caused by a 
combination of pharmacokinetic and pharmacodynrunic factors, leading to 
potentially marked differences in the shape of the dose-response curve for 
different human subpopulations (Gillette, 1985). 
Sensitive populations may also exist by virtue of increased activity 
levels. By increasing the absorption rate for inhaled substances, and 
decreasing the blood flow rate to the liver, increased activity levels modify 
the delivered dose of a substance. This m9dification in pharmacokinetics is 
especially important when considering threshold effects associated with 
short-term inhalation exposures; increased activity would decrease the time 
necessary to achieve equilibrium in blood and tissue concentrations. 
Infants represent a special risk population for several reasons. Relative 
to older children and adults, they absorb chemicals more readily from the 
gastrointestinal tract, but have lower protein binding efficiencies are less 
able to metabolize and excrete them (WHO, 1986). Toxic substances may also 
exert adverse effects on organ systems still undergoing develop~ent, such as 
the nervous, immunologic, gastrointestinal, and respiratory systems. 
Furthermore, as Figure 11.7 shmvs, weight gain in infants is higher than any 
other age group. Weight gain is evidenced by a period of rapid cell 
division. This period of rapid growth also takes place at a time when the 
body's metabolic and immunologic capabilities are not fully developed (WHO, 
1986), thus leaving the infant more potentially vulnerable to tumor 
inititators and other genetic toxins. Infants may also be at special risk by 
virtue of their relatively high degree of oral and dermal contact with toxic 
substances in the environment. This issue was raised in Chapter 8. 
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Unfortunately, lack of data, as well as an inadequate conceptual 
understanding of the mechanisms behind many chemically-induced effects, 
usually prevents a rigorous determination of risk in sensitive human 
populations. To compensate for these shortcomings, conservative assumptions 
and methodologies must be incorporated into the risk assessment. Among these 
is the assumption that some proportion of the human population will be at 
least as sensitive to the effects of a chemical as the most sensitive animal 











12. Health Effects of Reaction Products 
Some chemicals may be transformed into toxic substances as a result of 
chemical or biological reactions in the environment. A popular example of 
this is the atmospheric transformation of sulfur dioxide into sulfates. 
Reaction products, such as sulfates, are identified in the Exposure Assessment 
section (Chapter 9.1). The health effects of these reaction products should 
be reviewed, as the assessment should consider situations in which human 
exposure to a chemical's breakdown products occurs. The findings from this 
review of the health data, along with the findings from the exposure 
assessment, may form the basis for recommending that these reaction products 
undergo formal assessment themselves. The framework for this process has 
already been established in the Maine Bureau of Health's Hazardous Air 
Pollutant Program (Anderson, 1986). Consideration of breakdown products also 
has importance relative to Maine's groundwater monitoring program for 
pesticides. Ethylene thiourea, for example, an animal carcinogen and 
teratogen, is a breakdown product of widely used dithiocarbamate pesticides. 
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13. Environmental Effects 
Most risk assessment issues concern the direct human health effects of 
chemical exposure. There may be impacts, however, which indirectly affect 
human health by disrupting the environmental support systems. These 
disruptions may either be associated with alterations in environmental 
chemistry, or with impacts on biological systems. While these modifications 
could be very subtle, they could also be the most significant of all effects 
caused by toxic substances. For impacts on the climate, large segments of the 
world's population may be affected, but with no direct relationship between 
exposure and effect. Some impacts, such as the extinction of a species or 
depletion of the ozone layer, may be irreversible or require centuries to 
reverse. Because of the difficulty in interpreting the parameters which 
measure these effects, however, there is a significant concern that the 
significance of such effects will not be understood in time to prevent serious 
environmental damage. 
13.1 Effects on Environmental Chemistry. 
The chemical equilibrium of the environment is maintained by a variety of 
chemical reaction cycles. Substances which are emitted in large enough 
quantities, or whose envirorunental persistence is relatively long, may cause 
significant alterations in these reaction cycles. For example, hydrocarbon 
and nitrogen oxide emissions in the lower· atmosphere can lead to the build-up 
of ozone to toxic levels by inhibiting reactions which destroy this gas. On 
the other hand, emissions of chlorofluorocarbons into the upper atmosphere may 
enhance the destruction of ozone, thus depleting the shield which protects the 
earth from harmful ultraviolet rays. In addition to identifying sensitive 
reaction cycles, the assessment of the impacts on environmental chemistry is 
further complicated by the possibility that some chemicals may e~~ance, 
whereas others may inhibit, the same reaction cycle. 
13.2 Ecosystem Effects. 
Substances may affect ecological systems, either by direct effects on 
sensitive plant and animal species, or by disrupting the biological 
interactions which occur among these species. Such ecosytem effects involve 
agricultural, terrestrial, freshwater, saltwater, and aerial species. For 
example, depletion of certain lichen species around London \vas an indicator of 
the air pollution in that city as far back as the mid nineteenth century. 
Surveys of chemical effects on plants and animals have also helped in the 
identification of potential and actual exposures to hazardous wastes. The 
effects of chlorinated pesticides, such as DDT, on the survival of terrestrial 
wildlife has been well documented. 
Investigations concerning the effects of a substance on the environment 
may thus serve a variety of purposes. Firstly, they may identify adverse 
effects not related to human toxicity, but which significantly alter the 
functioning of systems which support human life. They may also indicate a 
source of exposure with potentially adverse implications for human health. 
Finally, they may provide additional toxicological insight regarding how 
certain substances may affect human health. For risk assessment purposes, the 
findings of these studies have the greatest relevance when the qualitative 
assessment of chemical hazard is conducted (See Chapter 15). 
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14. Structure-Activity Relationships 
Most relevant information concerning health effects is drawn from studies 
of individual compounds. Toxicological information on certain compounds, 
however, may be supplemented through the study of related compounds. These 
compounds are related in the abilities to induce the same biological effect, 
and may either be structurally similar or dissimilar (Tichy, 1983). The magni-
tude of certain toxic effects may depend more on their physical properties 
than on their specific biochemical reactivities (Tichy, 1983). The correla-
tion between the threshold limit values (TLVs) and blood air partition coeffi-
cients for a number of chlorinated hydrocarbons is described in Figure 14.1. 
This relationship suggests that the general toxicity of these compounds 
may be predicted on the basis of their relative solubilities. In other cases, 
however, basing predictions of toxicity on structural similarities may lead to 
misleading conclusions. Benzo-a-pyrene, for example, is a potent mutagen and 
animal carcinogen whereas a structurally similar compound, benzo•e-pyrene, has 
not been found to be carcinogenic (IARC, 1983). This difference may be 
attributable to differences in the ways in which the compounds are activated 
to toxic metabolites (Selkirk and MacLeod, 1979). Conversely, structurally 
dissimilar compounds may produce similar biological effects, as is thE case 
with the wide variety of compounds which can induce prolife~ation of 
peroxi soma 1 enzymes (Reddy and Lal wa i, 19 83). Thus, while in formation on 
structure-activity relationships may be useful in risk assessment, the data 
should be cautiously interpreted. 
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Figure 14.1. Relationship Between Threshold Limit Value and Partition 
Coefficients for Various Chlorinated Solvents 
Source: Sa to, A., and Nakajima, T., 1979, "A Structure-Activity Relationship 




SECT I ON V: HAZARD ASSESSMENT 
The Hazard Assessment comprises both a qualitative and quantitative 
evaluation of the health risks associated with exposure to toxic substances. 
Of the two, the qualitative assessment involves a discussion of hazard that is 
more specific to the substance of interest. Due to limited databases for most 
chemicals, quantitative assessments usually must rely on generally accepted 
procedures which are applicable to a wide variety of chemicals. These include 
the use of default uncertainty factors when estimating the degree of health 
hazard in sensitive human populations, as well as default low dose 
extrapolation models for estimating the health risks associated with 
non-threshold effects. Despite its limitations, however, the quantitative 
risk assessment findings have more practical relevance for risk management and 
risk communication purposes than do the findings of the qualitative risk 
assessments. Issues associated with this situation are discussed in the Risk 
Characterization section (Section VI). 
15. Appraisal of Hazard Identification Studies. 
In the appraisal of the Hazard Identification studies, all potential 
health effects of concern are evaluated with reference to the overall 
biological significance of chemical exposure. By comparing the findings of 
the studies, the consistency of the toxic response pattern can be evaluated. 
In this comparison, the severities of the toxicological endpoints are 
assessed, along with the abilities of the studies to detect these endpoints 
and the dose-response relationships found. This evaluation then forms the 
basis for a discussion of the mechanisms of action. After the empirical and 
conceptual basis for a chemically- induced health effect is evaluated, the 
strength of the association (or weight of evidence) between exposure and the 
occurrence of that effect in human beings is determined. 
15.1 Comparison of Study Findings. 
It is important that all the toxicologically relevant information 
identified in the assessment be evaluated. This evaluation should include a 
discussion of the non-positive as well as positive studies. Differences in 
study findings may result from differences in study design, study quality, the 
species, strain, or sex under investigation, the level of histopathological 
examination, the endpoints evaluated, and the likelihood of detecting an 
effect. This evaluation should also include a discussion of other known or 
suspected risk factors for the health effects identified in the previous 
section. 
Two factors affecting the results observed in the health studies are the 
design of the studies and the particular health endpoints measured. The first 
factor can b~ addressed by statistical comparisons of the various studies to 
determine their abilities to detect a particular effect. The second factor is 
important because various _tests have been developed to identify and measure 
the potential for a substance to cause particular health effects. These tests 
may vary si,gnificantly in their sensitivities to detect these effects. 
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Spirometry tests of lung function, for example, may not be sensitive enough to 
detect subtle changes in airway resistance (Berkow, 1982). Because the lower 
respiratory tract is particularly susceptible to damage, failure to detect an 
effect from spirometry tests does not necessarily imply the absence of an 
effect. On the other hand, if an effect is observed from spirometry tests, it· 
is a good indication that significant lung damage has occurred. Thus, 
consideration of test sensi ti vi ty is important when determining the effect 
severity and in subsequent derivations of action levels. 
Aside from the evaluation of the individual health endpoints, the 
consideration of the spectrum of identified health effects is also a relevant 
area of discussion in the appraisal of health hazards. Assessment of the full 
range of health effects which a substance may produce is helpful when 
postulating a mechanism of action (See Chapter 15.2). Different health 
effects may be correlated with one another (for example, genetic toxicity, 
carcinogenicity, and developmental toxicity). Therefore, this particular 
assessment may provide important evidence for weight of evidence determina-
tions, even in the absence of a precisely defined toxicological mechanism. 
The dose-response relationship is still another important area of 
investigation with regard to the appraisal of the hazard identification 
studies. Generally stated, as the dose of the chemical increases, so should 
its toxicity. The most obvious explanation for the lack of a consistently 
positive relationship between chemical exposure and health effect is that the 
chemical causes no toxicity. Yet, the absence of a consistent dose-response 
relationship may also be caused by a number of other factors. These include 
competing mechanisms, pharmacokinetic characteristics, and statistical 
limitations created by a small sample sizee Such factors should be assessed 
when evaluating the nature of the dose-response curve. 
The shape of the dose response curve may provide valuable qualitative 
information concerning the nature of the response. The steepness of the curve 
may be useful in estimating threshold or no effect levels. Comparisons 
between different dose-response curves may also provide information concerning 
the relationships between pharmacokinetic and toxicological responses, or the 
inter-relationships between the different toxic responses. Similar to the 
benefit gained by comparing the spectrum of toxic responses, comparisons of 
dose-response relationships may also be useful in describing possible 
mechanisms of action, as well as in the overall weight of evidence 
determinations. An example of a relationship between the metabolism and 
hepatotoxicity of tetrachloroethylene is described in Figure 15.1. The 
parallels between metabolite formation and hepatotoxicity suggest that a 
metabolite of tetracloroethylene might responsible for its toxicity to the 
liver. 
15.2 Evaluation of Health Effect Severity. 
An assessment of the hazard identification findings should include an 
analysis of health effect severity. This analysis is necessary for two 
principal reasons. Firstly, it could provide much toxicologically relevant 
information from a relatively limited database, such as might be associated 
with a single well-conducted animal bioassay for . carcinogenicity. Secondly, 
it should provide a basis for gauging a quantitative degree of health concern, 
as is needed when action levels are derived for chemical exposures using 
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Figure 15 .1. Relationship Between Tetrachloroethylene (PER) Dose and 
Toxicokinetic Parameters in Mice. a) relationship between PER dose and the 
amount of total urinary metabolite excreted per day; b) relationship between 
PER dose and the increase in liver weight. 
Source: BuLen, J.A. and O'Flaherty, E.J., 198:3, "Delineation of the Role of 
Metabolism in the Hepatotoxicity of Trichloroethylene and Perchloroethylene: A 
Dose-Effect Study," Toxicol. Appl. Pharmacal., Vol. 78, pp. 105-122. 
There are se\·eral parameters associated with cancer bioassays which may 
provide a qualitative concern regarding the potency of the carcinogenic 
response. These parameters are described in Table 15.1. Not all qualitative 
indicators of carcinogenic potency correlate well with quantitative potency 
estimates (Gold et al., 1986). Many potent carcinogens, however, have been 
found to cause tumors in multiple species and multiple sites, with relatively 
short latency periods, and with a large proportion of malignant tumors (MUnro 
and Krewski, 1981). They have also demonstrated significant biological 
activity in short-ter~ tests (Munro and Krewski, 1981). 
Squire (1981) developed a quantitative ranking system for animal 
carcinogens based on qualitative indicators of potency. According to his 
system, qualitative indicators of carcinogenicity, such as the ones listed in 
Table 15.1, are given numerical weights. The maximum score a chemical could 
receive is 100. Recommended regulatory actions would become progressively 
more severe as the numerical ranking becomes closer to 100. A score of 100, 
for example, may be very likely to result in a recommendation to ban the 
chemical. Although this system does not directly translate bioassay result 
into a measure of a human cancer risk level, it does provide a method for 
assessing the relative potencies of carcinogens based on qualitative 
considerations. At the present time, however, this quantitative approach 
appears to be too arbitrary for risk assessment purposes. 
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Qualitative criteria have also been developed for comparing the relative 
severities of developmental effects. The severity of the effects generally 
follows the paradigm established by Wilson (1973): in order of increasing 
potency, effects range from revers~ble embryotoxici ty and fetotoxici ty, to 
teratogenicity, to fetal death. Severity indices for developmental effects 
can be derived by taking the logarithm of the ratio between the lowest adult 
toxic (or lethal) dose and the lowest developmental dose (NRC, 1986). 
Finally, indices have been developed from which chemicals can be compared 
on the basis of their acute or chronic toxicity. For example', indices which 
compare relative general toxicity potencies have been developed by several 
regulatory agencies (USEPA, 1981). A summary of these systems is presented in 
Table 15.2. While this table only includes values based on oral and 
inhalation exposure, criteria regarding dermal exposures have also been 
established (USEPA, 1981), and should be followed accordingly. Criteria for 
evaluating the severity of an acute/chronic effect have been developed by the 
Massachusetts Department of Envirorunental Quality Engineering (MDEQE, 1985), 
and are presented in Table 15.3. 
15.3 Evaluation of the Evidence Regarding Mechanisms of Action. 
Ideally, all of the toxicological effects identified in the Hazard 
Identification section should be explained by some sort of biochemical 
mechanism. The extent to which these mechanisms can be derived from 
scientific studies is limited by an incomplete understanding of normal 
biological processes, and by an incomplete understanding of the biochemical 
processes leading to chemically-induced illness. Therefore, an adequate 
understanding of the toxicological mechanisms is not a prerequisite to the 
assessment of chemically-induced adverse health effects. 
When sufficient data are available to describe the mechanism of action, 
however, they can provide a sound scientific basis for interpreting the 
results of the health effects studies. This information can also represent a 
starting point for evaluating the effects of a large number of chemicals on a 
particular health parameter. Furthermore, it may provide the basis for 
predicting how certain chemicals may interact with one another. As important 
and promising as information regarding the mechanism of action can be to risk 
assessment, it should be used with caution. Specifically, hypotheses 
regarding mechanisms of action should not be used to discount the findings of 
well conducted toxicological or epidemiological studies, unless there is 




Important Characteristics of Carcinogenic Potency. 
a) The proportion of animals bearing neoplasms at each exposure level. 
The nunber of neoplasms per animal. 
The number of different types of neoplasm. 
The nunber of species affected. 
b) The magnitude of the dose at which the carcinogen~c response occurs. 
c) The proportion of malignant and benign lesions. 
d) The nature and degree of other pathological cr~nges. 
e) The organ or target tissue in which the carcinogenic response occurs. 
It should be recognized that an increase in the number of tumors of a 
type which occurs spontaneous 1y in a high proportion of the strain of 
animal being used (e.g., liver tumors or pulmonary adenomas in certain 
strains of mice) carries less weight in the estimation of potency than 
does the appearance of tumors in other organs. 
f) The latency period before tumor development. The shorter the latency 
period the more potent is the chemical. 
g) The sensitivity of the experimental model. 
h) G1emical similarity to other kno~u carcinogens. 
i) GEnetic toxicity and activity in short-tenn tests for carcinogenicity. 
j) Biochemical reactivity with DNA, R~A, am protein. 
k) Further infonnatior: obtained from othtr toxicological studies such as 
kinetic am metabolic data. The significance of these in the 
estima.tion of potency to man is not clear in every case. Fundamental 
differences in genetic make-up bet·ween animaJs am man, which can lead 
to wide variations in response to the action of chemicals, inclu:ie 
differences in illiDune arrl hormonal status, among others. 
Sources: Munro, I .C., and Krewski, D. R., 1981, "Risk Assessment and 
Regulatory Decision Making," Food ·cosmetic Toxicol., Vol. 19, p. 556; 
Purchase, I.F.H., 1985, "CarcfiiO'gen1c R1sk Assessment: A Toxicologist's 
View," in D.G. Hoel et al. (eds.), Risk Quantification and Regulatory Policy, 
Cold Spring Harbor Laboratory, pp. lsr=f82. 
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Table 15.2 
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Mild or Transient Irritant Effects (e.g. runny nose, 
eye irritation, coughing). 
MOderate to Severe Irritant Effects; Mild 
Transient systemic effects; effects 
considered to be reversible (e.g., 
anoxia, incoordination, fatigue, 





Irreversible Pulmonary Effects; Serious Systemic 
Effects; chronic or persistent effects; cumulative 
effects; effects involving multiple sites or organ 
systems (e.g., cirrhosis, emphysema, epilepsy, 
peripheral nerve damage). 
Source: MDEQE (Massachusetts Department of Environmental Quality 
Engineering), 1985, Chemical Health Effects Assessment Methodology, 
Massachusetts Department of Environmental Quality Engineering, Boston, Mass., 
p. 99. 
15.4 Weight of Evidence Determinations. 
Weight of evidence refers to likelihood that particular health effects 
occur in human populations as a result of chemical exposure. Weight of 
evidence determinations do not directly consider potency. Rather, they 
determine the data adequacy concerning the association between toxic substance 
exposure and a particular adverse health effect. Judgments are made with 
respect to both human and animal studies, and can be classified as 
"sufficient," "limited," "inconclusive," "inadequate," or "negative." These 
judgments, therefore, reflect the conclusions made in the evaluation of 
individual studies (See Chapter 5.1). 
The weight of evidence from epidemiological and toxicological studies 
increases with the strength of the association, the presence of a 
dose-response relationship, and the number and proportion of corroborating 
studies. Replicated studies reduce the possibility that apparently positive 
results were observed by chance alone. Replicated studies done by different 
investigators further add to the weight of evidence by addressing any 
intralaboratory biases. The strongest evidence is derived from studies on 
human populations. With respect to animal studies, if an effect can be 
induced in different sexes, strains, or species, the likelihood that the 
effect will also occur in human populations is increased. In vitro studies 
are also used in weight of evidence determinations. Generally, they are used 
as evidence in support of epidemiological or toxicological studies. They are 
useful when assessing similarities in activity among structurally related 
compounds or in postulating possible mechanisms of action. 
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For all health effects, weight of evidence determinations should 
distinguish between primary effects and secondary effects which may result 
from an initial toxic effect on the cell. These determinations also need to 
consider the possibility that significant toxicity may prevent the effect of 
concern from being detectable or becoming manifest. Preliminary assays in 
genetic toxicity experiments should be able to determine substance dose levels 
which result in significant cytotoxicity (WHO, 1985). Likewise, subchronic 
assays should be run to determine maximum tolerated doses for cancer bioassays 
and maternally toxic doses for experiments on developmental toxicitye 
15.4.1 Genetic Toxicity. 
Weight of evidence for genetic toxicity refers to the likelihood that 
exposure to a chemical will result in some sort of DNA damage. The weight of 
evidence increases as the test systems showing a positive response more 
closely reflect actual human exposures. Within this context, two issues 
warrant special consideration. The first issue concerns the preference for 
experimental conditions which reflect the response of the entire organism, as 
opposed to the response of cells cultured in vitro. This preference is based 
on the fact that there are physiological fi:lfluences on toxicity which cannot 
be studied in vitro. 
The second issue concerns the preference for species most closely related 
phylogenetically to human beings. This preference is based on the fact that 
potential differences in cell biology may exist which could lead to misleading 
interpretations of the test results. Of particular importance is the 
difference between procaryotic and eucaryotic cell types. Eucaryotes differ 
from procaryotes with respect to many characteristics. For example, 
eucaryotic cells contain a nuclear membrane, have multiple chromosomes, have 
histones bound to these chromosomes, have large numbers of repetitive 
nucleotide sequences, divide by mitosis, and contain several organelles such 
as lysosomes (Calabrese, 1983; Stanier et al., 1976). These differences could 
account for significant variations in the responses of these two cell types to 
genetic toxins. 
Eucaryotic organisms may also differ in their responses to genetic 
toxins. For example, human beings exhibit substantially greater DNA exc1s1on 
repair capacity than do rodents (Calabrese, 1983). On the other hand, human 
peripheral lymphocytic chromosomes have been found to be twice as sensitive 
than those of mice to the induction of translocations by ionizing radiation 
(Calabrese, 1983). Techniques to directly and accurately measure the effects 
of suspected genetic toxins on human populations are currently being 
developed, and may soon be available for widespread use (Thilly and Call, 
1986; OTA, 1986). 
In addition to the overall preference for phylogenetic closeness and in 
vivo experiments, findings from all well conducted experiments should be 
exa'iiiined for reproducibility, a consistent dose-response curve, and the type 
of genetic lesion produced (WHO, 1985). Whole animal experiments may lack 
sufficient sensitivity for detecting potentially genotoxic compounds, despite 
the fact that these experiments consider in vivo conditions (WHO, 1985). 
Furthermore, although reflective of responses--In procaryotic organisms, 
results from bacterial assays correlate strongly with known carcinogens and 
non-carcinogens in eucaryotic organisms (MCCann et al., 1975; Purchase et al., 
1978). McCann et al. (1975) found that approximately 90 percent of 
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carcinogens were also bacterial mutagens and that 90 percent of 
non-carcinogens failed to show mutagenic activity, when Salmonella typhimurium 
was used as the test organism. These findings were corroborated by Purchase 
et al. (1978). The ability of the Salmonella assay to detect carcinogens may 
even be greater if certain classes of compounds are excluded (OTA, 1981). 
This high degree of correlation has been recently questioned, as more 
chemicals have been tested and found not to conform to this paradigm (Tennant 
et al., 1987). Nonetheless, the correspondence between the Salmonella assay 
and the animal cancer bioassay findings reinforces the need to consider 
bacterial assays in carcinogenicity assessments. Conversely, a lack of 
mutagenicity in the bacterial assays should not necessarily alter the weight 
of evidence conclusions drawn from well conducted animal bioassays. 
The Massachusetts Department of Environmental Quality Engineering 
developed weight of evidence guidelines based on various national and 
international risk assessment committees (MDEQE, 1985). These guidelines are 
presented in Table 15.4, with expanded documentation presented in Table 15.5. 
While the U.S. Environmental Protection Agency has no specific reco~~endations 
for the evaluation of mutagenicity test results relevant to chronic diseases 
such as cancer (USEPA, 1986a), it has developed guidelines relating 
specifically to germ cell mutations (USEPA, 1986b). These guidelines are 
presented in Table 15.6. 
A separate weight of evidence determination for genetic toxicity may be 
unnecessary when positive toxicological or epidemiological data are available 
on carcinogenicity, developmental toxicity, and other potentially relevant 
chronic effects. In the absence of such information regarding these effects, 
the guidelines presented above provide a useful basis for making weight of 
evidence determinations regarding genetic toxicity. The presentation of this 
evidence should also be accompanied by statement regarding the level of 
testing. By doing so, the assessment could distinguish between 
classifications based on the weighing of positive and negative results and 
those based on lack of data. 
15.4.2 Carcinogenicity. 
The weight of evidence determination for tarcinogenici ty concerns \vhether 
or not a substance can be considered as a human carcinogen. Epidemiological 
studies and animal bioassays are the primary areas of investigation from which 
weight of evidence determinations are made. Both areas, however, are subject 
to limitations regarding their abilities to demonstrate causal connections 
between human exposure and carcinogenesis. Epidemiological studies have 
limited abilities to rigorously characterize exposed and non-exposed 
populations, to identify enough of these individuals to produce statistically 
meaningful results, and to separate the potential effects of a particular 
substance from those of other risk factors. Studies designed to address these 
obstacles generally require large amounts of time and resources to follow 
study populations over time. 
Animal bioassays are limited by the fact that they are not direct 
qualitative or quantitative measures of a human response. Such limitations 
are becoming increasingly relevant in light of the growing numbers of 
chemicals identified in the animal studies as being potentially carcinogenic. 
Only about 30 chemicals or chemically-related processes have been positively 
associated with human cancer, while a few hundred have been found to be 
carcinogenic in laboratory animals (IARC, 1982; NTP, 1985). 
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Table 15.4 
Scoring for Mutagenicity According to the MDEQE'S Chemical Health 

















Group I: Two or More A. 
-~------ or ---------------------------------
Group I I: Four or More A 
-------- or ---------------------------------
Group III: Six or More A. 
-------- or ---------------------------------
Group I: One 
-------- and ~-------------------------------· A. 
Group I I: One or More · 
-------- or -----------------------------------------
Group I: One 
-------- and --------------------------------• A. 
Group II I : Two : 
Group I: One B 
-------- or -----------------------------------------
Group II: Three i B 
-------- or -----------------------------------------
Group III: FourorFive ! B 
-------- or -----------------------------------------
Group II: One or Two i 
------- e and ---------------------------------., B 
Group I II: Three i I 









Group III: Two or Three I C I 
-------- or ---------------------------------·------- j 
~~~~-~~'and ~~-~~-~~----------------------1 C I 
Group I I I: One or Two 1 ___j 
Group I II : One ! D : 
No Data or Non-positive Data E 
~IDEQE (Massachusetts Department of Environmental Quality Engineering), 1985, 
Chemical Health Effects Assessment Hethodology, Massachusetts Department of 
Environmental Quality Engineering, Boston, Mass., p. 167. 
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Table 15.5 
Categories of MUtagenicity Tests Used in MDEQE'S 
Weight of Evidence Protocol 
, TEST DESCRIPTION/WE 
Group I: Mammalian, In Vivo 
Mouse Specific Locus Test 
Mouse Spot Test 
Dom1nant Skeletal Mutation 
Dominant Cataract Assay 
Dominant Lethal Test - Rodents 
Heritable Translocation Test - Rodents 
Micronucleus Test - Mouse 
Group II: Primary Short-Term Tests 
Chinese Hamster LunQ (V79) Cells, All Loci 
Chinese Hamster Ovacy (CHO) Cells 
Mouse Lymphoma (LS178Y) Cells, TK Locus 
S. typhimurium, histidine reversion (Ames Test - TA98, Tl\100, TA1535, Tl\1537-8) 
E. coli (WP2/WP2 uvra) - reverse mutation 
Sex-Linked Recessive Lethal Test - Drosophila m. 
Host-~ediated Assay Studies 
Mammalian Cytogenetics, bone marrow/lymphocyte or leucocyte 
Ma~~alian Cytogenetics, oocyte, early err:]ryo/male germ cell 
Mammalian Cytogenetics, lymphocyte, leucocyte/cell culture 
Mammalian Cytogenetics, all mammalian 
!>1icronucleus Test, 1 ymphocyte 
Micronucleus Test, mammalian cell 
Heretible (reciprocal) Translocation Test - Drosophila 
Sister Chromatid Exchange - lymphocyte 
Sister Chromatid Exchange- cells/embryonic lung fibroblasts (WI-38)/lymphocyte 
Sister Chromatid Exchange - in vivo/in vitro 
A. nidulans - cross over studies 
S. cerevisiae, homozygous - recombination/gene conversion 
E. coli pol A (~3110-P3478) - with 59/without 59 
B. subtilis rec (H17-~5/17A4ST) - spot test 
Human Sperm Morphology 
Cell Transformation Studies - B.UB/C-3T3 I C3H/10Tl/2 
Cell Transformation Studies - mouse prostate 
Cell Transformation Studies - Syrian hamster embryo 
Cell Transformation Studies - SA7 Fischer rat cells 
Group II I: Secondary Short-Term Tests 
Forward/Reverse Mutation, S. cerevisiae (YEF/YER) & S. pombe (YEY/YEZ) 
Fon.-ard/Reverse Mutation, 1\. nidulans 
Forward/Reverse Mutation, N. crassa 
Plant Gene Mutation Studies 
Body Fluid Ass1y - urine 
Aneuploidy Studies, whole sex chromosome - loss/~ain 
Aneuploidy Studies, S. cerevisiae/ A. nidulans/ N. crassa 
Micronucleus Test - plants 
Plant Chromosome Studies 
Mammalian Sperm ~orphology - mouse/rabhit/rat 
Mammalian Sperm Morphology - mouse Fl assay 
Unscheduled DNA Synthesis - human diploid fibroblast 
Unscheduled DNA Synthesis - mouse germ cells 
Unsch~duled DNA Synthesis - rat primary hepatocyte 
Source: MDEQE (M:l.ssaChusetts Department of Environmental Quality Ei-lg1neering) 
1985, Chemical Health Effects Assessment Methodology, Massachusetts Department 
of Envirorunental Quality Engineering, Boston, Mass., p. 161. 
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Table 15.6 
Weight of Evidence Hierarchy for Germ Cell Mutations. 
1. Positive data derived from human germ-cell mutagenicity studies, when 
available, will constitute the highest level of evidence for human 
mutagenicity. 
2. Valid positive results from studies on heritable mutational events (of any 
kind) in mammalian germ cells. 
3. Valid positive results from mammalian germ-cell chromosome aberration 
studies that do not include an intergeneration test. 
4. Sufficient evidence for a chemical's interaction with mammalian germ 
cells, together with valid positive mutagenicity test results from two assay 
systems, at least one of which is mammalian (in vitro or in vivo). The 
positive results may both be for gene mutations or both l:or~romosome 
aberrations; if one is for gene mutations and the other for chromosome 
aberrations, both must be from mammalian systems. 
5. Suggestive evidence for a chemical's interaction with mammalian germ 
cells, together with valid positive mutagenicity evidence from two assay 
systems as described under 4, above. Alternatively, positive mutagenicity 
evidence of less strength than defined under 4, above, when combined with 
sufficient evidence for a chemical's interaction with mammalian germ cells. 
6. Positive mutagenicity test results of less strength than defined under 4, 
combined with suggestive evidence for a chemical's interaction with mammalian 
germ cells. 
7. Although definitive proof of non-mutagenicity is not possible, a chemical 
could be classified operationally as a non-mutagen for human germ cells, if it 
gives valid negative test results for all endpoints of con~ern. 
8. Inadequate evidence bearing on either mutagenicity or chemical interaction 
with mammalian germ cells. 
Source: USEPA (U.S. Environmental Protection Agency). 1986b, "Guidelines for 
Mutagenicity Risk Assessment," Federal Register, Vol. 51, pp. 34005-34012. 
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According to the u. S. Environmental Protection Agency (USEPA, 1986a) and 
the International Agency for Research on Cancer (!ARC, 1982), in the absence 
of adequate human evidence, a chemical which is found to cause cancer in 
laboratory animals should be presumed to cause cancer in human beings as 
well. The strength of the association, however, depends on the weight given 
to the animal studies and to the negative epidemiological studies. Criteria 
for assessing the weight of evidence for chemical carcinogens have been 
developed by both agencies (USEPA, 1986a; !ARC, 1987; !ARC, 1982). The two 
classification systems are very similar, especially" when the USEPA criteria 
are compared with the more recent !ARC criteria (!ARC, 1987). The only major 
difference is that !ARC considers as limited evidence those "neoplasms which 
may occur spontaneously in high incidences in certain strains," whereas USEPA 
considers this evidence sufficient unless other information is available to 
justify a lower classification.. The reasoning employed by the USEPA is more 
consistent with the principles of worst case risk assessment than the 
reasoning employed by !ARC. The USEPA criteria, therefore, are adopted by the 
Maine Bureau of Health to provide general policy guidance. These USEPA 
criteria for evaluating human and animal evidence are presented in Tables 15.7 
and 15.8. 
Three issues pertaining to these criteria require special attention. The 
first issue concerns the criteria which must be met before a causal 
association can be inferred from epidemiological studies. Again according to 
the U. S. Environmental Protection Agency (USEPA, 1986b) and the International 
Agency for Research on Cancer (!ARC, 1982), three criteria must be met : (1) 
there is no identified bias which could explain the association, (2) the 
possibility of confounding has been considered and ruled out as explaining the 
association, and (3) the association is unlikely to be due to chance. 
The second issue concerns the ·distinction between benign and malignant 
tumors in animal studies. Although USEPA and !ARC placed specific emphasis on 
the presence of malignant tumors, this distinction may only be warranted in 
special circumstances. No chemical has yet been identified that produces only 
benign neoplasms (Williams and Weisburger, 1986). Also, many chemicals which 
induce primarily benign tumors in one species or strain induce malignant 
tumors in other species or strains (CDHS, 1985). Furthermore, truly benign 
tumors in rodents are consider to be rare and may actually represent· a stage 
in the progression to malignant tumors (OSTP, 1985). Finally, !ARC has stated 
that the discrimination between benign and malignant tumors is not as 
important an issue as it was once considered to be (!ARC, 1980). Thus, the 
incidence of only benign tumors should be·considered as evidence in support of 
the presumption of human carcinogenicity. When benign and malignant tumors 
appear together, their incidences may be combined, subject to established 
guidelines (NTP, 1984). 
The third issue concerns the occurrence of false positives in animal 
studies. Typical bioassay protocols require analysis of 20 to 30 sites in 
both sexes of two species at two dosage levels (OSTP, 1985). The possibility 
needs to be addressed, therefore, that a statistically significant response 
may occur by chance. For a random binomial distribution in which 20 sites are 
evaluated at a 0.05 significance level, the probability of a false positive is 
about 0.64 for a single dose-sex-species combination, and about 0.87 for both 
sexes (Gart et al., 1979). Tests done at multiple doses yield even larger 
probabilities for false positives, according to this random distribution 
assumption (Gart et al., 1979). This argument has been criticized, however, 
on the grounds that the bioassay data represent counts, not continuous data 
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Assessment of Evidence for Carcinogenicity from Studies in Human Beings 
i. Sufficient evidence of carcinogemClty, which iMicates that there 
is a causal relat1onsh1p between the agent and human cancer. 
ii. Limited evidence of carcinogenicity, which indicates that a causal 
interpretation 1s credible, but that alternative explanations, such as chance, 
bias, or confounding, could not adequately be excluded. 
iii. Inade~ate evidence, which indicates that one of three conditions 
prevailed: (a) ~ere were few pertinent data; (b) the available studies, while 
showing evidence of association, did not exclude chance, bias, or confounding, 
and therefore a causal interpretation is not credible. 
iv. No Data, which indicates that data are not available. 
v. No EVIdence, which ir¥iicates that no association was foum between 
exposure ana an 1ncreased risk. of cancer in well-designed and well-conducted 
independent analytical epidemiological studies. 
Source: USEPA (U.S. Environmental Protection Agency). 1986a, "Guidelines for 
Carcinogen Risk Assessment," Federal Register, Vol. 51, pp. 33991-34003. 
Adapted from: IARC (International Agency for Research on Cancer), 1982, 
Chemicals, Industrial Processes and Industries Associated with Cancer in 
Humans, !ARC Monographs Supplement 4,Lyon, France. 292 pp. 
Table 15.8 
Assessment of Evidence for Carcinogenicity from Studies in Experimental -~imals 
i. Sufficient evidence of carcinogenicity, which indicates that there 
is an increased Incwence of malignant ttJDours or canbined malignant anJ 
benign tumors: (a) in multiple species or .st_rains;. or (b). in ~ultiple 
experiments (e.g, with different routes of adm1nlstrat1on ?r ~s1ng different 
dose levels); or (c) to an unusual degree with regard to 1nc1dence, s1te or 
type of tumour, or age at onset. Additional evidence may be provided by data 
on dose-response effects, as well as information from short-term tests or on 
chemical structure. 
11. Limited evidence of carcinogenicity, which means that the data 
suggest a carc1nogen1c effect but are ~imited because: (a) the s~udi~s 
involve a single species, strain or expenment and do not meet the en ten a 
for sufficient evidence described in i(c); (b) the experiments are restricted 
by inadequate dosage levels, inade~ate .duration of ex~sure to t.he agent, 
-·inade~ate period of follow-up, poor surVlva1, too few ammals, or Inadequate 
reporting; or (c) an increase in the ~ncid~nc~ of benign tumors only. . 
iii. Inadecpate evidence~ w!'nch 1nd1cate.s that becau.se of maJor 
q.~alitative or quantltatlve hmltatlons, the st~d1es ~annot be 1nterpreted as 
showing either the presence or absence of a carc1nogen1c effect. 
iv. No data, which indicates that data are not available. 
v. No evr<Ience, which indicates that there is no increased incidence of 
neoplasms Tn at least two well-designed and well-conducted animal studies in 
different species. 
Source: USEPA (U.S. Environmental Protection Agency). 1986a, "Guidelines for 
Carcinogen Risk Assessment," Federal Register, Vol. 51, pp. 33991-34003. 
Adapted from: IARC (International Agency for Research on Cancer), 1982 
Chemicals, Industrial Processes and Industries Associated with Cancer i~ 
!±:.01ans, IARC ~bnographs Supplement 4,Lyon, France. 292 pp. 
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(OSTP, 198S; Gart et al., 1979). When the nature of the _bioassay data is 
considered, many investigators believe that the overall false positive rate 
does not greatly exceed O.OS (Gart et al., 1979; OSTP, 198S). One reason for 
this concerns the background rate of tumor formation in laboratory animals. 
There are relatively few sites in commonly treated laboratory animals for 
which enough tumor bearing animals would be observed so that one could find by 
chance alone a significantly increased tumor incidence at the O.OS level (Gart 
et al., 1979). For these sites (for example, those sites with background 
tumor rates above S percent), certain considerations may apply to ensure that 
the elevated response did not occur by chance. These include the requirement 
of corroboration of the response from other bioassays, or the imposition of a 
more stringent significance level. Haseman (198S), for example, recommended 
that a chemical be regarded as carcinogenic if it produces a high dose 
increase in a common tumor that is statistically significant at the 0. 01 
level, or a high dose increase in in an uncommon tumor that is statistically 
significant at the 0 .OS level. Another recommendation is the use of the 
Bonferroni correction, which divides the significance level by the number of 
dose groups (Gart, 1979). According to this modification, if the significance 
level for an elevated tumor response in a one dose experiment is 0 .OS, the 
significance level for an elevated tumor response in a two dose experiment 
would be 0.02S. Such adaptations to statitistical tests should be considered 
when evaluating the likelihood of a false positive finding in a bioassay. 
In addition to the criteria developed for evaluating human and animal 
evidence, criteria have also been developed by the U. S. Environmental 
Protection Agency (USEPA, 1986a) and the International Agency for Research on 
Cancer (Vaino, 1987) to determine the overall weight of evidence criteria 
regarding a substance's human carcinogenic potential. These classification 
systems, which are presented in Tables lS .9 and lS .10, rely largely on the 
criteria which were developed for evaluating human and animal evidence. 
Overall, the IARC classification system appears to place less weight on the 
animal evidence than does the USEPA. Both systems, however, are designed to 
be flexible in order to incorporate other relevant data into the weight of 
evidence determination. It is, therefore, difficult to establish precisely 
how various substances will be evaluated according to these different· 
classification systems. 
Although useful to a cancer policy, the guidance provided by the weight of 
evidence criteria just described may still not address all concerns relevant 
to a proper determination of human carcinogenic potential. Criteria are 
needed to help avoid arbitrary judgments. They can provide the assessment 
process with a basis for deciding which chemicals clearly should or should not 
be considered as human carcinogens. Often, however, the carcinogenicity data 
bases associated with a particular substance are not easily amenable to strict 
classification. A thorough analysis of the data is generally required in 
these situations. 
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* Quoting the USEPA, "the above assignments are presented for illustrative 
purposes. There may be nuances in the classification of both animal and human 
data indicating that different categorizations than those given in the table 
should be assigned. Furthermore, these assignments are tentative and may be 
modified by ancillary evidence. In this regard all relevant information 
should be evaluated to determine if the designation of the overall weight of 
evidence needs to be modified. Relevant factors to be included along with the 
tumor data from human and animal studies include structure-activity 
relationships, short-term test findings, results of appropriate physiological, 
biochemical, and toxicological observations, and comparative metabolism and 
pharmacokinetic studies. The nature of these findings may cause an adjustment 
of the overall categorization of the weight of evidence." 
Group A Human Carcinogen 
Group B Probable Human Carcinogen 
Group Bl - Reserved for agents for which there is limited evidence of car-
cinogenicity from epidemiologic studies. 
Group B2 - Reserved for agents for which there is sufficient evidence from 
animal studies and for which there is inadequate evidence, or no 
data from epidemiologic studies. 
Group C Possible Human Carcinogen 
Group D Not Classifiable as to Human Carcinogenicity 
GroupE Evidence_of Non-Carcinogenicity for Humans 
Source: USEPA (U.S. Environmental Protection A.gency). 1986a, "Guidelines for 
Carcinogen Risk Assessment," Federal Register, Vol. 51, pp. 33991-34003. 
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Table 15.10 
IARC Classification System for Assessing the Overall Weight of 
Evidence for Human Carcinogenicity 
Strength of Evidence from Animal Studies 
Sufficient Limited Inadequate No Data 
Strength Sufficient 1 1 1 1 
of 
Limited 2A 2A*/2B 2A*/2B 2A*/2B 
Evidence 
from Inadequate 2A**/2B zB+/3 3 3 
Human 
No Data 2A**/2B zB+/3 3 3 
Studies 
Negative 3 3 3/4+ 3/4+ 
* = "exceptionally" solely on the basis of limited evidence in humans. 













Carcinogenic to Humans 
Probably Carcinogenic to Humans 
Possibly Carcinogenic to Humans 
Not Classifiable as to its Carcinogenicity to Humans 
Probably not Carcinogenic to Humans 
Source: H. Vaino, Chief, Unit of Carcinogen Identification and Evaluation, 
International Agency for Research on Cancer, Letter to Elizabeth Bourque, 
Massachusetts Department of Public Health, January 20, 1987. 
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15.4.3 Reproductive and Developmental Toxicity. 
The weight of evidence determination for reproductive effects concerns 
whether or not a substance can be considered as a human reproductive toxin. A 
similar determination is made regarding developmental effects. These 
determinations rely primarily on evidence from animal studies, as reproductive 
and developmental toxicity endpoints have been inadequately monitored in human 
populations (Workshop, 1986; Dixon, 1986). In contrast to the weight of 
evidence determinations for carcinogenicity, no international or federal 
criteria exist to evaluate the weight of evidence regarding these effects. As 
a general principle, a substance associated with a significant increase in a 
developmental effect in any well conducted animal bioassay should indicate a 
human health concern. Furthermore, the substance should be considered as a 
human reproductive or developmental toxin unless it can be adequately 
demonstrated that the response occurred by chance or that the observed 
response is not relevant to human risk assessment. 
The probability that an adverse reproductive outcome occurred by chance 
depends in part on the number of endpoints evaluated. Although a general 
consideration for the evaluation of all health effects, chance occurrence is 
particularly important in relation to these effects. Several toxicological 
endpoints have been identified (See Chapter 11.2 .3). Furthermore, many of 
these endpoints are not independent events. Examples of this interdependency 
include the relationship between fetal weight and litter size, and the 
competition between teratogenicity and embryolethali ty as the dosage levels 
increase. Such considerations need to be addressed when assessing the 
biological significance of elevations in adverse reproductive outcomes. 
When assessing the relevance of an adverse reproductive or developmental 
effect, the degree of consistency among the studies should also be 
considered. With regard to animal studies, the strength of the association 
between exposure and effect increases with the proportion of positive studies 
and the severity of the response observed. Special consideration is warranted 
when similar studies produce conflicting results. In the absence of adequate 
data on human beings, however, positive findings from a well conducted animal 
bioassay may constitute a sufficient basis for presuming that the substance 
could cause adverse developmental effects in human beings. 
The human data base, although generally limited, should also be considered 
in the weight of evidence determination. A small number of chemicals have 
been directly identified as posing reproductive or developmental risks to 
human beings (See, for example, Schardein, 1985; Dixon, 1986). Also, although 
laboratory animals may be considered sufficiently sensitive as far as 
detecting potential human teratogens, they may vary considerably in their 
specificity to chemicals with no known human teratogenic potential. Only 28 
percent of the chemicals no known human teratogenic potential were also found 
to be negative in all animals tested for teratogenicity (Brown and Nigel, 
1983). It is currently unknown the extent to which this reflects a true lack 
of specificity in the animal models, differences in dosing regimens, or the 
limited nature of the human data base for teratogens (Brown and Nigel, 1983; 
IRLG, 1986; NRC, 1986). Therefore, human evidence is usually inadeqate to 
negate the findings of reproductive or developmental toxicity in experimental 
animals. 
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15.4.4 Other Acute/Chronic Toxicity. 
Weight of evidence determinations may be made for effects other than 
mutagenicity, carcinogenicity, or reproductive and developmental toxicity. 
Health concerns associated with exposure to toxic substances encompass more 
than these three endpoints. Often, however, at tent ion is given to these 
effects because they represent sensitive indicators of an adverse health 
impact in response to chemical exposures. 
Any substance can be toxic if it is administered at high enough doses, as 
Paracelsus noted several hundred years ago. A substance may induce different 
toxic responses through different mechanisms, however. Hexane, for example, 
may directly cause narcosis; it may also cause peripheral neuropathy after 
being metabolized to 1,2-hexanedione (Clayton and Clayton, 1982). 
Toxicological mechanisms which are responsible for acute lethality, for 
example, may not be relevant to the evaluation of subtler acute or chronic 
effects (such as sensitive, but biologically significant, neurologic or 
immunologic toxicity). Yet, information is not generally available regarding 
the subtle, non-carcinogenic, long-term effects of chemicals on different 
organ systems. This may represent a serious deficiency in the toxicological 
data base for a chemical. A discussion of the weight of evidence for such 
toxic interactions, therefore, should address the extent of the data base, and 
the sensitivity of tests in which positive results were observed. 
In the absence of adequate human evidence, the strength of the association 
between exposure and a particular effect increases with the proportion of 
animals showing a positive response. It should be emphasized, hov.rever, that 
there is no a priori method to determine whether or not a response in a 
laboratory an1mal IS Indicative of a human response. As with the assessment 
of carcinogenic or developmental effects, animal models may differ markedly in 
their abilities to identify acute or chronic effects in human beings (Connelly 
and Bridges, 1986). While it is possible that a substance may produce an 
effect in laboratory animals which is not relevant to human beings, it is also 
possible that several, if not all, of the animals tested may not be as 
susceptible as human beings to a chemical exposure. Examples of cases in 
which animal models have failed to predict human responses are presented in 
Table 15.11. Unless there is sufficient information to the contrary, 
therefore, it must be assumed that human beings are at least as susceptible as 
the most susceptible animal species to chemical exposure effects. 
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Table 15.11 










Toxic Outcome Observed 













All Mammals Tested 
All Mammals Tested 
All Mammals Tested 
All Mammals Tested 
Rats and Rabbits 
All Species Tested 
All Species Tested 
Most Rat Strains 
All but Hairless 
Source: Connelly, J .. C., and Bridges, J.W .. , 1986, "Species Variation in Target 
Organ Toxicity," in G.M. Cohen (ed.), Target Organ Toxicity, Vol. I, CRC Press 
Boca Raton, FL, p. 91. 
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16. Quantitative Evaluation of Dose-Response Relationships. 
The quantitative evaluation of the dose-response relationships focuses on 
those studies which can quantitatively correlate health effects with 
exposure. First, criteria are needed in order to determine which studies are 
adequate for quantitative risk assessment. Also, procedures are needed to 
estimate equivalent doses when the quantitative assessment involves 
extrapolations between species or between different exposure regimens. The 
remainder of the quantitative evaluation is concerned with the derivation of 
action levels. Action levels are derived from studies on relatively small 
populations of human beings or laboratory animals, but are expected to 
represent quantitative indices of health concern for the entire population. 
Therefore, consideration should be given to the intraspecies and interspecies 
variability in toxicity. This consideration is addressed through two 
approaches: 1) the application of uncertainty factors to the data in the 
experimental range and 2) low dose extrapolation of the dose-response curve by 
using mathematical models. 
16.1 Selection of Studies for Quantitative Risk Assessment. 
Once a weight of evidence determination has found that there is a positive 
association between chemical exposure and a particular health effect, an 
assessment of the degree of associated health hazard as a function of exposure 
dose should be conducted. Before a quantitative assessment can be done, 
however, a determination has to be made regarding which of the studies can be 
used in this assessment. Selection criteria should consider two risk 
assessment policy objectives: 1) the need for the assessment to provide 
conservative, worst-case risk estimates in the face of scientific uncertainty, 
and 2) the need for the assessment to reflect the best scientific 
understanding of the issue. 
The first objective is addressed by selecting the studies which show the 
most sensitive toxic responses, and by selecting the experimental groups which 
are the most susceptible to exposure related effects. Identification and 
quantification of subtle effects reduces the uncertainty in the estimation of 
action levels. Basing the risk estimates on the most susceptible experimental 
group reduces the likelihood that the response in human populations is 
underestimated. The second objective is addressed by selecting studies which 
are superior in terms of design and conduct, which most closely reflect or 
predict the human responses, which are most applicable to the exposure route 
of concern, and which provide the best quantitative estimates of 
dose-response. · The need to consider these two policy objective often results 
in the selection of multiple studies relevant to a specific health effect. It 
is a matter of scientific judgment as to which of the resulting risk estimates 
is the most appropriate for the characterization of human health risks. 
Situations often arise in which no studies on a particular substance are 
considered adequate for quantitative risk assessment. In these cases, risk 
characterization must rely solely on qualitative considerations. Default 
action levels, based on the presumption that public health risks should be 
kept to a minimum when data are inadequate to evaluate risks, may be developed 
for these substances. These action levels may lack the scientific 
justification necessary to be considered in a risk assessment policy. They 
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should, nonetheless, be considered within the context of an overall public 
health policy. 
16.2 Calculation of Equivalent Exposure Units. 
In order for toxic effects to be precisely compared quantitatively, 
equivalent dose units have to be derived between the test population and the 
human population of concern. The most direct measure of chemical dose 
involves the concentration of either the chemical or its toxic metabolite of 
the chemical at a site of action. Often, however, data are insufficient to 
calculate this value for either population, and surrogate estimates need to be 
derived. Such surrogates may be the administered·dose, the absorbed dose, the 
absorbed dose adjusted for interspecies differences in pharmacokinetics, or 
the metabolized dose. 
The administered dose of the parent chemical is frequently used as a 
surrogate for the dose of the active chemical (either the parent chemical or 
one or more of its metabolites) at the site of action. This dose may be 
expressed in a variety of ways. Inhalation studies, for example, commonly 
express administered dose in terms of a mass of chemical per unit volume of 
air (e.g., mill igrams/m3) or volume of chemical per unit volume of air (e.g. 
parts per million). Oral studies may express administered dose in terms of 
the chemical concentration in food or water (e.g. parts per million). 
A consideration in the calculation of an equivalent administered exposure 
dose between the study population and the human population of concern is the 
need to adjust for differences in chemical uptake. For a given concentration 
of a substance in air, food, or water, the actual intake differs significantly 
between human beings and laboratory animals, and between adults, children and 
infants. Mimimum food, water, and air intake requirements vary in relation to 
body size (Guyton, 1947; Adolph, 1949). Adjustments are therefore needed to 
address the relationship between body size and intake rates. Further 
adjustments may be needed to address other factors associated with intake 
differences. These include differences in activity levels, and in food and 
water consumption patterns. Inhalation rates for selected human and rodent 
populations are presented in Table 16.1. Depending on the comparisons 
required of the assessment, intake parameters other than those listed in Table 
16.2 may need to be considered as well. With this information, the 
administered dose can be standardized to body mass, such as the mass of 
chemical administered per unit body weight per day (mg/kg/day). 
While the admininstered dose is usually identified in the health effects 
studies, it may not correlate well with the toxicological response. Reliance 
on the administered dose may lead to imprecise estimates of human health risks 
if pharmacological differences associated with different absorption or 
different metabolic characteristics are not considered. The absorbed and 
delivered doses may vary with the exposure routes, dose levels, or species. 
Metabolic differences within species and between species may also signficantly 
influence the amount of the proximal toxin that reaches the site of action. 
If the proximal toxin is the parent compound, the concentration of the active 
compound at the site of action decreases as metabolism increases. If a 
metabolite is the proximal toxin, the concentration of the active compound at 
the site of action increases as metabolism increases. The quantitative 
association between dose and response can thus be greatly improved by efforts 
to estimate the dose of the chemical actually delivered to the site of action. 
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Table 16.1 
Inhalation Rates for Selected Human and Rodent Populations 
Population 
70 Kilogram Adulta 
10 Kilogram Infantb 
Rat (300 grams)C 





















a Source: I. Astrand, 1983, "Effect of Physical Exercise on Uptake, 
Distribution and Elimination of Vapors in Man," in V. 
Fiserova-Bergerova (ed.), Modeling of Inhalation Exposure to 
Vapors: Uptake, Distribution, and ~limination, Vol. 2, pp. 
107-130. These calculations assume-r6 liours at rest and 8 hours at 
a light activity level. 
b Source: International Commission on Radiological Protection, 1975, Report 
of the Task Group on Reference Man, Pergamon Press, Oxford, p. 
346.---These calculatiOns assume 14-nlours at rest and 10 hours at a 
light activity level. 
c Source: A.C. Guyton, 1947, "Measurement of the Respiratory Volumes of 
Laboratory Animals," Amer. J. Physiol., Vol. 150, pp. 70-77. The 
allometric equation is_: __ -
Resp. Vol. (ml/min) = 2.10 x Bw3/4 
If information is inadequate to quantitatively estimate an absorbed or 
metabolized dose for either the study population or the human population of 
concern, the standardized administered dose represents the best basis from 
which equivalent exposures can be derived from the available data. When 
adequate, however, pharmacokinetic data may help to relate the ~dministered 
dose to the absorbed dose and, further, to the dose of the active compound at 
the tissue exhibiting the toxic response. For certain well studied compounds, 
adequate pharmacokinetic data are available from animal studies. Frequently, 
however, information is lacking from which a qualitative and quantitative 
profile of human absorption and metabolism can be constructed, particularly at 
environmental exposure levels. Assumptions consistent with worst case 
assessment methodologies therefore have to be made regarding the actual extent 
of human absorption, distribution, and metabolism. 
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In certain instances, the pharmacological and toxicological data may 
indicate that a scaling factor applied to the absorbed dose is appropriate 
when dose comparisons are made between species. A commonly used scaling 
factor is based on interspecies differences in surface area. The typical 
surface area adjustment, presented in the following equation, uniformly 
reduces the weight-adjusted dosage for human beings compared with that 
determined for smaller laboratory test animals (NRC, 1986). 
Human Dose (mg/kg) = Animal Dose (mg/kg) x (animal bw/human bw)l/3 
This adjustment is based on the assumption that surface area is a function of 
the body weight raised to the two-thirds power. Because of differences in 
body shape between animals, this allometric relationship is not a precise one 
(Calabrese, 1983; Lu, 1985). It has been a useful approximation, however, in 
certain clinical applications. Figure 16.1 demonstrates the effect of the 
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Interspecies Adjustment Factor 
Figure 16.1. Experimental Animal Weights Versus an Interspecies Scaling 
Factor Using the Surface Area Relationship. Enclosed areas along the function 
represent general ranges of average body weights of experimental animals. 
Rabbit values are represented by the box with solid lines. 
Source: Dourson, M.L., 
Experimental Support of 
Pharmacol., Vol. 3, p. 229. 
and Stara, J.F., 1983, 
Uncertainty (Safety) 
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The surface area- adjustment has been found to remove much of the 
interspecies variability associated with the toxicity and effectiveness of 
certain non-metabolizable anticancer drugs (Freireich et al., 1966; Pinkel, 
1958). It also pr9duces a stronger correlation among species than a straight 
body weight extrapolation with regard to several physiological parameters, 
including blood flow (Ramsey and Anderson, 1984), enzyme activity (Calabrese, 
1983), renal clearance (Adolph, 1949), and drug half-lives and concentrations 
in plasma and tissue (Calabrese, 1983). According to the National Research 
Council (NRC, 1986), for certain compounds, a specified effect level in human 
beings may be estimated from the corresponding effect level in rodents after 
this surface area adjustment is applied. 
There are limitations, however, regarding the application of surface area 
adjustments in interspecies scaling. Specific interspecies differences in 
absorption, metabolism, distribution, or excretion may render the surface area 
adjustment inappropriate for quantitative risk assessment. Thus, the 
adjustment should only be used when there is evidence that adjusting for _ 
surface area related differences would provide a better estimate of delivered 
dose than alternative approaches. It is possible, for example, that a more 
specific scaling factor than the general surface area adjustment may be 
derived from the available information. Particularly, if the pharmacokinetic 
studies show that metabolism is significantly different between the test 
animals and human beings, interspecies adjustments should reflect those 
differences. On the other hand, if there are no data to justify the use of a 
scaling factor, estimates of delivered dose should rely estimates of absorbed 
or administered dose. 
Uncertainties associated with the estimation of the delivered dose of a 
toxic chemical to the site of action may be reduced through the use of 
pharmacokinetic modelling. Before such modelling is accepted as the 
quantitative basis for the assessment of the dose-response relationship, 
however, the parameters which provide the basis for the model output should be 
carefully examined. Such consideration is particularly relevant if the models 
are developed primarily from animal data, or if the findings from high dose 
exposures are to be applied to low dose exposure situations. Failure to 
consider these differences could result in imprecise estimates of delivered 
dose in the human populations of concern. 
16.3 Derivation of Action Levels Using Mathematical Models. 
Most risk assessment applications require the estimation of health risks 
at dose levefs below those in the experimental dose ranges. Two methods are 
currently used to address this issue. The first method involves the 
application of mathematical models to extrapolate the dose response curve 
below the experimental range. The second method involves the application of 
uncertainty factors to either the lowest observed adverse effect level (LOAEL) 
or the no observed adverse effect level (NOAEL) in the study population in 




Of the two low dose risk estimation approaches, the mathematical modelling 
approach is preferable if the ef feet is presumed to exhibit no threshold, or 
if adequate experimental data are available and enough is known about the 
toxic effect to presume the shape of the dose response curve at 
sub-experimental doses. This approach is preferable because it makes use of 
more dose-response data. Therefore, it conforms more closely to the key risk 
assessment policy objectives of considering all the available data and 
ensuring that the risk assessment findings reflect the best scientific 
understanding of a chemical's toxicity. When information is inadequate to 
extrapolate the dose-response into the low dose region, however, the 
uncertainty factor method must be employed. While the uncertainty factor 
approach may not make as much use of the toxicological data as the 
mathematical modelling approach, it is also true that the available 
information in these situations does not permit more sophisticated risk 
assessment techniques to be employed. Thus, when data are inadequate for low 
dose extrapolation using mathematical models, the best scientific 
understanding is limited to the relatively crude uncertainty factor method. 
This method is described following the discussion on mathematical models. 
Most practical applications of low dose mathematical modelling have 
involved the estimation of cancer risks. Cancer risk assessment has relied on 
this method because its non-threshold assumption is inconsistent with the 
population threshold assumption implicit in the uncertainty factor method. On 
the other hand, models have been developed which employ a population threshold 
assumption with regard to both quantal and continuous data (Crump, 1984; NRC, 
1986). These models also consider all the dose-response data and experimental 
factors such as sample size. They may prove to be very useful if adequate 
dose-response data are available, particularly if uncertainty exists regarding 
the determination of the no observed adverse effect level. They are not 
generally used at the present time, however, primarily because sufficient data 
rarely exist for such an extrapolation (Dourson et al., 1986; NRC, 1977). 
At the present time, carcinogenicity is the only health effect for which a 
non-threshold assumption has been generally applied. Although genetic 
toxicity is also presumed exhibit no threshold, this health endpoint is not 
usually employed in the derivation of action levels. Findings from laboratory 
studies indicate that intrauterine death, as well as other embryotoxic 
effects, follow a dose-response relationship with an apparent threshold at 
some level below the experimental dose range (Wilson, 1980). Therefore, no 
effect levels for developmental effects in human beings may be estimated from 
the dose response data or from the application of uncertainty factors to no 
observed effect or lowest observed effect levels in the animal studies (IRLG, 
1986). 
No criteria have been developed to determine when mathematical models can 
be applied to non-carcinogenic effects data. Conversely, criteria have not 
been sufficiently developed to determine when the uncertainty factor method 
should be applied to carcinogenicity data. Thus, in the absence of sufficient 
information to the contrary, low dose extrapolation for carcinogenicity should 
involve mathematical modelling while low dose extrapolation for 
non-carcinogenic effects should involve the use of uncertainty factors. 
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16.3.1 The Selection of the Appropriate Mathematical Model. 
Two general types of mathematical models are commonly used in 10\v dose 
extrapolation for carcinogenic effects: tolerance distribution models 
(including the probit, logit, and Weibull models), and mechanistic or 
stochastic models (including the one-hit, multi-hit, and multi-stage models). 
The tolerance distribution models are based on the assumption that each 
individual in the population has his own tolerance to the substance, and that 
these tolerances follow some distribution function, such as the normal 
distribution. The mechanistic models are premised on the assumption that a 
positive response for each aniQial is the result of the random occurrence of 
one or more biological events. Although these two modelling concepts rest on 
different premises, it is possible for a mechanistic argument to lead to a 
tolerance distribution (USEPA, 1987). For example, the gamma multi-hit model 
follows the same distribution regardless of whether one assumes a random 
occurrence of "hits", or whether one assumes that each individual in the 
population has a particular tolerance level to a chemical (USEPA, 1987). 
Thus, the distinction between the mechanistic and tolerance distribution 
models is not always clear (USEPA, 1987). 
Adaptations of the tolerance distribution and mechanistic model types have 
been developed for certain situations. For example, the population threshold 
models mentioned above are var~ations on these models (Crump, 1984). Also, 
time-to-tumor models (including the Weibull distribution, Armitage-Doll, 
Hartley-Sielken models) are adapt ions of the tolerance distribution models, 
with adjustments made for latency periods (Hogan and Hoel, 1982; Park and 
.Snee, 1983; Munro and Krewski, 1981; Krewski et al., 1983). The time-to-tumor 
models have the potential to provide more complete information regarding the 
actual carcinogenic process. Sufficient uncertainty currently . exists 
regarding the ability of bioassays to consistently determine time-to-tumor, 
however, that their applicability may be limited in most risk assessments 
(OSTP, 1985; USEPA, 1986a). 
The mechanisms of carcinogenicity are still not precisely understood, 
despite an increased understanding regarding the overall initiation, 
development, and progression of neoplasms. Thus, both tolerance distribution 
and mechanistic models lack empirical justification. All models may fit the 
experimental range generally well, although they may produce widely divergent 
estimates of risk in the low dose region (USEPA, 1986a; OSTP, 1985). A 
general description of the basic curves generated by low dose extrapolation 
models is presented in Figure 16.2. The threshold curve (Curve A) is not 
currently considered to adequately reflect the risks associated with low level 
exposure to carcinogens. This conclusion may change for at least certain 
carcinogens, however, when issues associated with the mechanisms of 
chemically-induced carcinogenesis become better resolved. Supralinear models, 
such as those conforming to Curve D, are not generally considered to be 
biologically plausible (OTA, 1981). Therefore, the most commonly discussed 
low dose extrapolation models are characterized by either a linear or 
sublinear curve in the low dose region. 
Both linear and sublinear low dose extrapolation models generate curves 
which cross the origin and therefore, are consistent with a non-threshold 
assumption for the population. Determ~ning the shape of the curve in the 
sub-experimental range, however, requires consideration of the uncertainty 
associated with the observed dose-response. Most extrapolation models depend 
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on few data points. Cancer bioassay· results, for example, generally include 
only two data points in addition to the control. Even when adequate data are 
available, extrapolation models must consider variations in individual 
sensitivity. There is, therefore, uncertainty as to the true shape of the 
dose-response curve. The upper 95 percent confidence limit is generally used 
to estimate the upper bound on what the true dose-response relationship is. 
If the normal distribution of responses in the exposed population reflects the 
general population distribution, then there is only a 5 percent probability 
that the response of the general population is greater than that predicted by 
using the upper 95 percent confidence limit of the dose response curve. 
Another concern which must be addressed when determining the shape of the 
cancer dose-response curve at sub-experimental doses is whether the chemical 
is acting independently or addi ti vely to the background response. Because 
chemical carcinogens do not behave uniquely, it is likely that any exposure 
could act in a simple additive way with background risks (Brown, 1975; Crump, 
1985). Although certain studies (e.g. Russell et al., 1982) indicate that 
sublinear responses to low doses of carcinogens may occur, the shape of the 
dose-response curve in the low dose region is an still unresolved issue (NRC, 
1986). After a review of this issue, the National Research Council has 
concluded that, as a general rule, low dose extrapolation models for chemical 
carcinogens should incorporate the assumption of background additivity (NRC, 
1986). The assumption of additivity generally leads to the assumption of low 






















DOSE OF CARCINOGENIC AGENT 
Figure 16.2. Four Dose-Response Relationships Postulated for Low-Dose 
Extrapolation. a) Threshold; b) Probit (Sublinear); c) Linear; d) Gamma -
k = 0.5 (Supralinear). 
Source: Tomatis, L., et al., 1982, "Experimental Studies in the Assessment of 
Human Risk," in D. Shottenfeld and JeF. Fraumeni, Jr. (eds.), Cancer 
Epidemiology and Prevention, W.B. Saunders Company, Philadelphia, p. 68. 
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Of the mechanistic models, the multistage models are the most commonly 
used and accepted (Peto, 1977; OSHA, 1980; USEPA, 1986a). Conceptually, they 
are the most consistent with our current understanding of the multistage 
nature of carcinogenesis (Day and Brown, 1980; Hogan and Hoel, 1982). A 
specific variation of these models, the linearized multistage model, 
incorporates the assumption of low dose linearity through restrictions placed 
on its upper 95 percent confidence limit. The upper 95 percent confidence 
limit of the dose-response curve is determined by maximizing the linear term 
of the model. Of the other models, the multi-hit model is generally less 
conservative than the multistage model (Munro and Krewski, 1981). It has also 
been criticized as having significant practical problems with its application, 
including the estimation under certain situations of a supralinear 
dose-response in the low dose region (OSTP, 1985). The one-hit model is more 
conservative than the multistage model, although it has been criticized·as not 
adequately reflecting tumor responses in the experimental region (OSTP, 
1985). A modification designed to address this shortcoming of the one hit 
model is a straight linear extrapolation from the lowest observed response 
rate to the background rate or origin (Hogan and Hoel, 1982; Hallenbeck and 
Cunningham, 1986; Gaylor, 1985). The only assumption needed is that the 
dose-response curve from which the linear extrapolation is made is convex. 
Like the one-hit model, however, the 1 inear extrapolation technique has been 
criticized as not being sufficiently reflective of the observed data and for 
being overly conservative and for not making use of all the available 
dose-response data (Hogan and Hoel, 1982; OSTP, 1985). 
The tolerance distribution models have been used in describing a variety 
of toxicological phenomena. The probi t model, for example, is used in the 
detemination of median lethal dose levels levels among experimental animals 
(Tomatis et al., 1982). These models, therefore, may have applicability when 
evaluating response patterns for threshold effects. Despite the fact that it 
precisely reflects laboratory data in the observed response region, this model 
tends to become very flat at low doses, and therefore predicts risk values 
that are substantially lower than those calculated from the linearized 
mechanistic models. An adaptation of the probit model was developed by Mantel 
and Bryan (1961) to address this possible shortcoming • According to this 
model, carcinogenic risks are estimated from an upper confidence limit on an 
extrapolated dose-response curve with a slope of one. Although this 
modification was considered by the authors to add sufficient conservatism into 
the modelling process, this may not be necessarily true. The logit and 
Weibull models generally tend to be more conservative than the probit model at 
low doses, with the Wei bull model being the most conservative of the three 
(USEPA, 1987). 
The selection of the appropriate low dose extrapolation model for cancer 
risk assessment purposes thus depends on a number of considerations. Firstly, 
the selection must conform to the general risk assessment policy objectives of 
adopting a conservative approach regarding scientific uncertainty, of 
considering as much of the relevant available data as possible, and of 
ensuring that the risk assessment findings reflect the best scientific 
understanding of the chemical's toxicity. Also, the selection should 
specifically consider that the upper 95 percent confidence limit on risk be 
used to account for uncertainties in the dose-response, and that the 
dose-response curve be linear at low doses. 
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The tolerance distribution models may not be sui table for two reasons: 
they are not as conservative as the multistage model, and they may not 
generate a linear dose-response curve at low doses, even if the upper 95 
percent confidence limit on risk is used (MUnro a~d Krewski, 1981). With the 
exception of the multi -stage model, the mechanistic models warrant concerns 
because they generally do not consider all of the available dose-response 
data. On the other hand, the linearized multistage model is relatively 
conservative and ensures low dose linearity when risks are based on its upper 
95 percent confidence limit. Also, it considers all of the available 
dose-response information and is conceptually consistent with the current 
scientific understanding of the multistage process of carcinogenicity. In the 
absence of sufficient to indicate the use of an alternative model for low dose 
cancer risk assessment, therefore, the 1 inearized multistage model should be 
selected .. 
Despite the widespread use of mathematical models in cancer risk 
assessment, there is still considerable uncertainty concerning the role of low 
level chemical exposure in the development of human cancers. For the most 
part, these models rely on general curve fitting procedures with basic 
assumptions concerning biological variability and the activity of carcinogens 
in the sub-experimental dose range. It is difficult, for example, to 
quantitatively correlate mathematical modelling with possible biological 
differences between early and late stage, genotoxic and non-genotoxic, or 
chemical and biological carcinogens. It is also difficult to quantitatively 
consider other potential factors such as genetic susceptibility, hormonal 
balance, immunologic competence, and nutritional influences. Ongoing research 
is directed towards the development of mathematical models which more closely 
reflect human carcinogenesis than the current models (Armitage, 1985). Future 
risk assessment policy revisions should consider these newer models within the 
general policy objectives of worst case risk assessment and having the 
assessments reflect the best scientific understanding of a chemical's toxicity. 
16.3.2 The Determination of Appropriate Model Input Information. 
Several variables concerning dose and response are required as input into 
low dose extrapolation models for carcinogenesis. Specifically with· regard to 
the linearized multistage model, these variables include the number of animals 
per dose group (including the control group), the number of animals with the 
tumor of interest in each group, the dose levels, the degree of the 
polynomial, and the type of risk to be determined (extra risk or additional 
risk). The process for deriving appropriat~_ dose estimates is discussed in 
Chapter 16.2. Policy issues concerning the process by which appropriate 
response parameters are estimated focus specifically on the proper assessement 
of tumor incidence. Issues identified thus far by the Maine Bureau of Health 
pertain to the selection of the appropriate biological endpoints, to 
adjustments which may be necessary regarding the raw tumor incidence data, and 
to the use of additional or extra risk~ Other policy issues associated with 
the choice of model inputs will be incorporated into the policy if discussion 
is determined to be necessary. 
Selection of Appropriate Biological Endpoints. One issue associated with 
the estimation-of tumor incidence in response to chemical exposure concerns 
how tumors are grouped for quantitative assessment. With regard to animal 
bioassays, two basic approaches are generally available. The first approach 
to grouping tumors considers that cancer is a group of distinct neoplastic 
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diseases, and that the endpoint of interest is the elevation of a specific 
tumor type or site. According to this approach, incidence data for any tumor 
site or type may be used in low dose extrapolation. The conclusion could be 
made from the results of this extrapolation that the risk associated with any 
specific tumor site and type should be no greater than the risk associated 
with the most sensitive type/site response. The major limitation of this 
approach is that the resulting risk estimates may not adequately predict the 
increased incidence of any type of cancer associated with exposure to a 
potential carcinogen. On the other hand, data are generally available 
regarding the tumor incidence rates at specific sites, thus making this 
approach applicable for routine risk assessment purposes. 
The second approach to tumor grouping considers that cancer is the 
endpoint of interest and that elevation in overall cancer incidence is the 
appropriate parameter for quantitatively assessing the cancer response. 
Measures of this response include: 1) comparisons of total tumor bearing 
animals among the exposed and control populations, and 2) the pooling of all 
animals with significantly elevated tumor sites or types relative to the 
untreated controls. The first measure of overall cancer response is subject 
to the limitation imposed by the fact that some sites (for example, the rat 
testes) have a very high background incidence. This high background incidence 
could mask the significance of a treatment related effect between treated and 
control populations unless, possibly, the tumor response is measured 
relatively early in the study (IARC, 1980). The limitation imposed on 
quantitative assessment by tumor types with high background rates may be 
overcome by using the second measure of the overall tumor response. Pooling 
significantly elevated tumor sites or types is recommended by the U.S. 
Environmental Protection Agency (USEPA, 1986a) and, when adequate data are 
available, represents an appropriate measure of total carcinogenic risk. On 
the other hand, the exact number of animals with significantly elevated tumor 
responses may be difficult to determine from the bioassay data. Pooling 
should address the requirement that an animal with a significantly elevated 
tumor response at multiple sites not be counted more than once. When multiple 
sites are significantly elevated, information is often unavailable concerning 
the incidence pattern in each animal. In addition, depending on the tumor 
rates for the individual sites or types in the cGntrol animals, pooling the 
data may result in a less . conservative estimate of cancer risk than an 
estimate based on the most sensitive tumor response. 
Cancer risk estimates derived from epidemiological studies may use both 
the tumor-specific approach and the approach of pooling significantly elevated 
tumors at specific sites. The issues associated with the selection of tumor 
incidence data from epidemiological studies are similar to those associated 
with the animal bioassays. Yet, before epidemiological data can be used in 
modelling procedures, additional concerns specific to the analysis should be 
addressed. These concerns involve variations in background tumor rates 
attributable to such factors as age, lifestyle, genetic make-up, and other 
potentially confounding influences. 
The choice of whether or not to use the specific tumor incidences depends 
on the data availability. If adequate data are available to pool the tumor 
incidences at specific sites, the use of these data into low dose 
extrapolation models could provide an estimate of overall cancer risk. The 
process of estimating overall cancer risks when adequate information is 
available is consistent with basic risk assessment policy objectives. 
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Inclusion of pooled data does~ not necessarily mean, however, that the 
resulting cancer risks estimates are given preference to those based on tumor 
specific information. Such a decision should also consider the design and 
conduct of the study, the specific tumors involved, and the relative degree of 
conservatism afforded by these two approaches. 
Another policy issue pertaining to the quantitative evaluation of tumor 
incidence is the segregation of tumors according to their stages of 
development.. Given that benign tu!flors for a specific site and type usually 
represent a stage in the development of malignant tumors, the incidences of 
benign and malignant tumors generally should be combined in or.der to derive a 
conservative estimate of potential cancer risk. On the other hand, separate 
analyses of these tumor stages could provide a better understanding of the 
severity of the carcinogenic response. Both combined and separate analyses, 
therefore, could be complementary to each other as long as the objectives of 
worst case risk assessment are fulfilled. Guidelines for combining specific 
benign and malignant tumors have been developed by the National Toxicology 
Program (NTP, 1984), and should be followed so that inappropriate groupings of 
benign and malignant tumors can be avoided. 
Adjustments of Tumor Incidence Data from Animal Bioassays. After the 
appropriate biological endpoints for mathematical modelling purposes have been 
determined, adjustments in the tumor incidence rates may_ sometimes be 
required. An important adjustment addresses premature mortality. In light of 
the latency period associated with carcinogenicity, it is possible that some 
animals may die before a tumor has had a chance to develop. Thus, \vhen 
determining the actual number of animals at risk in the bioassay, these early 
deaths need to be excluded. Such a consideration also applies to the analysis 
of interim sacrifices, as it is unknown what proportion of the non-tumor 
bearing animals would have developed tumors had they been allowed ·to live 
until the end of the study. The issue of premature mortality can be most 
readily addressed by elimating from the analysis all animals which died before 
the appearance of the first tumor and all interim sacrifices. 
Additional Risk Versus Extra Risk. The final consideration regarding 
model Input Information IS whether tJ.1e cancer risk estimates should be based 
on additional risk or extra risk. The additional risk approach estimates the 
cancer risk over background: 
Additional Risk = P(d) - P(O). 
The extra risk approach estimates the cancer risk among those individuals who 
would not develop cancer in the absence of exposure to the carcinogen: 
Extra Risk= (P(d) - P(0))/(1 - P(O)). 
Extra risk is used to account for tumors with high background rates relative 
to the human population (for example, liver tumors in B6C3Fl mice). In these 
situations, extra risk estimates should be used, as this adjustment addresses 
potential inherent interspecies differences in susceptibility to cancer. When 
background tumor rates in experimental animals are very low, there is little 
difference between cancer risk estimates based on additional risk and extra 
risk. 
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16.3.3 Presentation of the Mathematical MOdelling Results. 
Given basic input information, mathematical models may produce a variety 
of information outputs. The 1 inearized multi -stage model output provides 
estimates of parameters describing the shape of the dose-response curve, and 
the upper 95 percent confidence limit on that curve. It also provides esti-
mates of dose levels corresponding to a given level of risk, and risk levels 
corresponding to a given dose. The specification of action levels for carci-
nogens varies from agency to agency. As a general policy, however, the Maine 
Bureau of Health considers an exposure level corresponding to a lifetime 
cancer risk of one per one hundred thousand as a basis for a public health 
concern. At a minimum, the exposure level corresponding to this cancer risk 
level should be presented. 
The equation for the maximum likelihood estimate (MLE) describes the shape 
' of the dose-response curve which provides the best fit to the experimental 
data. This value represents only a point estimate of risk and lacks the 
confidence associated with the upper bound risk estimate. Nonetheless, the 
MLE should be presented along with the 95 percent confidence limit in order to 
provide an indication of the correspondence between the upper bound on risk 
and the experimental data. At a minimum, the cancer risk estimates presented 
should include those based on worst case assumptions, as such estimates are 
necessary if the risk assessment is to reflect a conservative approach to 
scientific uncertainty. It is possible, however, that more than one MLE and 
upper confidence limit on risk may be presented, depending on the uncertainty 
regarding the input variables. Inclusion of multiple risk estimates may add 
to the assessment by providing a quantitative indication of the range of 
uncertainty associated with the estimation of potential human cancer risk. 
Cancer risk estimates derived from animal bioassays are usually based on 
tumor incidences associated with lifetime exposures. In addition, most 
epidemiological studies consider exposure durations which last for a 
significant portion of a normal human lifespan. These exposure periods should 
be reflected in the presentation of the human cancer risk estimate by basing 
the estimate on lifetime exposure. Often, cancer risk estimates may be needed 
for less than lifetime exposure periods. As there is generally inadequate 
information from which to compare cancer risks resulting from long-term 
exposure to those resulting from shorter term exposure, cancer risks for less 
than lifetime exposures should be based on the product of exposure dose and 
exposure duration unless a more precise estimate of cancer risk can be 
derived. Also, for cancer risks to be translated from a mg/kg/day dose to an 
exposure concentration in an environmental medium, a reference body weight is 
needed for the general population. A general procedure in this regard is to 
base cancer risks on a reference adult weight of 70 kilograms unless another 
reference weight is shown to be preferable to a given risk assessment. 
16.4 Derivation of Action Levels Using the Uncertainty Factor Approach. 
Uncertainty factors should be used when available chemical-specific health 
data are inadequate to estimate either a no effect or a de minimus exposure 
level for a threshold effect in the general population~ The uncertainty 
factor·approach rests on two basic assumptions. The first assumption is that 
a population threshold exists below which chemical exposure causes no adverse 
health impacts. The second assumption is that for any given area of 
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uncertainty, chemical exposure produces the most toxic response that can 
reasonably be estimated from the available health data. Current scientific 
understanding of chemical carcinogenesis does not generally allow for the 
assumption of a population threshold. Therefore, the uncertainty factor 
approach should only be used in the assessment of potential human cancer risks 
when sufficient scientific justification is available, or when interim 
guidance is needed for suspected carcinogens which lack an adequate 
quantitative data base for cancer risk estimation purposes (See Chapter 
16.4.5). 
Risk extrapolation procedures for non-carcinogenic effects involve the 
identification of sensitive health effects, the determination of either a 
lowest observed adverse effect level (LOAEL) or a no observed adverse effect 
level (NOAEL), and the application of appropriate uncertainty factors to 
address the probability that certain subgroups of the population may respond 
more sensitively then what is indicated by the experimental data. It then 
follows that a level below that which causes the most sensitive response in 
sensitive populations should also protect human beings from all adverse 
effects resulting from exposure to a particular chemical. 
Four concerns may have to be addressed by the uncertainty factor approach 
in reference to any given health effect: 1) the estimation of a response level 
in sensitive human populations from the available epidemiological or animal 
toxicology studies, 2) the estimation of a no adverse effect level in 
sensitive human populations when only LOAELs are available, 3) the estimation 
of a chronic no adverse effect level when only sub~hronic data are available, 
and 4) the estimation of a no adverse effect level for a sensitive health 
effect when only data on relatively more severe health effects are available. 
Depending on the nature of the data base, some or all of these concerns should 
be addressed in the risk assessment. The final outcome of this procedure is 
the derivation of an estimated no adverse effect level (ENAEL) for the general 
population with regard to a particular sensitive health endpoint and exposure 
duration. 
The development of appropriate criteria for use in the uncertainty factor 
approach is presented in the following discussion. In certain cases, the risk 
assessment may be unable to use the uncertainty factor approach because of an 
inadequate health effects data base. Interim guidance may still be needed, 
however, for risk management purposes. Recommendations concerning procedures 
for developing interim guidance on inadequately studied chemicals are 
discussed in Chapter 16.4.5. 
16.4.1 Consideration of Intraspecies and Interspecies Variability. 
The major area of uncertainty in the derivation of action levels for 
threshold effects concerns the potentially wide range of population 
variability in both susceptibility and sensi ti vi ty to the adverse effects of 
chemical exposure. Few chemicals have been so extensively studied that their 
entire range of health effects in human populations can be precisely defined. 
Therefore, an adverse observed in an animal population should also be presumed 
to occur in at least some human population, unless adequate information exists 
to demonstrate that the effect is a species-specific response. If human data 
are available, the policy issue concerns the potential range of variability 
between the study population and a sensitive human population. In estimating 
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these ranges in variability, it is reasonable to assume that more uncertainty 
is associated with the extrapolation of animal data than with the extra-
polation of human data. 
If it is assumed that there is a general qualitative correspondence 
between human susceptibility to a toxic effect and the occurrence of that 
effect in some laboratory species, risk assessment concerns then focus on the 
quantitative correspondence between the response in any given laboratory model 
or human population and the response in sensitive human populations. If it is 
further assumed that the response in laboratory animals is quantitatively 
similar to some human population, the risk assessment policy issue becomes one 
of determining the potential range of variability between the animal response 
and the response of a sensitive human population. 
According to the procedure just described, consideration of intraspecies 
and interspecies differences begins with an estimate of the human variability 
in sensitivity to the toxic effects of chemical exposure. A factor of 10 has 
commonly be used to account for variations in sensitivity among human 
populations (NRC, 1977; Dourson and Stara, 1983; Hogan and Hoel, 1982). It is 
possible, however, that this factor may be inadequate to protect certain 
sensitive populations. Gillette (1985) noted that even among small groups of 
test subjects, clearance of environmental chemicals may easily vary 20- to 
50-fold. Calabrese (1983) examined variations on human responses to certain 
xenobiotics as well as 'differences in risks to diseases for specific sensitive 
populations. He noted that variations in human responses may range up to two 
or three orders of magnitude, and that a 10-fold uncertainty factor may 
sometimes be inadequate for up to 20 percent of the human population. 
Indirect estimates of the range of human variability have been made based 
on animal models. Dour son and Stara (1983) conducted a probi t analysis on 
acute rat lethality data for 490 toxicants. The slopes ranged from 1.4 to 
64. They then calculated the dose reductions required to drop the median 
response (e.g., the LDSO) to a level which would result in deaths of only the 
most sensitive members of the population (LD13). The frequencies of the 
slopes plotted against the dose adjustments needed to reduce lethality to the 
LD13 level. These results are presented in Figure 16.3. The authors 
calculated that for approximately 92 percent of the slopes, a 10-fold 
reduction in dose would drop the response to below the LD13. Furthermore, 
they stated that average slope of 7.8 needed only a 2.4-fold reduction in dose 
to reach this level. On the basis of this information, they concluded that 
the 10-fold factor may be overly conservative with respect to the "average" 
chemical, but sufficient to protect the population from most chemicals. 
There are limitations associated with the use of such animal models for 
the purpose of estimating the potential human variability in responses to 
toxic chemicals. Firstly, the data base used by Dourson and Stara are based 
on a relatively homogenous population of rats. Furthermore, the toxicological 
endpoint (LDSO) may not correlate well with more sensitive measures of 
toxicity. Finally, when compared with the human studies, it appears that the 
animal studies may significantly underestimate the potential human variability. 
In light of these considerations, an appropriate conceptual model for 
assessing intraspecies and interspecies differences is one that focuses on the 
wide variability in the human responses to chemical exposures. A hundred-fold 
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Figure 16.3. Frequency of Studies Versus the Intraspecies Adjustment Factor 
~equired to Reduce the Median Lethal Response in Rats to That of the Most 
Sensitive Responders. 
Source: Dourson, M.Lo, and Stara, J.F., 1983, "Regulatory History and 
Factors," Reg.. To xi col .. ::.xperimental Support of Uncertainty (Safety) 
Pharmacol., Vol. 3, pQ 227 .. 
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Figure 16.4. A Simplified Graphical Representation of the Relative 
Uncertainties Associated with Intraspecies and Interspecies Differences in 
Response to Toxic Chemical Exposure. The graph assumes a lognormal 
distribution in human sensitivity. 
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comparative interspecies data, it must be assumed that animals may be up to 
100 times less sensitive to the effects of exposure than a sensitive human 
population. As there is less uncertainty associated with predictions based on 
human data, it is less likely that the mean response observed in an 
epidemiological study would represent the least sensitive response among human 
populations. Rather, it is more likely that a 10-fold uncertainty factor 
would adequately address potential intraspecies difference among human 
beings. An illustration of the conceptual basis for using intraspecies and 
intraspecies uncertainty factors is presented in Figure 16.4. 
Tpese uncertainty factors are consistent with those generally used by the 
National Academy of Sciences (NRC, 1977) and the U.S. Environmental Protection 
Agency (Dour son and Star a, 19 83). The approach just described effectively 
provides a 10-fold interspecies uncertainty factor to estimate an average 
response in human populations from animal data. Justification for this factor 
is provided by studies which have compared similar toxic responses between 
human beings and laboratory animals (Dourson and Stara, 1983). Such 
comparisons have raised speculations that interspecies differences may result 
from factors correlated with animal surface area (Dourson and Stara, 1983). 
If this is true, it is also possible that species are equally sensitive to a 
given chemical when the doses at the site of action are equivalent. Thus, if 
adjustments have been made to account for interspecies differences in 
delivered dose, and it can be demonstrated that the experimental animal is as 
equaliy sensitive as human beings after such adjustments have been made, then 
a modification of this uncertainty factor may be warranted. Often, however, 
the distinction cannot be made concerning the relative contributions of 
delivered dose differences and inherent differences in sensi ti vi ty to the 
overall assessment of interspecies variability. In these cases, the 
uncertainty factor for animal data should not be modified, regardless of the 
way in which equivalent dose units are expressed. 
16.4.2 Databases Which Lack NOAELS. 
Another issues associated with quantitative assessment using the 
uncertainty factor approach is the derivation of the estimated no adverse 
effect level for exposed populations in studies which lack adequately derived 
no observed adverse effect levels (NOAELS). The NOAEL is dependent on the 
sample size, as the two are inversely related to one another (M..mro and 
Krewski, 1981; Hogan and Hoel, 1982). If, for example, the actual probability 
of a toxic response occurring at a specific dose is 7 percent, and if 10 
animals were exposed, there would be a 50 percent chance that all of the 
exposed animals would fail to show the response (Hogan and Hoel, 1982). Thus, 
if the data do not contain a NOAEL for a particular effect, or if the 
postulated NOAEL is in question, an uncertainty factor should be applied to 
the LOAEL. 
Confidence in the estimation of no adverse effect levels may be increased 
through analysis of the shape of the dose response curve. An assessment of 
the curve's trend helps in some cases to distinguish between a lowest observed 
adverse effect level (LOAEL) and a no observed adverse effect level (NOAEL). 
Structure-activity data may also provide additional information for evaluating 
the dose-response curve. 
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Comparisons have been made regarding the relationships between LOAELS and 
NOAELS, based on rat toxicology studies involving 33 different chemicals 
(Dour son and Stara, 1983). A summary of the results is presented in Figure 
16.5. The results show that all ratios were 10 or less, with most being 5 or 
less. The quality of these data are subject to the same caveats as those 
associated with the quality of the NOAEL data. Also, it is unknown to ltvhat 
extent these comparisons reflect true ratios of LOAELS to NOAELS and to \vhat 
extent these findings are influenced by general dose selection procedures. 
Nonetheless, on the basis of this limited data base, it seems reasonable to 
apply a factor of 5 or 10, depending on the available dose-response 
information, when estimating a no effect level from a lowest observed effect 
level. 
16.4.3 Databases Which Lack Chronic NOAELS or LOAELS. 
A third concern relevant to the uncertainty factor approach involves the 
estimation of chronic action levels in the absence of adequately conducted 
chronic effects studies. In these cases, such estimates must rely on the 
results from studies using shorter exposure durations. It is possible that 
exposure limits designed to protect the public from subacute or subchronic 
effects of a particular chemical may not be adequate if populations are 
chronically exposed. Therefore, uncertainty factors should be applied to 
NOAELS or LOAELS identified in subacute or subchronic studies. These factors 
address the possibility that longer term exposures may produce adverse health 
effects at lower concentrations than those which produced subacute or 
subchronic effects. 
The quantitative basis for this uncertainty factor comes from a studies 
which compared the lowest (signified in the study as "minimal") observed 
effect levels in rats exposed to the same chemical for varying exposure 
periods (Weil et al., 1969; Weiland McCollister 1963). Specifically, these 
studies compared the lowest observed effect levels in rats for 1-day 
(subacute), 90-day (subchronic), and 2-year exposure periods. The comparisons 
used data on 20 compounds, predominantly pesticides and surfactants. Weil et 
al. (1969) derived equations to predict the median and upper 95 percent 
confidence limits on the lowest observed effect levels to adjust from a 7-day 
exposure to a 90-day exposure and from either a 7-day or 90-day exposure to a 
2-year exposure. Their findings are presented in Table 16.2. The findings of 
the Weil and McCollister (1963) study, as adapted by Dourson and Stara (1983), 
are presented in Figure 16.6. 
These comparisons (Weil et al., 1969; Weil and McCollister 1963; Dourson 
and Stara, 1983) indicate that a factor of 10 should be adequate to adjust 
NOAELS or LOAELS from either a subacute to a subchronic exposure duration, or 
from a subchronic to a chronic exposure duration. According to these 
comparisons, a factor of 35 should be adequate when adjusting from a subacute 
to a chronic effect. The subacute to subchronic uncertainty factor should be 
considered with much caution, however, as it is possible that critical health 
effects associated with longer term exposures would not be adequately 
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16.4.4 Databases Without Adequate Information of Sensitive Effects. 
When comparative information is available, the uncertainty factor approa~h 
should consider the severity and sensitivity of the effect. Some target 
organs and organ systems, such as the nervous and reproductive systems, may 
manifest a wide spectrum of toxic responses (NRC, 1986). Databases sufficient 
to characterize these responses are generally limited, however (NRC, 1986). 
It may be likely, therefore, that substances associated with neurotoxicity or 
reproductive/develo~~ental toxicity through limited testing may also cause 
subtler effects on these systems which current testing procedures do not 
detect. 
No formal guidance has been developed concerning the use of uncertainty 
factors to address effect severity and sensitivity. Until formal guidance is 
developed, the determination of whether or not an uncertainty factor should be 
applied, how large that uncertainty factor should be, is an issue specific to 
the individual risk assessments. Determinations regarding such uncertainty 
factors should rest largely on the understanding of the quantitative 
relationships between progressively more severe toxicological responses 
associated with a given organ or organ system. If there is no quantitative 
basis for the establishment of an uncertainty factor, this shortcoming should 
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Figure 16.6. Frequency of Studies Versus the Ratio of Subchronic to Chronic 
Exposures for Either NOAELS, LOAELS, or Composite NOAEL-LOAEL Values. 
Source: Dourson, M.L., and Stara, J.F., 1983, 
Experimental Support of Uncertainty (Safety) 
Pharmacol., Vol. 3, p. 231. 
"Regulatory History and 
Factors," Reg. Toxicol. 
General guidance regarding the progression of concern regarding effect 
severity has been outlined by the Massachusetts Department of Environmental 
Quality Engineering (MDEQE, 1985). This guidance appears in MDEQE's paradigm 
acute/chronic effects, presented in Table 15.3. According to this outline, 
mild or transient effects are assigned a severity value of 1 (or representing 
the least severe effect). Irreversible effects are assigned the highest 
severity value of 3. A value of 2 is assigned to intermediate effects. 
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16.4.5 Default Procedures Using the Uncertainty Factor Approach. 
There may be several situations in which no adequate quantitative data are 
available for quantitative risk extrapolation. If action levels are required 
of the assessment, the use of alternative approaches is warranted. These may 
involve the use of structure-activity data or generic default approaches. The 
State of Michigan (SAAC, 1981), for example, estimated an uncertainty factor 
of 0.00002 to be applied to LD50 or LCSO data in order to derive an acceptable 
exposure level for non-criteria air pollutants which fall into this category. 
This factor was based on the finding by MacNamara (1976) that the upper 95 
percent confidence limit of the ratips between the no observed adverse effect 
level to the LD50 was 0.002. Further application of a hundred-fold 
uncertainty factor to this upper confidence limit results in the recommended 
default uncertainty factor. 
The use of uncertainty factors is not generally recommended when deriving 
action levels for known or suspected carcinogens. There may be certain 
situations, however, when adequate information is unavailable for the 
quantitative assessment of carcinogenic effects. Factors of as high as 5,000 
applied to the no observed adverse effect level (NOAEL) have been recommended 
to provide interim public health guidance in these situations (Hogan and Hoel, 
1982). Such factors have been criticized for being arbitrary and not 
sufficiently conservative with regard to non-threshold effects. On the other 
hand, little guidance is available· concerning the assessment of potential 
carcinogens with an inadequate quantitative data base. Until such guidance 
becomes available, therefore, an uncertainty factor of 5, 000 may be used to 
set an upper bound on exposure when adequate quantitative data are lacking and 
interim guidance is needed. The lower bound on exposure to known or suspected 
carcinogens should be zero. 
16.4.6 Presentation of the Results from the Uncertainty Factor Approach. 
After the appropriate uncertainty factors have been selected and 
quantified, a summary of the risk derivation process should be presented. 
This summary should include the estimated no adverse effect levels (ENAELS) 
for each health effect and exposure duration of concern. The uncertainty 
factors and interspecies adjustments should be presented in such a way that 
the quantitative relationship between the ENAEL and the experimental findings 
is clear. The uncertainty factors factors established in this risk assessment 
policy are presented in Table 16.3. 
The ENAEL may vary depending on the the reference human population which 
serves as the basis for that level. This is because air, water, and food 
intake requirements decrease per unit of body weight as body weight 
increases. Thus, for a given concentration of a chemical in these media, a 
small child would be expected to receive a greater intake on a mg/kg basis 
than an adult. 
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Intake differences are particularly relevant when acute, subacute, or 
subchronic effects are considered. Chronic effect levels are usually based on 
studies which are carried out over the lifetime, or a large proportion of the 
lifetime, of an experimental cohort. The reference human population for these 
effects, therefore, is usually the average adult weighing 70 kilograms (NRC, 
1977). The reference population for acute, subacute, or subchronic effects is 
generally the 10 kilogram infant (NRC, 1977). When developmental effects are 
being specifically considered, the reference human population is the 60 
kilogram female. The intake doses for these reference human populations 
should be derived in Chapter 16.2. 
Table 16.3 
Summary of the Uncertainty Factors Used in the Quantitative 
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SECTION VI: RISK CHARACTERIZATION 
Risk characterization, according to the National Research Council (NRC, 
1983a), is "the description of the nature and often the magnitude of human 
risk, including attendant uncertainty." Thus, in the risk characterization 
section, three areas of risk assessment are integrated: 1) the quantitative 
relationship between dose and effect, based on the existing data; 2) the 
quantitative estimates of population exposure to a substance; and 3) the 
assessment of the critical areas of uncertainty associated with the risk 
assessment. The characterization of health risks may be largely dependent on 
the way in which uncertainty is quantitatively integrated into the 
dose-response assessment and the exposure assessment. The worst case risk 
assessment reflects the maximum degree to which uncertainty is quantitatively 
considered. The risk assessment has the obligation to present the worst case 
assessment, as it represents the highest upper bound estimate of health risk, 
given the limitations imposed by scientific uncertainty and science policy 
choices made in deciding worst case assumptions. Characterizations based on 
assumptions less extreme than the worst case may be presented as part of a 
general description of the uncertainty surrounding the action levels. In 
presenting these alternative characterizations, however, the assessment should 
clearly state both the arguments and evidence which indicate why the 
alternatives may give a better estimate of the actual risk than the worst case 
assumption, and the arguments and evidence which support why the the worst 
case assumption should be favored. 
The worst case assumptions which form the basis of the risk 
characterization may vary according to the policy choices made in deciding 
what these assumptions are. The risk characterization could therefore benefit 
from a comparison of the assessment's worst case characterization with those 
of other assessments. This comparison could provide risk managers with a 
perspective concerning the areas of scientific consensus and disagreement 
regarding the risk assessment findings, and the particular risk assessment 
issues that underlie these areas of agreement and disagreement. In addition, 
comparisons with existing standards and guidelines, as well as with the health 
concerns associated with alternatives to the substance of concern in the risk 
assessment, may provide the risk manager with additional perspectives from 
which the assessment's findings may be interpreted. 
17. Risk Assessment Findings. 
The risk assessment findings comprise a summary of what is known and what 
is not known about the substance's health risks. These findings include the 
conclusions that can be drawn from the exposure assessment, hazard 
identification, and hazard assessment sections. The findings are then 
compared to those of other assessments. Following this comparison is ·a 
qualitative appraisal of the existing data base. This appraisal is very 
important to the assessment, as it provides a context for evaluating the 
extent to which the derived action levelss reflect overall health concerns. 
It also provides the context for characterizing the specific risk assessment 
areas which, if addressed more extensively, would be most likely to lessen the 
uncertainty associated with the recommended action levels. 
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17.1 Characterization of Health Risks Associated with Exposure. 
The characterization of health risks associated with exposure integrates 
the findings from the quantitative estimates of exposure (Chapter 9) and the 
quantitative health risk assessment (Chapter 16). Health risks should be 
presented for each health effect evaluated and for each exposure duration of 
concern. The criterion which connects a health endpoint, an exposure level, 
and an exposure duration is the action level. Depending on the particular 
health effect, the action level may be expressed as an estimated no adverse 
effect level (ENAEL) or as a cancer risk level. In either case, the action 
level, when compared to a particular exposure level and duration, provides the 
basis for determining whether a current or projected exposure warrants a 
public health concern. 
The quantitative characterization of health risks should be accompanied by 
a discussion of the qualitative factors related to the derivation of the 
action levels. These factors include the toxicological importance of the 
health endpoints, the study populations used in the risk extrapolation (for 
example, laboratory animals, occupational cohorts, sensitive human 
populations), the population subgroups most susceptible to exposure-related 
effects, and the types of risk factors which could influence the substance's 
toxicity. 
In addition to the characterization of human health risks, the 
environmental and ecological impacts associated with the substance could be 
characterized. Such characterizations are warranted for two reasons. 
Firstly, they serve to provide a more complete description of the adverse 
impacts resulting from the presence of a particular substance in the 
envirorunent o Secondly, adverse impacts on the environment may indirectly 
affect human health by causing disruptions in the basis processes which 
sustain human life. Thus, the complete characterization of the human health 
impacts associated with exposure to a particular substance should include 
indirect, as well as direct, human health impacts. 
17.2 Comparison with Findings of Previous Assessments. 
The comparison of the risk assessment findings with the findings of 
previous assessments provides a context for evaluating the areas of scientific 
consensus and disagreement regarding the health risks of a particular 
substance. Differences may occur as a result of different risk assessment 
policy choices or because of new findings. The reasons for these differences 
should be discussed. When differences occur as a result of different pol icy 
choices, the discussion should address the scientific issues underlying these 
choices, and why the policy choice made in the assessment is preferable to the 
other choices. Specifically, the discussion should focus on comparing the 
assessments with respect to general policy objectives of considering all the 
relevant data, of having the assessment reflect the best scientific 
understanding of the issue, and of having the assessment reflect a 
conservative approach to the evaluation of scientific uncertainty. 
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17.3 Appraisal of Current Data Base. 
The characterization of human health risks associated with exposure should 
be understood within the context of what is still not known about the 
substance's toxicity and exposure potential. Depending on the level of 
investigation given to a particular chemical, the amount of scientific 
ignorance may prove to be more significant than the actual data used in 
deriving the action levels. Every area of a risk assessment could probably be 
improved by more information. The main objective of the appraisal of 
uncertainty, however, is to present a summary of those key areas of the risk 
assessment for which adequate information was found to be lacking. The 
presentation of this information represents a key element of the risk 
assessment, for it stresses the importance that the process of evaluating 
health risks is continually open to improvement. A discussion of these areas 
of uncertainty associated with the risk assessment should help the risk 
manager to understand better the differences among risk assessments, and the 
degree to which future findings could change the current characterization of 
health risks. · 
Much of the toxicological data is derived from studies in which human 
beings or laboratory animals were exposed to relatively high doses of a 
substance. These studies, at least the human studies, may have direct 
relevance for individuals in occupational environments. Yet, the 
environmental situations of most concern are generally characterized by 
long-term, low level exposures to pollutants. Application of toxicological 
data to the assessment of ambient exposures, therefore, must consider toxicity 
differences resulting from different exposure levels, routes, and durations as 
well as possible interspecies and intraspecies variations in sensitivity. 
Such considerations are especially important in light of the fact that most 
risk assessments must rely on data generated from animal studies. The use of 
animal data introduces uncertainty into the estimation of human risk, as 
animals may vary widely in their responses to toxins. There is generally no a 
priori way of determining which animal will be the most predictive of a 
part1cular toxic response in human beings. Further uncertainty is introduced 
if the the animals are exposed to a chemical by a route different from normal 
human exposures. 
There are approximately 70,000 synthetic chemicals in commerce, of which 
25,000 are in common use (NRC, 1983a, 1983b). Approximately 500 to 1,000 new 
chemicals are introduced annually in the marketplace (OTA, 1981). Risk 
assessments are generally expected to derive acceptable exposure limits for 
the general population from a limited database. A recent study by the 
National Research Council (NRC, 1984), however, concluded that adequate 
information for complete health assessments exists for only 18 percent of 
1,900 pharmaceutical products, 10 percent of 3,350 pesticide ingredients, 5 
percent of 8,600 food additives, and 2 percent of 3,400 cosmetic ingredients. 
Only a very small percentage of chemicals in the environment have been tested 
for carcinogenicity (NAS, 1983), teratogenicity (Schardein, 1985), or 
neurotoxicity (Anger and Johnson, 1986). Investigations concerning the 
interactive effects of chemicals have been rare (USEPA, 1984). A summary of 
the NRC findings is presented in Figure 17.1 (NRC, 1984). 
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Drugs and Excipients 1 ,815 
Used in Drug Formulations 
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Figure 17.1. Ability to Conduct Health-Hazard Assessment of Selected 
Substances in Seven Categories. 
Source: NRC. (National Research Council), 1984, Toxicity Testing: Strategies 
to Determine Needs and Priori ties, National Academy Press, Washington, D.C., 
P:ll8. ----- ---
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18. Comparison of Findings with Existing Standards and Guidelines. 
Existing standards and guidelines- reflect, to varying degrees, the 
findings of previous assessme~ts. They may differ substantially from 
assessment findings, however, dependfng on how largely non-health related 
concerns were considered in their development. Such concerns may include risk 
management issues of technological feasibility, the degree of protection to be 
provided to the population, or the sampling and analytical limitations 
associated with substance identification and quantification. In addition, 
some guidelines may be based on default risk extrapolation procedures which 
are not directly comparable to the low-dose extrapolation procedures used in 
formal risk assessments. The ways in which the risk assessment findings 
differ from existing standards and guidelines may need to be explained. 
Specific attention should be focused on the extent to which the consideration 
of risk management criteria accounts for these differences. 
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19. Risks Associated with Alternative Substances~ 
A concern relevant to the entire process of risk assessment involves the 
degree of attention given to the substance undergoing investigation relative 
to other substances. It is· possible, for example, that a risk management 
decision might encourage the use of an alternative substance with equal or 
even greater toxicity than the substance assessed, but without a corresponding 
level of analysis applied to it. This concern is especially relevant if the 
action levels indicate that severe use restrictions may be warranted for the 
substance undergoing assessment. 
Deciding whether or not the health risks of alternative substances should 
be considered in the risk assessment depends on the assessment's stated 
purpose and scope. If such considerations are to be made, the assessment 
should define the level of analysis to be given to these substances. In 
general, the analysis need only be sufficient to alert the risk manager to the 
potential health concerns of the alternatives. Particularly, the analysis 
should emphasize the data availability and general findings for the following 
health effects categories: genetic toxicity, carcinogenicity, reproductive and 
developmental toxicity, and other acute/chronic toxicity. This task may be 
accomplished by a review of secondary sources and, possibly, a literature 
search using relevant computer databanks. In addition, efforts have been made 
to develop comparative databases for chemicals which produce similar health 
effects (see, for example, Gold et al. (1984) and Ames et al. (1987) for 
carcinogenic compounds). Reference to these databases may be useful in order 
to provide the risk manager with a broader perspective of the health 
implications associated with different public policy choices. Separate risk 
assessments on the alternatives may be required, however,. before specific 
comparisons of ·health risks can be made between these substances and the 




The conclusions of the risk assessment shoutd present the key findings of 
the investigation. The ultimate conclusion of the risk assessment should be 
whether or not an actual or projected exposure to a substance presents a 
public health concern. Regardless of the determination, a description of the 
evidence upon which this conclusion is based should be presented. This 
description should include a summary of the scientific uncertainties 
associated with this evidence. If the exposure is associated with a public 
health concern, the conclusions should also specify the health effects ·of 
concern, a description of the severity of the effects, and a description of 
the populations at risk. 
Conclusions are relatively easy to make when the available information 
demonstrates that exposure of a specified level of a substance will or will 
not present a public health concern. These determinations may be applicable 
for certain well studied compounds. For the preponderance of chemicals, 
however, there is inadequate information on either exposure or toxicity. This 
shortcoming may place limitations of vary degrees on the conclusions that can 
be drawn from the data. 
Depending on the level of scientific ignorance, risk assessment findings 
may or may not be useful in the development of an appropriate public health 
response to a chemical exposure situation. The measure of an effective public 
health response is its ability to maintain or reduce incidences of premature 
deaths and preventable adverse health effects. In order to best satisfy this 
criterion, the general public health policy should be that all avoidable 
exposures to toxic substances be prevented, except for those exposures in 
which a public health benefit can be realized. Risk assessment findings are 
thus most applicable to public health policy decisions either when an exposure 
cannot be prevented or when' a preventable exposure has already occurred. The 
conclusions of the risks assessments should be interpreted within the context 
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